Multispecific antibodies and methods of use thereof

JP2023549537A5Inactive Publication Date: 2024-11-20AB THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528957
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-08-26
Filing Date
2021-11-16
Publication Date
2024-11-20
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapies for non-small cell lung cancer (NSCLC) face challenges due to resistance development, particularly with EGFR and cMET signaling pathways, necessitating simultaneous inhibition of both receptors for effective treatment.

Method used

Development of multispecific antibodies, such as 1H1-cMET/EGFR-Fc(WT)-V3 and trispecific antibodies like 1H1cMET/1A12cMET/EGFR(WT), which target both cMET and EGFR, inhibiting receptor interactions and downstream signaling pathways, enhancing efficacy over existing bispecific antibodies like JNJ372.

Benefits of technology

These multispecific antibodies demonstrate improved binding, receptor inhibition, and cytotoxicity, effectively inhibiting EGFR and cMET pathways, offering enhanced therapeutic potential for NSCLC and other malignancies with aberrant signaling.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to a multispecific antibody (e.g., a bispecific antibody) or antigen-binding fragment thereof. In one aspect, the multispecific antibody or antigen-binding fragment thereof binds to cMET and / or EGFR, or a combination thereof. The antibody or antigen-binding fragment thereof that binds to cMET (tyrosine protein kinase Met) comprises a heavy chain antibody variable domain (VHH) comprising complementarity-determining regions (CDRs) 1, 2, and 3. TIFF2023549537000008.tif101128
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Priority claims This application claims the benefit of U.S. Provisional Patent Application No. 63 / 114,479, filed November 16, 2020, and U.S. Provisional Patent Application No. 63 / 237,526, filed August 26, 2021, the entire contents of which are incorporated herein by reference.

[0002] Technical Field The present disclosure relates to multispecific antibodies or antigen-binding fragments thereof. [Background technology]

[0003] background Multispecific antibodies are engineered proteins capable of simultaneously binding to two or more distinct epitopes. This allows for a wide range of applications, including redirecting T cells against tumor cells, simultaneously blocking two distinct signaling pathways, dual targeting of different disease mediators, and delivering payloads to target sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) marked major milestones in the development of multispecific antibodies.

[0004] Multispecific antibodies have a wide range of applications, and therefore there is a need to continue developing a variety of therapeutic agents based on multispecific antibodies. Summary of the Invention

[0005] overview The present disclosure relates to antibodies or antigen-binding fragments that specifically bind to cMET and / or EGFR, or a combination thereof. In some embodiments, the present disclosure relates to the development of bispecific antibodies that target cMET / EGFR. In some embodiments, the antibodies described herein can treat non-small cell lung cancer (NSCLC).

[0006] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that binds to cMET (tyrosine protein kinase Met), comprising a heavy chain antibody variable domain (VHH) comprising complementarity-determining regions (CDRs) 1, 2, and 3.

[0007] In some embodiments, the VHH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VHH CDR1 amino acid sequence, the VHH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VHH CDR2 amino acid sequence, and the VHH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VHH CDR3 amino acid sequence. In some embodiments, the amino acid sequences of the selected VHH CDR1, 2, and 3 are as follows: (1) The amino acid sequences of the selected VHH CDR1, 2, and 3 are shown in SEQ ID NOs: 1, 2, and 3, respectively; (2) The amino acid sequences of the selected VHH CDR1, 2, and 3 are shown in SEQ ID NOs: 4, 5, and 6, respectively; (3) The amino acid sequences of the selected VHH CDR1, 2, and 3 are shown in SEQ ID NOs: 7, 8, and 9, respectively; and (4) The amino acid sequences of the selected VHH CDR1, 2, and 3 are shown in SEQ ID NOs: 10, 11, and 12, respectively. It is one of them.

[0008] In some embodiments, the VHH comprises CDR1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 1, 2, and 3, respectively.

[0009] In some embodiments, the VHH comprises CDR1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 4, 5, and 6, respectively.

[0010] In some embodiments, the VHH comprises CDR1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 7, 8, and 9, respectively.

[0011] In some embodiments, the VHH comprises CDR1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 10, 11, and 12, respectively.

[0012] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that binds to cMET, comprising a heavy chain antibody variable domain (VHH) comprising an amino acid sequence at least 80% identical to a selected VHH sequence. In some embodiments, the selected VHH sequence is selected from the group consisting of SEQ ID NOs: 19-22 and 77-84. In some embodiments, the VHH comprises the sequence of SEQ ID NO: 19, 77, 78, 79, 80, 81, or 84. In some embodiments, the VHH comprises the sequence of SEQ ID NO: 20. In some embodiments, the VHH comprises the sequence of SEQ ID NO: 21. In some embodiments, the VHH comprises the sequence of SEQ ID NO: 22, 82, or 83.

[0013] In some embodiments, the antibody or antigen-binding fragment specifically binds to cMET.

[0014] In some embodiments, the antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

[0015] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof comprising VHH CDR1, 2, 3 of an antibody or antigen-binding fragment thereof as described herein.

[0016] In some embodiments, the antibody or antigen-binding fragment comprises a human IgG Fc.

[0017] In some embodiments, the antibody or antigen-binding fragment comprises two or more heavy chain antibody variable domains.

[0018] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that cross-competes with an antibody or antigen-binding fragment thereof as described herein.

[0019] In one aspect, the present disclosure relates to a multispecific antibody or antigen-binding fragment thereof comprising a first antigen-binding site that specifically binds to EGFR and a second antigen-binding site that specifically binds to cMET.

[0020] In some embodiments, the first antigen-binding site comprises a heavy chain variable region (VH) and a light chain variable region (VL). In some embodiments, the VH and VL associate with each other to specifically bind to EGFR.

[0021] In some embodiments, the heavy chain variable region (VH) comprises complementarity determining regions (CDRs) 1, 2, and 3. In some embodiments, the VH CDR1 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 13, the VH CDR2 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 14, and the VH CDR3 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 15. In some embodiments, the light chain variable region (VL) comprises CDR1, 2, and 3. In some embodiments, the VL CDR1 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 16, the VL CDR2 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 17, and the VL CDR3 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 18.

[0022] In some embodiments, the heavy chain variable region (VH) comprises an amino acid sequence at least 90% identical to SEQ ID NO: 23, and the light chain variable region (VL) comprises an amino acid sequence at least 90% identical to SEQ ID NO: 24.

[0023] In some embodiments, the second antigen-binding site specifically binds to cMET, and the second antigen-binding site comprises a first heavy chain antibody variable domain (VHH1) comprising complementarity determining regions (CDRs) 1, 2, and 3. In some embodiments, the VHH1 CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VHH1 CDR1 amino acid sequence, the VHH1 CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VHH1 CDR2 amino acid sequence, and the VHH1 CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VHH1 CDR3 amino acid sequence. In some embodiments, the selected VHH1 CDR1, 2, and 3 amino acid sequences are as follows: (1) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 1, 2, and 3, respectively; (2) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 4, 5, and 6, respectively; (3) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 7, 8, and 9, respectively; and (4) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 10, 11, and 12, respectively. It is one of them.

[0024] In some embodiments, the first heavy chain antibody variable domain (VHH1) comprises an amino acid sequence that is at least 80% identical to a selected VHH sequence. In some embodiments, the selected VHH sequence is selected from the group consisting of SEQ ID NOs: 19-22 and 77-84. In some embodiments, a multispecific antibody or antigen-binding fragment thereof as described herein further comprises a third antigen-binding site that specifically binds to cMET.

[0025] In some embodiments, the third antigen-binding site specifically binds to cMET, and the third antigen-binding site comprises a second heavy chain antibody variable domain (VHH2) comprising complementarity-determining regions (CDRs) 1, 2, and 3. In some embodiments, the VHH2 CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VHH2 CDR1 amino acid sequence, the VHH2 CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VHH2 CDR2 amino acid sequence, and the VHH2 CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VHH2 CDR3 amino acid sequence. In some embodiments, the selected VHH2 CDR1, 2, and 3 amino acid sequences are as follows: (1) The amino acid sequences of the selected VHH2 CDR1, 2, and 3 are shown in SEQ ID NOs: 1, 2, and 3, respectively; (2) The amino acid sequences of the selected VHH2 CDR1, 2, and 3 are shown in SEQ ID NOs: 4, 5, and 6, respectively; (3) The amino acid sequences of the selected VHH2 CDR1, 2, and 3 are shown in SEQ ID NOs: 7, 8, and 9, respectively; and (4) The amino acid sequences of the selected VHH2 CDR1, 2, and 3 are shown in SEQ ID NOs: 10, 11, and 12, respectively. It is one of them.

[0026] In some embodiments, the second heavy chain antibody variable domain (VHH2) comprises an amino acid sequence that is at least 80% identical to a selected VHH2 sequence. In some embodiments, the selected VHH2 sequence is selected from the group consisting of SEQ ID NOs: 19-22 and 77-84.

[0027] In some embodiments, the VH and VL are linked by a linker peptide sequence to form an scFv. In some embodiments, the linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0028] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH), a first hinge region, and a first Fc region; (b) a second polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a second hinge region, and a second Fc region; and (c) a third polypeptide comprising a light chain variable region (VL). In some embodiments, the first VHH specifically binds to cMET. In some embodiments, the VH and VL associate with each other and specifically bind to EGFR.

[0029] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0030] In some embodiments, the first Fc region and / or the second Fc region comprises a sequence at least 80% identical to SEQ ID NO: 30 or 31.

[0031] In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 43 or 44. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 45 or 46. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 47.

[0032] In some embodiments, the first polypeptide further comprises a second VHH that specifically binds to cMET. In some embodiments, the second VHH is linked to the N-terminus of the first VHH via a linker peptide sequence.

[0033] In some embodiments, the linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0034] In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 48 or 49. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 50 or 51. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 52.

[0035] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0036] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH), a first hinge region, and a first Fc region; and (b) a second polypeptide comprising, from N-terminus to C-terminus, a single-chain variable fragment (scFv), a second hinge region, and a second Fc region. In some embodiments, the first VHH specifically binds to cMET. In some embodiments, the scFv comprises a heavy chain variable region (VH), a first linker peptide sequence, and a light chain variable region (VL). In some embodiments, the VH and VL associate with each other and specifically bind to EGFR.

[0037] In some embodiments, the first linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0038] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0039] In some embodiments, the first Fc region and / or the second Fc region comprises a sequence at least 80% identical to SEQ ID NO: 30 or 31.

[0040] In some embodiments, the first polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 53 or 54. In some embodiments, the second polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 55 or 56.

[0041] In some embodiments, the first polypeptide further comprises a second VHH that specifically binds to cMET. In some embodiments, the second VHH is linked to the N-terminus of the first VHH via a second linker peptide sequence.

[0042] In some embodiments, the second linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0043] In some embodiments, the first polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 57 or 58. In some embodiments, the second polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 59 or 60.

[0044] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0045] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH1), a first linker peptide sequence, a first heavy chain variable region (VH1), a first hinge region, and a first Fc region; (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH2), a second linker peptide sequence, a second heavy chain variable region (VH2), a second hinge region, and a second Fc region; and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other and specifically bind to EGFR.

[0046] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0047] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0048] In some embodiments, the sequences of VHH1 and VHH2 are identical. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80% identical to SEQ ID NO: 32. In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 61 or 62. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 63. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 61 or 62. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 63.

[0049] In some embodiments, the sequences of VHH1 and VHH2 are different. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80% identical to SEQ ID NO: 30 or 31. In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 64 or 65. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 66 or 67. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68. In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 85. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 86. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68.

[0050] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0051] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain variable region (VH1), a first hinge region, a first Fc region, a first linker peptide sequence, and a first heavy chain antibody variable domain (VHH1); (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain variable region (VH2), a second hinge region, a second Fc region, a second linker peptide sequence, and a second heavy chain antibody variable domain (VHH2); and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and / or VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other and specifically bind to EGFR.

[0052] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0053] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0054] In some embodiments, the sequences of VHH1 and VHH2 are identical. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80% identical to SEQ ID NO: 32. In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 69 or 70. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 71. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 69 or 70. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 71.

[0055] In some embodiments, the sequences of VHH1 and VHH2 are different. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80% identical to SEQ ID NO: 30 or 31. In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 72 or 73. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 76. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 74 or 75. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 76.

[0056] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0057] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH), a first hinge region, and a first Fc region; (b) a second polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a second hinge region, and a second Fc region; and (c) a third polypeptide comprising a light chain variable region (VL). In some embodiments, the first VHH specifically binds to cMET. In some embodiments, the VH and VL associate with each other and specifically bind to EGFR. In some embodiments, the first polypeptide further comprises a second VHH that specifically binds to cMET. In some embodiments, the second VHH is linked to the N-terminus of the first VHH via a linker peptide sequence.

[0058] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0059] In some embodiments, the first Fc region and / or the second Fc region comprises a sequence at least 80% identical to SEQ ID NO: 30 or 31.

[0060] In some embodiments, the linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0061] In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 48 or 49. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 50 or 51. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 52.

[0062] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0063] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH), a first hinge region, and a first Fc region; and (b) a second polypeptide comprising, from N-terminus to C-terminus, a single-chain variable fragment (scFv), a second hinge region, and a second Fc region. In some embodiments, the first VHH specifically binds to cMET. In some embodiments, the scFv comprises a heavy chain variable region (VH), a first linker peptide sequence, and a light chain variable region (VL). In some embodiments, the VH and VL associate with each other to specifically bind to EGFR. In some embodiments, the first polypeptide further comprises a second VHH that specifically binds to cMET. In some embodiments, the second VHH is linked to the N-terminus of the first VHH via a second linker peptide sequence.

[0064] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0065] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0066] In some embodiments, the first Fc region and / or the second Fc region comprises a sequence at least 80% identical to SEQ ID NO: 30 or 31.

[0067] In some embodiments, the first polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 57 or 58. In some embodiments, the second polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 59 or 60.

[0068] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0069] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH1), a first linker peptide sequence, a first heavy chain variable region (VH1), a first hinge region, and a first Fc region; (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH2), a second linker peptide sequence, a second heavy chain variable region (VH2), a second hinge region, and a second Fc region; and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other to specifically bind to EGFR. In some embodiments, the sequences of VHH1 and VHH2 are different.

[0070] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0071] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0072] In some embodiments, the first Fc region and / or the second Fc region comprises a sequence at least 80% identical to SEQ ID NO: 30 or 31.

[0073] In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 64 or 65. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 66 or 67. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68.

[0074] In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 85. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 86. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68.

[0075] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0076] In one aspect, the present disclosure relates to a polypeptide complex comprising: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain variable region (VH1), a first hinge region, a first Fc region, a first linker peptide sequence, and a first heavy chain antibody variable domain (VHH1); (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain variable region (VH2), a second hinge region, a second Fc region, a second linker peptide sequence, and a second heavy chain antibody variable domain (VHH2); and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and / or VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other to specifically bind to EGFR. In some embodiments, the sequences of VHH1 and VHH2 are different.

[0077] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 37-42.

[0078] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 25-29.

[0079] In some embodiments, the first Fc region and / or the second Fc region comprises a sequence at least 80% identical to SEQ ID NO: 30 or 31.

[0080] In some embodiments, the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 72 or 73. In some embodiments, the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 76. In some embodiments, the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 74 or 75. In some embodiments, the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 76.

[0081] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering, and / or a glutamic acid (Glu) at position 332 according to EU numbering.

[0082] In one aspect, the present disclosure relates to a nucleic acid, including a polynucleotide, encoding an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, or a polypeptide complex as described herein. In some embodiments, the nucleic acid is DNA (e.g., cDNA) or RNA (e.g., mRNA).

[0083] In one aspect, the present disclosure relates to a vector comprising one or more of the nucleic acids as described herein.

[0084] In one aspect, the present disclosure relates to a cell comprising a vector as described herein. In some embodiments, the cell is a CHO cell.

[0085] In one aspect, the present disclosure relates to a cell comprising one or more of the nucleic acids as described herein.

[0086] In one aspect, the present disclosure relates to a method of producing an antibody or antigen-binding fragment thereof, comprising: (a) culturing a cell as described herein under conditions sufficient for the cell to produce the antibody or antigen-binding fragment; and (b) harvesting the antibody or antigen-binding fragment produced by the cell.

[0087] In one aspect, the present disclosure relates to an antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, or a polypeptide complex as described herein, covalently linked to a therapeutic agent. In some embodiments, the therapeutic agent is a cytotoxic or cytostatic agent.

[0088] In one aspect, the present disclosure relates to a method of treating a subject having cancer, the method comprising administering to the subject a therapeutically effective amount of a composition comprising an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, a polypeptide complex as described herein, or an antibody-drug conjugate as described herein.

[0089] In some embodiments, the subject has a cancer that expresses cMET. In some embodiments, the subject has a cancer that expresses EGFR.

[0090] In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is non-small cell lung cancer (NSCLC).

[0091] In one aspect, the present disclosure relates to a method of reducing the rate of tumor growth, comprising contacting tumor cells with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, a polypeptide complex as described herein, or an antibody-drug conjugate as described herein.

[0092] In one aspect, the present disclosure relates to a method of killing tumor cells, the method comprising contacting the tumor cells with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, a polypeptide complex as described herein, or an antibody-drug conjugate as described herein.

[0093] In one aspect, the present disclosure relates to a method of killing tumor cells, the method comprising contacting the tumor cells with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, a polypeptide complex as described herein, or an antibody-drug conjugate as described herein.

[0094] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof as described herein, a multispecific antibody or antigen-binding fragment thereof as described herein, a polypeptide conjugate as described herein, and a pharmaceutically acceptable carrier.

[0095] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an antibody-drug conjugate as described herein and a pharmaceutically acceptable carrier.

[0096] In one aspect, the present disclosure provides a multispecific antibody or antigen-binding fragment thereof comprising a heavy chain antibody variable domain (VHH) as described herein, or a heavy chain variable region (VH) and a light chain variable region (VL) as described herein.

[0097] In one aspect, the present disclosure provides a bispecific antibody or antigen-binding fragment thereof comprising a heavy chain antibody variable domain (VHH) as described herein, or a heavy chain variable region (VH) and a light chain variable region (VL) as described herein.

[0098] In one aspect, the present disclosure provides a multispecific antibody or antigen-binding fragment thereof that specifically binds to cMET. In one aspect, the present disclosure provides a multispecific antibody or antigen-binding fragment thereof that specifically binds to EGFR.

[0099] In one aspect, the present disclosure provides a multispecific antibody that targets both cMET and EGFR. In some embodiments, the multispecific antibody described herein has comparable or even higher binding ability to cMET and / or EGFR than JNJ372 or a JNJ372 analog. In some embodiments, the multispecific antibody described herein is more effective than JNJ372 or a JNJ372 analog in blocking the interaction between cMET and a cMET ligand (e.g., HGF). In some embodiments, the multispecific antibody described herein is more effective than JNJ372 analog in blocking the interaction between EGFR and an EGFR ligand (e.g., EGF). In some embodiments, the multispecific antibody described herein is comparable or even more effective than JNJ372 or a JNJ372 analog in inhibiting the phosphorylation of cMET and / or EGFR. In some embodiments, the multispecific antibodies described herein are more effective than JNJ372 or JNJ372 analogs in inhibiting phosphorylation of downstream signaling pathways (e.g., the ERK and / or Akt pathways) involved in cancer cell survival and proliferation.

[0100] The present disclosure provides a multispecific antibody or antigen-binding fragment thereof that binds to EGFR and cMET. A multispecific antibody (e.g., a bispecific antibody or a trispecific antibody) or antigen-binding fragment thereof is an artificial protein that can simultaneously bind to two or more different types of epitopes. The epitopes can be in the same antigen or in different antigens. In some embodiments, a multispecific antibody or antigen-binding fragment thereof can have two, three, four, five, six, or more antigen-binding sites. In some embodiments, an antigen-binding site has one heavy chain variable region and one light chain variable region. In some embodiments, an antigen-binding site has one VHH.

[0101] The present disclosure provides multispecific antibodies or antigen-binding fragments thereof that bind to EGFR and cMET. The present disclosure further provides anti-EGFR antibodies or antigen-binding fragments thereof having anti-cMET VHHs, and VHs and VLs. These VHHs, VHs, and VLs can be used to generate various multispecific antibodies or antigen-binding fragments as described herein.

[0102] As used herein, the term "antibody" refers to any antigen-binding molecule that contains at least one (e.g., one, two, three, four, five, or six) complementarity-determining region (CDR) (e.g., any of the three CDRs from an immunoglobulin light chain or any of the three CDRs from an immunoglobulin heavy chain) and can specifically bind to an epitope in an antigen. Non-limiting examples of antibodies include monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, single variable domain (VHH) antibodies, chimeric antibodies, human antibodies, and humanized antibodies. In some embodiments, an antibody can contain the Fc region of a human antibody. The term antibody also includes derivatives, such as multispecific antibodies, bispecific antibodies, single-chain antibodies, diabodies, and linear antibodies formed from these antibodies or antibody fragments.

[0103] As used herein, the term "antigen-binding fragment" refers to a portion of a full-length antibody, which portion can specifically bind to an antigen. In some embodiments, the antigen-binding fragment contains at least one variable domain (e.g., a heavy chain variable domain, a light chain variable domain, or a VHH). Non-limiting examples of antibody fragments include, for example, Fab, Fab', F(ab')2, and Fv fragments, ScFv, and VHH.

[0104] As used herein, the terms "subject" and "patient" are used interchangeably throughout the specification to describe a human or non-human animal to which treatment according to the methods of the present invention is provided. Veterinary and non-veterinary applications are contemplated in this disclosure. A human patient can be an adult human or a young human (e.g., a human under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. Included are, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., pigs, miniature pigs), horses, dogs, cats, cows, and other domestic, farm, and zoo animals.

[0105] As used herein, when referring to an antibody or antigen-binding fragment, the phrases "specifically binding" and "specifically bind" mean that the antibody or antigen-binding fragment interacts more favorably with its target molecule than with other molecules because the interaction depends on the presence of a specific structure (i.e., an antigenic determinant or epitope) on the target molecule; in other words, the reagent recognizes and binds to a molecule containing a specific structure, rather than all molecules in general. An antibody that specifically binds to a target molecule can be referred to as a target-specific antibody. For example, an antibody that specifically binds to EGFR can be referred to as an EGFR-specific antibody or an anti-EGFR antibody.

[0106] As used herein, the term "bispecific antibody" refers to an antibody that binds to two different epitopes. The epitopes can be on the same antigen or on different antigens.

[0107] As used herein, the term "trispecific antibody" refers to an antibody that binds to three different epitopes, which can be on the same antigen or on different antigens.

[0108] As used herein, the term "multispecific antibody" refers to an antibody that binds to two or more different epitopes. The epitopes can be on the same antigen or on different antigens. A multispecific antibody can be, for example, a bispecific antibody or a trispecific antibody. In some embodiments, a multispecific antibody binds to two, three, four, five, or six different epitopes.

[0109] As used herein, "VHH" refers to the variable domain of a heavy chain antibody. In some embodiments, the VHH is a humanized VHH.

[0110] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably to refer to polymers of amino acids of any length, of at least two amino acids.

[0111] As used herein, the terms "polynucleotide," "nucleic acid molecule," and "nucleic acid sequence" are used interchangeably herein to refer to polymers of nucleotides of any length, of at least two nucleotides, and include, but are not limited to, DNA, RNA, DNA / RNA hybrids, and modifications thereof.

[0112] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.Methods and materials are described herein for use in the present invention; other suitable methods and materials known in the art can also be used.Materials, methods and examples are only illustrative and are not intended to be limiting.All publications, patent applications, patents, sequences, database entries and other references mentioned herein are incorporated by reference in their entirety.In case of conflict, the present specification, including definitions, will control.

[0113] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. [Brief explanation of the drawings]

[0114] [Figure 1] Figure 1 shows the luminescence signal of a competitive ELISA assay. The binding between cMET and Hu-HGF was measured in the presence of 16 unique clones. RFU is the mean relative fluorescence unit. [Figure 2] Cross-reactivity of 16 unique clones to human cMET (anti-Hu) and monkey cMET (anti-Cyno) is shown. [Figure 3] Figure 1 shows VHH expression levels of 1D5, 1F3, 1H1, and 2C7 clones as measured by biolayer interferometry (BLI). [Figure 4] Figure 1 shows the results of ELISA for VHH proteins binding to cMET. Media and PBS are negative controls. [Figure 5] Figure 1 shows the luminescence signal of a competitive ELISA assay. The binding between cMET and Hu-HGF was measured in the presence of cMET VHH clones 1D5, 1H1, and 2C7. 11F11 is an isotype control. [Figure 6] The schematic structure of 1H1-cMET / EGFR-Fc(WT)-V3 is shown. [Figure 7] Figure 1 shows the results of cMET binding ELISA for 1H1-cMET / EGFR-Fc(WT)-V3. JNJ372 analog (JNJ BsAb) is a positive control. 11F11 is an isotype negative control. [Figure 8] Figure 1 shows the results of EGFR binding ELISA of 1H1-cMET / EGFR-Fc(WT)-V3. JNJ372 analog (JNJ BsAb) is a positive control. 11F11 is an isotype negative control. [Figure 9] 1 shows the results of a titration ELISA for the binding of 1H1-cMET / EGFR-Fc(WT)-V1 (1H1 v1), 1H1-cMET / EGFR-Fc(WT)-V3 (1H1 v3), and a JNJ372 analog to cMET. [Figure 10] 1 shows the results of a titration ELISA for the binding of 1H1-cMET / EGFR-Fc(WT)-V3 (1H1 v3) and JNJ372 analogs to EGFR. [Figure 11] The luminescence signal of the competitive ELISA assay is shown. The binding between cMET and Hu-HGF was measured in the presence of EGFR in 1H1-cMET / EGFR-Fc(WT)-V3 and the JNJ372 analog. 11F11 is an isotype control. Hu-HGF-B is a biotinylated human HGF control without the addition of any antibody. [Figure 12-1] Figure 12A shows the EGF / EGFR blocking effect of 1H1-cMET / EGFR-Fc(WT)-V3 and the JNJ372 analog of EGFR. EGF-B is biotinylated EGF. [Figure 12-2]Figure 12B shows an immunofluorescence image of NCIH1975 cells treated with PBS alone. Figure 12C shows an immunofluorescence image of NCIH1975 cells incubated with 11F11 and then treated with biotinylated EGF. Figure 12D shows an immunofluorescence image of NCIH1975 cells treated with biotinylated EGF alone. Figure 12E shows an immunofluorescence image of NCIH1975 cells incubated with a JNJ372 analog and then treated with biotinylated EGF. Figure 12F shows an immunofluorescence image of NCIH1975 cells incubated with 1H1-cMET / EGFR-Fc(WT)-V3 and then treated with biotinylated EGF. [Figure 13A] The percentage of NCIH1975 cells with phosphorylated cMET is shown. Cells were treated with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3, and then treated with HGF. HGF is a positive control without any antibody treatment. NC is an isotype control. [Figure 13B] The percentage of NCIH1975 cells with phosphorylated EGFR is shown. Cells were treated with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3, and then treated with EGF. "EGF + no Ab" is a positive control without any antibody treatment. NC is an isotype control. [Figure 14A] Figure 1 shows the ratio of phosphorylated ERK (pERK) in NCI-H1975 cells grown in the presence of Hu-HGF. Cells were treated with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3. [Figure 14B] Figure 1 shows the ratio of phosphorylated Akt (pAkt) in NCI-H1975 cells grown in the presence of Hu-HGF. Cells were treated with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3. [Figure 15A] 1 shows the ADCC effects of JNJ372 analogs and 1H1-cMET / EGFR-Fc(WT)-V3. [Figure 15B] CDC effects of JNJ372 analogs and 1H1-cMET / EGFR-Fc(WT)-V3 are shown. [Figure 15C] 1 shows the cancer cell-killing effects of JNJ372 analogs and 1H1-cMET / EGFR-Fc(WT)-V3 (1H1 v3). [Figure 16] Figure 16A shows the schematic structure of an exemplary cMET / EGFR bispecific antibody with a bispecific-V1 format, and Figure 16B shows the schematic structure of an exemplary cMET / EGFR trispecific antibody with a trispecific-V1 format. [Figure 17] Figure 17A shows the schematic structure of an exemplary cMET / EGFR bispecific antibody with a bispecific-V2 format, and Figure 17B shows the schematic structure of an exemplary cMET / EGFR trispecific antibody with a trispecific-V2 format. [Figure 18] Figure 18A shows the schematic structure of an exemplary cMET / EGFR bispecific antibody with a bispecific-V3 format, and Figure 18B shows the schematic structure of an exemplary cMET / EGFR trispecific antibody with a trispecific-V3 format. [Figure 19] Figure 19A shows the schematic structure of an exemplary cMET / EGFR bispecific antibody with a bispecific-V4 format, and Figure 19B shows the schematic structure of an exemplary cMET / EGFR trispecific antibody with a trispecific-V4 format. [Figure 20A] Shown is the percentage of cells stained by pHrodo-labeled secondary antibody after incubation with JNJ372 analog, 1H1-cMET / EGFR-Fc(WT)-V3, or 1H1-cMET / EGFR-Fc(WT)-V3 Tri. [Figure 20B] Images of cells stained with pHrodo-labeled secondary antibody after incubation with JNJ372 analog, 1H1-cMET / EGFR-Fc(WT)-V3, or 1H1-cMET / EGFR-Fc(WT)-V3 Tri are shown. [Figure 21A] Figure 1 shows a cMET VHH-Fc epitope binning assay for the humanized VHH of cMET-1H1 (SEQ ID NO: 19). [Figure 21B]Figure 1 shows a cMET VHH-Fc epitope binning assay for the VHH of cMET-1A12 (SEQ ID NO: 20). [Figure 22A] Antibody binding curves to H1975 cells and calculated EC50 values ​​are shown. Anti-His IgG was used as a negative control. [Figure 22B] Antibody binding curves and calculated EC50 values ​​for H1975.HGF cells are shown. Anti-His IgG was used as a negative control. [Figure 22C] Antibody binding curves and calculated EC50 values ​​for EGFR mutant C797S-BaF3 cells are shown. Anti-His IgG was used as a negative control. [Figure 23A] Antibody blocking curves and calculated EC50 values ​​for EGF / EGFR interaction using H1975 cells are shown. Anti-His IgG was used as a negative control. [Figure 23B] Antibody blocking curves and calculated EC50 values ​​for EGF / EGFR interaction using H1975.HGF cells are shown. Anti-His IgG was used as a negative control. [Figure 23C] Antibody blocking curves and calculated EC50 values ​​for EGF / EGFR interaction using EGFR mutant C797S-BaF3 cells are shown. Anti-His IgG was used as a negative control. [Figure 24A] Antibody blocking curves and calculated EC50 values ​​for cMET / EGF interaction using H1975 cells are shown. Anti-His IgG was used as a negative control. [Figure 24B] Antibody blocking curves and calculated EC50 values ​​for cMET / EGF interaction using H1975.HGF cells are shown. Anti-His IgG was used as a negative control. [Figure 25A]A set of Western blot results using H1975 cells stimulated with HGF (HGF-) is shown. Cells were also treated with 1H1cMET / 1A12cMET / EGFR(WT) ("trispecific"), 1H1-cMET / EGFR-Fc(WT)-V3 ("bispecific"), JNJ372 analog ("JNJ"), or negative control antibody ("Neg"). Antibody concentrations were 0.16 μg / ml or 4 μg / ml. Arrows highlight the inability of the JNJ373 analog, compared to the trispecific, in mediating EGFR degradation. [Figure 25B] A set of Western blot results using H1975.HGF cells (HGF+) is shown. Cells were also treated with 1H1cMET / 1A12cMET / EGFR(WT) ("TsAb"), 1H1-cMET / EGFR-Fc(WT)-V3 ("BsAb"), JNJ372 analog ("JNJ"), or negative control antibody ("Neg"). The antibody concentrations were 0.16 μg / ml or 4 μg / ml. [Figure 25C] A set of Western blot results using a cell line harboring the untreatable EGFR point mutation C797S is shown. Cells were also treated with 1H1cMET / 1A12cMET / EGFR(WT) ("trispecific Ab"), 1H1-cMET / EGFR-Fc(WT)-V3 ("bispecific Ab"), JNJ372 analog ("JNJ"), anti-His tag antibody ("anti-His"), or negative control antibody ("Neg"). The antibody concentrations were 0.16 μg / ml or 4 μg / ml. [Figure 26A] Figure 1 shows the cell proliferation curve of H1975 cells upon treatment with antibodies. Anti-His IgG was used as a negative control. [Figure 26B] Figure 1 shows the cell proliferation curve of H1975.HGF cells upon treatment with antibodies. Anti-His IgG was used as a negative control. [Figure 26C] Figure 1 shows the cell proliferation curve of C797S-BaF3 cells upon treatment with antibodies. Anti-His IgG was used as a negative control. [Figure 27A]Antibody internalization curves in H1975 cells and calculated IC50 values ​​are shown. Anti-His IgG was used as a negative control. [Figure 27B] Antibody internalization curves and calculated IC50 values ​​in C797S-BaF3 cells are shown. Anti-His IgG was used as a negative control. [Figure 27C] Antibody internalization curves and calculated IC50 values ​​in H1975.HGF cells are shown. Anti-His IgG was used as a negative control. [Figure 27D] Antibody internalization curves and calculated IC50 values ​​in D770-BaF3 cells are shown. Anti-His IgG was used as a negative control. [Figure 28A] Shown are the results of an ADCC assay using H1975.GFP.Luc cells and PBMCs at a target:effector ratio of 1:10. IC50 values ​​were also calculated for each antibody tested. Anti-His IgG was used as a negative control. [Figure 28B] Shown are the results of an ADCC assay using H1975.GFP.Luc.HGF cells and PBMCs at a target:effector ratio of 1:10. IC50 values ​​were also calculated for each antibody tested. Anti-His IgG was used as a negative control. [Figure 29A] The design of the efficacy study is shown. Tumor cell inoculation was performed on day -20. Antibody treatment (Tx) by intraperitoneal injection (IP) was performed on days 0, 4, 8, 12, 15, and 19. Tumor volume (TV) was monitored twice a week after the first treatment. The experiment was terminated on day 26. "Arm" in 4-arm refers to the treatment in the study. "4-arm" refers to the four treatments including the control. [Figure 29B] Group designations, dose levels, and dosing schedules are indicated. [Figure 29C] Absolute median tumor volumes of Balb / c NU / Nu mice inoculated with H1975 tumor cells and then treated with JNJ372 analogs or 1H1cMET / 1A12cMET / EGFR(WT) are shown. DPBS was used as a negative control. [Figure 30A]The design of the efficacy study is shown. Tumor cell inoculation was performed on day -20. Antibody treatment (Tx) by intraperitoneal injection (IP) was performed on days 0, 3, 7, 10, 14, 17, 21, and 24. Tumor volume (TV) was monitored twice a week after the first treatment. The experiment was terminated on day 28. "Arm" in 4-arm refers to the treatment in the study. "4-arm" refers to the four treatments including the control. [Figure 30B] Group designations, dose levels, and dosing schedules are indicated. [Figure 30C] 1 shows the mean tumor volume of Balb / c NU / Nu mice inoculated with H1975-Luc-GFP-HGF tumor cells and then treated with JNJ372 analogs or 1H1cMET / 1A12cMET / EGFR(WT). DPBS was used as a negative control. [Figure 31A] The design of the efficacy study is shown. Tumor cell inoculation was performed on day -20. Antibody treatment (Tx) by intraperitoneal injection (IP) was performed on days 0, 3, 7, 10, 14, and 17. Tumor volume (TV) was monitored twice a week after the first treatment. The experiment was terminated on day 22. "Arm" in 4-arm refers to the treatment in the study. "4-arm" refers to the four treatments including the control. [Figure 31B] Group designations, dose levels, and dosing schedules are indicated. [Figure 31C] 1 shows the mean tumor volume of Balb / c NU / Nu mice inoculated with C797S-BaF3 cells and then treated with JNJ372 analogs or 1H1cMET / 1A12cMET / EGFR(WT). DPBS was used as a negative control. [Figure 32] The CDR sequences of the VHHs derived from the cMET antibodies described in this disclosure are listed below. [Figure 33] The CDR sequences of the heavy chain variable region (VH) of the EGFR antibodies described in this disclosure are listed. [Figure 34] The CDR sequences of the light chain variable region (VL) of the EGFR antibodies described in this disclosure are listed. [Figure 35]The amino acid sequences of VHHs that specifically bind to cMET as described in this disclosure are listed below. [Figure 36] The amino acid sequences of VH and VL that specifically bind to EGFR as described in this disclosure are listed below. [Figure 37-1] The sequences described in this disclosure are listed below. [Figure 37-2] The sequences described in this disclosure are listed below. [Figure 37-3] The sequences described in this disclosure are listed below. [Figure 37-4] The sequences described in this disclosure are listed below. [Figure 37-5] The sequences described in this disclosure are listed below. [Figure 37-6] The sequences described in this disclosure are listed below. [Figure 37-7] The sequences described in this disclosure are listed below. [Figure 37-8] The sequences described in this disclosure are listed below. [Figure 37-9] The sequences described in this disclosure are listed below. [Figure 37-10] The sequences described in this disclosure are listed below. DETAILED DESCRIPTION OF THE INVENTION

[0115] Detailed Description Lung cancer is the leading cause of cancer-related deaths in the United States for both genders. Incidence and mortality rates are highest in developed countries. According to the World Health Organization (WHO), global lung cancer mortality is expected to continue rising, primarily due to increased global tobacco use, particularly in Asia. NSCLC (non-small cell lung cancer) accounts for approximately 85% of all lung cancers. The 5-year overall survival rate for NSCLC remains poor, ranging from 68% in patients with stage IB disease to 0%-10% in patients with stage IVA-IVB disease. Therefore, the development of effective therapeutic agents for NSCLC is essential.

[0116] Treatments for NSCLC can be broadly divided into two categories: immune checkpoint blockade (ICB) and molecular-targeted therapy. Despite significant clinical improvements, ICB can lead to the development of primary and secondary resistance. Molecular-targeted therapy targets oncogenic drivers of cancer. EGFR mutations are the most common targetable oncogenic driver mutations. On the other hand, aberrant c-Met signaling has been detected in many human cancers, including NSCLC. Furthermore, c-Met plays a crucial role in the development of resistance to targeted therapies, including those directed against EGFR. Therefore, simultaneously targeting both EGFR and c-Met may be an effective strategy.

[0117] Over the past 20 years, treatment of NSCLC and lung cancer has generally progressed from cytotoxic therapy to immunotherapy. Early-stage disease can be effectively treated with cytotoxic and surgical methods. However, a high percentage of tumors may recur, resulting in poor survival rates.

[0118] The development of more effective systemic therapies aimed at improving long-term survival rates primarily involves the use of immunotherapy and molecular-targeted therapies. A major advance in the management of advanced NSCLC occurred in 2015 with the approval of nivolumab (an anti-PD-L1, immune checkpoint blocker (ICB)) by the US FDA for patients whose disease progressed during or after platinum-based therapy. Despite significant clinical improvement, most patients ultimately become unresponsive to ICB therapy due to the development of primary or secondary resistance. This may be due to several reasons, including defects in cytokine signaling, MHC complex presentation, or increased levels of enzymes that catabolize tryptophan, which is required for optimal T cell function.

[0119] Molecularly targeted therapy for NSCLC patients began in the late 1990s with the use of gefitinib, an oral EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI). The physiological function of the epidermal growth factor receptor (EGFR) is to regulate the development and homeostasis of epithelial tissues. EGFR is a driver of tumorigenesis in lung and breast cancers, as well as glioblastoma. EGFR mutations are the most common targetable oncogenic drivers, accounting for approximately 25% of NSCLC cases (Kris, MG et al., "Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs." Jama 311.19 (2014): 1998-2006). Activating mutations in EGFR, such as exon 19 del and L858R on exon 21, render the majority of NSCLC tumor cells sensitive to the first-generation EGFR-TKIs gefitinib and erlotinib, as well as the second-generation EGFR-TKIs afatinib and dacomitinib. Of these, 50% of patients with these tumors develop acquired resistance due to the EGFR T790M mutation. This resistance led to the development of the third-generation EGFR-TKI drugs osimertinib (TAGRISSO) and rociletinib. With the widespread use of osimertinib, the EGFR C797S resistance mutation also emerged. In addition to secondary EGFR mutations, bypass mechanisms such as MET or ERBB2 amplification, Hippo pathway inhibition, and insulin-like growth factor 1 receptor (IGF1R) activation also contribute to resistance to EGFR-TKIs.

[0120] Aberrant cMET signaling has been implicated in the development and progression of many human cancers. This can be due to cMET overexpression, activating mutations in cMET, transactivation, autocrine or paracrine signaling, or cMET gene amplification. A significant association between EGFR signaling and cMET signaling has been recognized through studies of cancer treatment outcomes. cMET plays a crucial role in the development of resistance to targeted therapies, including EGFR-directed therapy. Similarly, mutations in EGFR and downstream genes such as KRAS, histological transformation, and activation of alternative pathways, including the cMET signaling pathway, have been identified as mechanisms of resistance to EGFR-targeted therapy. Consequently, blockade of one receptor tends to upregulate the other, leading to resistance to single-agent treatment. cMET amplification and / or high levels of HGF ligand expression have been observed in NSCLC patients with intrinsic or acquired resistance to EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. Conversely, MET-amplified lung cancer cells exposed to cMET inhibitors for extended periods of time develop resistance via the EGFR pathway.

[0121] Due to the signaling crosstalk between EGFR and cMet, combined inhibition of both receptors may lead to improved outcomes for patients with MET- and EGFR-driven cancers. Additionally, simultaneous inhibition may overcome or delay therapeutic resistance compared with blocking only one pathway. Dual inhibition of MET and EGFR has been investigated in advanced cancers using a combination of separate MET and EGFR inhibitors (the bivalent MET antibody emibetuzumab (LY2875358 Eli Lilly)) as monotherapy and in combination with erlotinib. However, the development of bispecific antibodies (BsAbs) against both EGFR and cMET represents a major advance in the treatment of NSCLC. Two leading BsAbs have been tested: LY3164530 from Eli Lilly and JNJ-61186372 (also known as amivantamab; JNJ372) from Janssen Labs and Genmab. Details of LY3164530 and JNJ-61186372 can be found, for example, in PCT / US2013 / 071288; Moores, S.L. et al., "A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors." Cancer research 76.13 (2016): 3942-3953; and Patnaik, A. et al., "A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer." Cancer Chemotherapy and Pharmacology 82.3 (2018): 407-418; each of which is incorporated herein by reference.

[0122] A Phase I clinical trial (ClinicalTrials.gov Identifier: NCT02221882) of the drug LY3164530 began in August 2014 and was completed on March 7, 2017. The primary objective of the trial was to evaluate the safety of LY3164530 in participants with cancer that was progressing and / or had spread to other parts of the body. The drug LY3164530 did not progress to Phase II due to the following reasons: a) lack of predictive markers for testing, b) increased toxicity, c) PK and PD issues, and d) dose adjustments due to adverse events. JNJ-61186372 was produced using Genmab's DuoBody® technology under a collaboration between Genmab and Janssen Biotech, Inc. (Moores, SL et al., "A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors." Cancer research 76.13 (2016): 3942-3953). JNJ-61186372 is being investigated in a Phase II clinical trial for treating non-small cell lung cancer (NSCLC) (ClinicalTrials.gov Identifier: NCT02609776). The trial began on May 24, 2016, with an ongoing trial schedule ending in July 2022. Additionally, the drug has been granted Breakthrough Therapy Designation for the Treatment of Non-Small Cell Lung Cancer by the US FDA.

[0123] The development of tumor-targeting small molecule kinase inhibitors, osimertenib, and BsAbs, such as JNJ61186372, has led to improved progression-free survival for many NSCLC patients. However, there is documented evidence of resistance to JNJ61186372 monotherapy and combination therapy (combined with osimertenib, TAGRISSO) in in vivo mouse models. In a study conducted to identify mechanisms of signaling-based resistance (Goodman, AM et al., "Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers." Molecular Cancer Therapeutics 16.11 (2017): 2598-2608), subcutaneous cell line xenografts were treated with either osimertinib, JNJ-61186372, or a combination for either a short period to determine target inhibition or a longer period to establish resistant tumors. Mass spectrometry-based phosphoproteomic analysis of these resected tumors was then performed to quantify bypass signaling or target reactivation. In short-term studies, osimertenib was found to be more effective than JNJ-61186372, as it had the strongest effect on tumor phosphotyrosine profiles. All tumors treated with osimertenib, regardless of combination treatment, showed higher correlation and were grouped. In contrast, tumors treated with JNJ-61186372 monotherapy showed greater intertumor heterogeneity and poor correlation with either osimertenib monotherapy or combination therapy. Additionally, tumors treated with osimertenib monotherapy showed a pronounced decrease in phosphorylation of EGFR, Shc1, and Gab1, indicating strong on-target inhibition of EGFR compared with modest decreases with JNJ-61186372 monotherapy.

[0124] In the present disclosure, we have created a multispecific antibody (e.g., 1H1-cMET / EGFR-Fc(WT)-V3) that targets both cMET and EGFR. In some embodiments, the antibody's structural format has two VHH domains that bind to cMET, while the primary IgG structure binds to EGFR. Experiments have shown that the multispecific antibody was more effective than a reference control bispecific antibody (e.g., a JNJ372 analog from Janssen labs) in terms of its binding ability to the cMET and / or EGFR receptors. Furthermore, the multispecific antibody described herein can also block the interaction between these receptors and their respective ligands. Functional assays have shown that the multispecific antibody compares favorably with, and in most cases is better than, the JNJ372 analog in successfully inhibiting not only the phosphorylation of the cMET and EGFR receptors but also the phosphorylation of downstream signaling pathways by inhibiting the phosphorylation of ERK and Akt proteins, which are involved in the proliferation, survival, and disruption of apoptosis pathways in cancer cells. The multispecific antibodies were also found to be more effective in complement-dependent cytotoxicity (CDC) compared to the JNJ372 analog. Thus, these data support the development of the multispecific antibodies described herein as drug candidates for patients with lung cancer and other malignancies associated with aberrant EGFR and cMET signaling.

[0125] Also in the present disclosure, a trispecific antibody targeting both cMET and EGFR (e.g., 1H1cMET / 1A12cMET / EGFR(WT)) was created. In some embodiments, the antibody has two separate VHH domains that bind to two different epitopes of cMET, while the primary IgG structure binds to EGFR. Experiments showed that the trispecific antibody was more effective than a reference control bispecific antibody (e.g., the JNJ372 analog from Janssen labs) in terms of its binding ability to the cMET and EGFR receptors. Furthermore, the trispecific antibody can also block the interaction between these receptors and their respective ligands. Functional assays revealed that the trispecific antibody compared favorably with the JNJ372 analog in successfully inhibiting not only the phosphorylation of cMET and EGFR receptors but also the phosphorylation of downstream signaling pathways by inhibiting the phosphorylation of MET and degrading the EGFR protein, which are involved in disrupting cancer cell proliferation, survival, and apoptosis pathways. Additionally, the trispecific antibody showed enhanced receptor internalization compared to the reference. Furthermore, the trispecific antibody was also found to be more effective in antibody-dependent cellular cytotoxicity than the JNJ372 analog. Furthermore, in vivo results showed that the trispecific antibody was more effective in tumor reduction than the JNJ372 analog. Therefore, these data support the development of the trispecific antibody described herein as a drug candidate for patients with lung cancer and other malignancies associated with aberrant EGFR and cMET signaling.

[0126] EGFR and cMET The epidermal growth factor receptor (EGFR, ErbB1, or HER1) is a 170 kDa type 1 transmembrane glycoprotein encoded by the c-erbB1 proto-oncogene. Epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2 / neu (ErbB-2), Herb-3 (ErbB-3), and Herb-4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity can result in cancer. EGFR signaling is initiated by ligand binding, followed by conformational changes, homodimerization or heterodimerization of the receptor with other ErbB family members, and trans-autophosphorylation of the receptor, which initiates a signaling cascade that ultimately affects a wide variety of cellular functions, including cell proliferation and survival. Increased expression or kinase activity of EGFR is associated with a variety of human cancers, making EGFR an attractive target for therapeutic intervention. Increased EGFR gene copy number and protein expression are both associated with favorable response to the EGFR tyrosine kinase inhibitor IRESSA™ (gefitinib) in non-small cell lung cancer.

[0127] c-Met, also known as the tyrosine protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein encoded by the MET gene in humans. The protein possesses tyrosine kinase activity. The primary single-chain precursor protein is posttranslationally cleaved to yield α and β subunits, which disulfide-link to form the mature receptor. Activation of c-Met by its ligand, hepatocyte growth factor (HGF), stimulates many cellular processes, including proliferation, motility, invasion, metastasis, epithelial-mesenchymal transition, angiogenesis / wound healing, and tissue regeneration. While the exact stoichiometry of HGF:c-Met binding is unknown, it is generally believed that two HGF molecules bind to two c-Met molecules, leading to receptor dimerization and autophosphorylation at tyrosines 1230, 1234, and 1235. Ligand-independent c-Met autophosphorylation can also occur due to gene amplification, mutations, or receptor overexpression.

[0128] c-Met is frequently amplified, mutated, or overexpressed in many types of cancer, including gastric, lung, colon, breast, bladder, head and neck, ovarian, prostate, thyroid, pancreatic, and CNS cancers. Missense mutations, typically located in the kinase domain, are commonly found in hereditary papillary renal cell carcinoma (PRCC) and in 13% of sporadic PRCCs (Schmidt et al., Oncogene 18: 2343-2350, 1999). c-Met mutations located in the semaphorin or juxtamembrane domain of c-Met are frequently found in gastric, head and neck, liver, ovarian, NSCLC, and thyroid cancers. c-Met amplification has been detected in brain, colorectal, gastric, and lung cancers and is often correlated with disease progression. Up to 4% and 20% of non-small cell lung cancers (NSCLC) and gastric cancers, respectively, exhibit c-Met amplification. Overexpression of c-Met is also frequently observed in lung cancer. Furthermore, in clinical samples, nearly half of lung adenocarcinomas exhibit high levels of c-Met and HGF, both of which correlate with enhanced tumor growth rate, metastasis, and poor prognosis.

[0129] Nearly 60% of all tumors that become resistant to EGF tyrosine kinase inhibitors either increase c-Met expression, amplify c-Met, or increase HGF, the only known ligand for c-Met, suggesting the existence of a compensatory pathway for EGFR through c-Met. c-Met amplification was first identified in cultured cells that became resistant to the EGFR kinase inhibitor gefitinib and showed enhanced survival through the Her3 pathway. This was further validated in clinical samples, where 9 of 43 patients with acquired resistance to either erlotinib or gefitinib showed c-Met amplification.

[0130] Current small and large molecule therapeutic approaches that antagonize the EGFR and / or c-Met signaling pathways for treatment may be suboptimal due to possible lack of specificity, potential off-target activity, and dose-limiting toxicity that can be encountered with small molecule inhibitors. Typical monospecific bivalent antibodies can result in clustering of membrane-bound receptors and unwanted activation of downstream signaling pathways. Monovalent antibodies (half-arm) with full-length heavy chains add significant complexity and cost to the manufacturing process.

[0131] The binding of a ligand such as EGF to EGFR stimulates receptor dimerization, autophosphorylation, activation of the receptor's internal cytoplasmic tyrosine kinase domain, and the initiation of multiple signal transduction and transactivation pathways involved in DNA synthesis (gene activation) and cell cycle progression or division control.Inhibition of EGFR signal transduction can result in the inhibition of one or more EGFRs.In some embodiments, EGFR ligands include EGF, TGFα, heparin-binding EGF (HB-EGF), amphiregulin (AR), and epiregulum (EPI).

[0132] Binding of HGF to c-Met stimulates receptor dimerization, autophosphorylation, activation of the receptor's internal cytoplasmic tyrosine kinase domain, and initiation of multiple signaling and transactivation pathways involved in the control of DNA synthesis (gene activation) and cell cycle progression or division; inhibition of c-Met signaling can result in the inhibition of one or more c-Met downstream signaling pathways; therefore, neutralizing c-Met can have a variety of effects, including inhibition of cell proliferation and differentiation, angiogenesis, cell motility, and metastasis.

[0133] The roles of EGFR and c-Met in cancer are discussed in, for example, WO2014081954A1, WO2008 / 127710, WO2009 / 111691, WO2009 / 126834, WO2010 / 039248, WO2010 / 115551, and US2009 / 0042906; Engelman et al. "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling." Science 316.5827 (2007): 1039-1043; Bean et al. "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib." Proceedings of the National Academy of Sciences 104.52, all of which are incorporated by reference herein in their entireties. (2007): 20932-20937.

[0134] Heavy chain antibody variable domain (VHH) Monoclonal and recombinant antibodies are important tools in medicine and biotechnology. Like all mammals, camelids (e.g., llamas) can produce conventional antibodies (e.g., IgG1), which consist of two heavy chains and two light chains linked together in a Y-shape by disulfide bonds. However, they also produce two unique subclasses of IgG, also known as heavy-chain antibodies: IgG2 and IgG3. These antibodies consist of only two heavy chains and lack the CH1 region, but still possess an antigen-binding domain at their N-terminus, called a VHH (or nanobody). Conventional Ig requires the association of variable regions from both the heavy and light chains to enable a high degree of diversity in antigen-antibody interactions. Isolated heavy and light chains still exhibit this ability, but with significantly lower affinity compared to paired heavy and light chains. A unique feature of heavy-chain antibodies is the ability of their monomeric antigen-binding region to bind antigens with specificity, affinity, and particularly diversity comparable to conventional antibodies, without the need for pairing with additional regions. This feature is primarily due to several large variations in the amino acid sequences of the variable regions of the two heavy chains, which induce profound conformational changes compared to normal Ig: key substitutions in the variable regions prevent the light chains from binding to the heavy chains, but also prevent the unbound heavy chains from being recycled by immunoglobulin-binding proteins.

[0135] The single variable domains of these antibodies (called VHHs, sdAbs, nanobodies, or heavy-chain antibody variable domains) are the smallest antigen-binding domains produced by the adaptive immune system. The third complementarity-determining region (CDR3) of the variable regions of these antibodies is often found to be twice as long as conventional ones. This results in an increased surface area for interaction with the antigen and increased diversity in antigen-antibody interactions, which compensates for the absence of light chains. VHHs have long complementarity-determining regions 3 (CDR3), allowing them to reach crevices on proteins inaccessible to conventional antibodies, including functionally interesting sites such as the active site of an enzyme or the receptor-binding canyon on the surface of a virus. Furthermore, the additional cysteine ​​residues allow the structure to be more stable, thus increasing the strength of the interaction.

[0136] Compared to conventional antibodies that possess the variable domains (VH and VL) of conventional antibodies, VHHs exhibit numerous advantages, including higher stability, solubility, expression yield, and refolding ability, as well as better in vivo tissue penetration. Furthermore, in contrast to the VH domain of conventional antibodies, VHHs exhibit no intrinsic tendency to bind to light chains. This facilitates the induction of heavy chain antibodies in the presence of functional light chain loci. Furthermore, because VHHs do not bind to VL domains, reshaping VHHs into multispecific antibody constructs is much easier than constructs containing conventional VH-VL pairs or single domains based on VH domains.

[0137] The present disclosure provides, for example, anti-cMET antibodies, modified antibodies thereof, chimeric antibodies thereof, and humanized antibodies thereof. The present disclosure also provides VHHs of these antibodies. These VHHs can be used in various multispecific antibody constructs as described herein.

[0138] The CDR sequences of cMET-1H1 (or 1H1) and cMET-1H1-derived antibodies (e.g., humanized antibodies) comprise the CDRs of the VHH domain as shown in SEQ ID NOs: 1, 2, and 3, respectively. The amino acid sequences of the VHH domains of the cMET-1H1 antibody are shown in SEQ ID NOs: 19, 77, 78, 79, 80, 81, and 84.

[0139] The CDR sequences of cMET-1A12 (or 1A12) and antibodies derived from cMET-1A12 (e.g., humanized antibodies) comprise the CDRs of the VHH domain as shown in SEQ ID NOs: 4, 5, and 6, respectively. The amino acid sequence of the VHH domain of the cMET-1A12 antibody is shown in SEQ ID NO: 20.

[0140] The CDR sequences of cMET-1E9 (or 1E9) and cMET-1E9-derived antibodies (e.g., humanized antibodies) comprise the CDRs of the VHH domain as shown in SEQ ID NOs: 7, 8, and 9, respectively. The amino acid sequence of the VHH domain of the cMET-1E9 antibody is shown in SEQ ID NO: 21.

[0141] The CDR sequences of cMET-1F3 (or 1F3) and cMET-1F3-derived antibodies (e.g., humanized antibodies) comprise the CDRs of the VHH domain as shown in SEQ ID NOs: 10, 11, and 12, respectively. The amino acid sequences of the VHH domains of the cMET-1F3 antibody are shown in SEQ ID NOs: 22, 82, and 83.

[0142] The amino acid sequences of various modified or humanized VHHs are also provided. Because there are various ways to modify or humanize llama antibodies (e.g., the sequences can be modified with various amino acid substitutions), the heavy and light chains of the antibody can have more than one version of the humanized sequence. In some embodiments, the humanized VHH domain is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of any of SEQ ID NOs: 19-22 and 77-84.

[0143] Furthermore, in some embodiments, the antibodies or antigen-binding fragments thereof described herein may also contain one, two, or three VHH domain CDRs selected from the group of SEQ ID NOs: 1-3, SEQ ID NOs: 4-6, SEQ ID NOs: 7-9, and SEQ ID NOs: 10-12.

[0144] In some embodiments, the antibody can have a heavy chain antibody variable domain (VHH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the CDR1 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VHH CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VHH CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VHH CDR3 amino acid sequence. The amino acid sequences of selected VHH CDR1, 2, and 3 are shown in Figure 32.

[0145] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain antibody variable domain (VHH) containing one, two, or three of: a VHH CDR1 with an insertion, deletion, or substitution of 0, 1, or 2 amino acids; a VHH CDR2 with an insertion, deletion, or substitution of 0, 1, or 2 amino acids; and a VHH CDR3 with an insertion, deletion, or substitution of 0, 1, or 2 amino acids, wherein VHH CDR1, VHH CDR2, and VHH CDR3 are selected from the CDRs in Figure 32.

[0146] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain antibody variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 1 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; SEQ ID NO: 2 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; or SEQ ID NO: 3 with 0, 1, or 2 amino acid insertions, deletions, or substitutions.

[0147] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain antibody variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 4 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; SEQ ID NO: 5 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; or SEQ ID NO: 6 with 0, 1, or 2 amino acid insertions, deletions, or substitutions.

[0148] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain antibody variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 7 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; SEQ ID NO: 8 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; or SEQ ID NO: 9 with 0, 1, or 2 amino acid insertions, deletions, or substitutions.

[0149] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain antibody variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 10 with zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 11 with zero, one, or two amino acid insertions, deletions, or substitutions; or SEQ ID NO: 12 with zero, one, or two amino acid insertions, deletions, or substitutions.

[0150] Insertions, deletions, and substitutions can be within the CDR sequence or at one or both ends of the CDR sequence. In some embodiments, CDRs are determined based on the Kabat numbering scheme. In some embodiments, CDRs are determined based on the Chothia numbering scheme. In some embodiments, CDRs are determined based on a combined numbering scheme.

[0151] The present disclosure also provides an antibody or antigen-binding fragment thereof that binds to cMET. The antibody or antigen-binding fragment thereof contains a heavy chain antibody variable domain (VHH) comprising or consisting of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VHH sequence. In some embodiments, the selected VHH sequence is SEQ ID NO: 19. In some embodiments, the selected VHH sequence is SEQ ID NO: 20. In some embodiments, the selected VHH sequence is SEQ ID NO: 21. In some embodiments, the selected VHH sequence is SEQ ID NO: 22. In some embodiments, the selected VHH sequence is SEQ ID NO: 77. In some embodiments, the selected VHH sequence is SEQ ID NO: 78. In some embodiments, the selected VHH sequence is SEQ ID NO: 79. In some embodiments, the selected VHH sequence is SEQ ID NO: 80. In some embodiments, the selected VHH sequence is SEQ ID NO: 81. In some embodiments, the selected VHH sequence is SEQ ID NO: 82. In some embodiments, the selected VHH sequence is SEQ ID NO: 83. In some embodiments, the selected VHH sequence is SEQ ID NO: 84.

[0152] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced into one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap. For illustrative purposes, sequence comparison and determination of the percent identity between two sequences can be accomplished using, for example, a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0153] The present disclosure also provides nucleic acids, including polynucleotides encoding polypeptides comprising immunoglobulin heavy chain antibody variable domains (VHHs), wherein the VHHs comprise CDRs as shown in Figure 32 or have a sequence as shown in Figure 35.

[0154] The antibodies and antigen-binding fragments can also be antibody variants (including derivatives and conjugates) of antibodies or antibody fragments, and multispecific (e.g., bispecific) antibodies or antibody fragments. Additional antibodies provided herein are polyclonal, monoclonal, multispecific (multimeric, e.g., bispecific), human antibodies, chimeric antibodies (e.g., human-mouse chimeras), single-chain antibodies, intracellularly produced antibodies (i.e., intrabodies), and antigen-binding fragments thereof.

[0155] In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc domain, which can originate from various types (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), classes (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclasses. In some embodiments, the Fc domain originates from an IgG antibody or antigen-binding fragment thereof. In some embodiments, the Fc domain comprises one, two, three, four, or more heavy chain constant regions.

[0156] The present disclosure also provides antibodies or antigen-binding fragments thereof that bind to cMET. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain antibody variable domain (VHH) CDR1 selected from SEQ ID NO: 1, 4, 7, or 10. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain antibody variable domain (VHH) CDR2 selected from SEQ ID NO: 2, 5, 8, or 11. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain antibody variable domain (VHH) CDR3 selected from SEQ ID NO: 3, 6, 9, or 12.

[0157] Anti-EGFR antibodies and antigen-binding fragments The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to EGFR. The antibodies and antigen-binding fragments described herein can bind to EGFR. These antibodies can be agonists or antagonists. In some embodiments, these antibodies can inhibit EGFR-related signaling pathways (e.g., block the binding between EGF and EGFR), thus treating cancer (e.g., NSCLC). In some embodiments, these antibodies can initiate CMC or ADCC.

[0158] The present disclosure provides, for example, anti-EGFR antibodies, chimeric antibodies thereof, and humanized antibodies thereof. In some embodiments, the CDR sequences of anti-EGFR antibodies and their derived antibodies (e.g., humanized antibodies) comprise the CDRs of the heavy chain variable domain of SEQ ID NOs: 13, 14, and 15. VHs having these VH CDRs can be paired with VLs having various different VL CDRs. In some embodiments, the CDR sequences of anti-EGFR antibodies and their derived antibodies (e.g., humanized antibodies) comprise the CDRs of the light chain variable domain of SEQ ID NOs: 16, 17, and 18.

[0159] The amino acid sequences of the heavy and light chain variable regions of the humanized antibody are also provided. Because there are various methods for humanizing mouse antibodies (e.g., the sequence can be modified with various amino acid substitutions), the heavy and light chains of the antibody can have more than one version of the humanized sequence. In some embodiments, the humanized heavy chain variable region (VH) is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 23. In some embodiments, the humanized light chain variable region (VL) is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 24.

[0160] The amino acid sequence of the heavy chain variable region of the anti-EGFR antibody is shown in SEQ ID NO: 23. The amino acid sequence of the light chain variable region of the anti-EGFR antibody is shown in SEQ ID NO: 24.

[0161] Furthermore, in some embodiments, the antibodies or antigen-binding fragments thereof described herein can also contain one, two, or three heavy chain variable region CDRs selected from the group of SEQ ID NOs: 13-15; and / or one, two, or three light chain variable region CDRs selected from the group of SEQ ID NOs: 16-18.

[0162] In some embodiments, the antibody a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the CDR1 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VH CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VH CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VH CDR3 amino acid sequence; and A light chain variable region (VL) comprising CDR1, 2, and 3, wherein the CDR1 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VL CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VL CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VL CDR3 amino acid sequence. The amino acid sequences of selected VH CDR1, 2, 3 and selected VL CDR1, 2, 3 are shown in Figure 33 (VH CDR) and Figure 34 (VL CDR).

[0163] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain variable domain containing one, two, or three of the CDRs of SEQ ID NO: 13 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; SEQ ID NO: 14 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; or SEQ ID NO: 15 with 0, 1, or 2 amino acid insertions, deletions, or substitutions.

[0164] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a light chain variable domain containing one, two, or three of the CDRs of SEQ ID NO: 16 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; SEQ ID NO: 17 with 0, 1, or 2 amino acid insertions, deletions, or substitutions; or SEQ ID NO: 18 with 0, 1, or 2 amino acid insertions, deletions, or substitutions.

[0165] Insertions, deletions, and substitutions can be within the CDR sequence or at one or both ends of the CDR sequence. In some embodiments, CDRs are determined based on the Kabat numbering scheme. In some embodiments, CDRs are determined based on the Chothia numbering scheme. In some embodiments, CDRs are determined based on a combined numbering scheme.

[0166] The present disclosure also provides an antibody or antigen-binding fragment thereof that binds to EGFR. The antibody or antigen-binding fragment thereof contains a heavy chain variable region (VH) comprising or consisting of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VH sequence, and a light chain variable region (VL) comprising or consisting of an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to a selected VL sequence. In some embodiments, the selected VH sequence is SEQ ID NO: 23, and the selected VL sequence is SEQ ID NO: 24.

[0167] The present disclosure also provides nucleic acids, including polynucleotides, encoding polypeptides comprising immunoglobulin heavy chains or immunoglobulin light chains. The immunoglobulin heavy chains or immunoglobulin light chains comprise CDRs as shown in Figures 33 and 34, respectively, or have sequences as shown in Figure 36. When the polypeptides are paired with a corresponding polypeptide (e.g., a corresponding heavy chain variable region or a corresponding light chain variable region), the paired polypeptides bind to EGFR (e.g., human EGFR).

[0168] Anti-EGFR antibodies and antigen-binding fragments can also be antibody variants (including derivatives and conjugates) of antibodies or antibody fragments, and multispecific (e.g., bispecific) antibodies or antibody fragments. Additional antibodies provided herein are polyclonal, monoclonal, multispecific (multimeric, e.g., bispecific), human antibodies, chimeric antibodies (e.g., human-mouse chimeras), single-chain antibodies, intracellularly produced antibodies (i.e., intrabodies), and antigen-binding fragments thereof. The antibody or antigen-binding fragment thereof can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. In some embodiments, the antibody or antigen-binding fragment thereof is an IgG antibody or antigen-binding fragment thereof.

[0169] Fragments of antibodies are suitable for use in the provided methods, so long as they retain the desired affinity and specificity of the full-length antibody. Thus, a fragment of an antibody that binds to EGFR will retain the ability to bind to EGFR.

[0170] In one aspect, the present disclosure provides a method for producing a cellular membrane comprising: (1) An immunoglobulin heavy chain or fragment thereof comprising a heavy chain variable region (VH) comprising complementarity-determining regions (CDRs) 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15, respectively, wherein the VH binds to EGFR when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 24; or (2) An immunoglobulin light chain or fragment thereof comprising a VL comprising CDR1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, wherein the VL binds to EGFR when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO: 23. The present invention relates to nucleic acids, including polynucleotides encoding polypeptides comprising:

[0171] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin heavy chain or a fragment thereof, comprising a VH comprising CDR1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15, respectively.

[0172] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin light chain or a fragment thereof, comprising a VL comprising CDR1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively.

[0173] In some embodiments, the VH, when paired with the VL, specifically binds human EGFR, or the VL, when paired with the VH, specifically binds human EGFR.

[0174] In some embodiments, the immunoglobulin heavy chain or fragment thereof is a humanized immunoglobulin heavy chain or fragment thereof, and the immunoglobulin light chain or fragment thereof is a humanized immunoglobulin light chain or fragment thereof.

[0175] In some embodiments, the nucleic acid encodes a single chain variable fragment (scFv). In some embodiments, the nucleic acid is a cDNA.

[0176] In one aspect, the present disclosure relates to a vector comprising one or more of the nucleic acids described herein.In one aspect, the present disclosure relates to a vector comprising two of the nucleic acids described herein, wherein the vectors encode a VL region and a VH region that bind to EGFR together.In one aspect, the present disclosure relates to a pair of vectors, wherein each vector comprises one of the nucleic acids described herein, and the pair of vectors encode a VL region and a VH region that bind to EGFR together.

[0177] In one aspect, the present disclosure relates to a cell comprising a vector or a pair of vectors described herein. In one aspect, the present disclosure relates to two of the nucleic acids described herein.

[0178] In some embodiments, the two nucleic acids encode both a VL region and a VH region that together bind EGFR.

[0179] In one aspect, the present disclosure provides a method for producing a cellular membrane comprising: a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 13, the VH CDR2 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 14, and the VH CDR3 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 15; and A light chain variable region (VL) comprising CDR1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 16, the VL CDR2 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 17, and the VL CDR3 region comprises an amino acid sequence at least 80% identical to SEQ ID NO: 18. The present invention relates to an antibody or antigen-binding fragment thereof that binds to EGFR (epidermal growth factor receptor), comprising:

[0180] In some embodiments, the VH comprises CDR1, 2, 3 having the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, 3 having the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively.

[0181] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that binds to EGFR, comprising a heavy chain variable region (VH) comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 23, and a light chain variable region (VL) comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 24.

[0182] In some embodiments, the VH comprises the sequence of SEQ ID NO:23, and the VL comprises the sequence of SEQ ID NO:24.

[0183] In some embodiments, the antibody or antigen-binding fragment specifically binds to human EGFR.

[0184] In some embodiments, the antibody or antigen-binding fragment is a single-chain variable fragment (scFV).

[0185] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof comprising the VH CDR1, 2, 3 and VL CDR1, 2, 3 of the antibody or antigen-binding fragment thereof as described herein.

[0186] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that cross-competes with an antibody or antigen-binding fragment thereof as described herein.

[0187] In some embodiments, the antibodies described herein are bispecific or multispecific antibodies.

[0188] Structure of the cMET / EGFR bispecific antibody In some embodiments, bispecific antibodies are designed to comprise VHHs that target cMET. Bispecific antibodies are described below.

[0189] cMET (tyrosine-protein kinase Met, or hepatocyte growth factor receptor (HGFR)) is a single-pass tyrosine kinase receptor essential for embryonic development, organogenesis, and wound healing. The present disclosure provides bispecific antibodies that bind to both cMET and EGFR. The bispecific antibodies can be used to treat cMET- or EGFR-positive cancers (e.g., non-small cell lung cancer) in a subject.

[0190] cMET / EGFR bispecific antibodies with particular structures are described below.

[0191] Bispecific-V1 structure As shown in Figure 16A, cMET / EGFR bispecific antibodies can be prepared to have a bispecific-V1 structure. Specifically, cMET / EGFR bispecific antibodies comprise: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH), a first hinge region, and a first Fc region; (b) a second polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a second hinge region, and a second Fc region; and (c) a third polypeptide comprising a light chain variable region (VL). In some embodiments, the first VHH specifically binds to cMET. In some embodiments, the VH and VL associate with each other to specifically bind to EGFR.

[0192] In some embodiments, the first hinge region and / or second hinge region comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29. In some embodiments, the first Fc region and / or second Fc region comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30 or 31.

[0193] In some embodiments, the cMET / EGFR bispecific antibody comprises knob-into-hole mutations. In some embodiments, the Fc region is an IgG1 Fc region. In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 43 or 44. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 45 or 46. In some embodiments, the third polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 47.

[0194] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0195] In some embodiments, the second polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 33. In some embodiments, the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 34.

[0196] Dual specificity - V2 structure As shown in Figure 17A, a cMET / EGFR bispecific antibody can be prepared to have a bispecific-V2 structure. Specifically, the cMET / EGFR bispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH), a first hinge region, and a first Fc region; and (b) a second polypeptide comprising, from N-terminus to C-terminus, a single-chain variable fragment (scFv), a second hinge region, and a second Fc region.

[0197] In some embodiments, the first VHH specifically binds to cMET. In some embodiments, the scFv comprises a heavy chain variable region (VH), a linker peptide sequence, and a light chain variable region (VL). In some embodiments, the VH and VL associate with each other to specifically bind to EGFR.

[0198] In some embodiments, the linker peptide sequence comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the linker peptide sequence comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 38 or 39. In some embodiments, the linker peptide sequence comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37). In some embodiments, the first hinge region and / or the second hinge region comprise a sequence at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30 or 31.

[0199] In some embodiments, the cMET / EGFR bispecific antibody comprises knobs-into-hole mutations. In some embodiments, the Fc region is an IgG1 Fc region. In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 53 or 54. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 55 or 56.

[0200] In some embodiments, the first polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 57 or 58. In some embodiments, the second polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 59 or 60.

[0201] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0202] Bispecific-V3 structure As shown in Figure 18A, a cMET / EGFR bispecific antibody can be prepared to have a bispecific-V3 structure. Specifically, a cMET / EGFR bispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH1), a first linker peptide sequence, a first heavy chain variable region (VH1), a first hinge region, and a first Fc region; (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH2), a second linker peptide sequence, a second heavy chain variable region (VH2), a second hinge region, and a second Fc region; and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other to specifically bind to EGFR, hi some embodiments, VH2 and VL2 associate with each other to specifically bind to EGFR.

[0203] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to SEQ ID NO: 38 or 39. In some embodiments, the first and / or second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0204] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29.

[0205] In some embodiments, the sequences of VHH1 and VHH2 are identical. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 32. In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 61 or 62. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 63. In some embodiments, the third polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 61 or 62. In some embodiments, the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:63.

[0206] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0207] In some embodiments, the first polypeptide and / or the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 33. In some embodiments, the second polypeptide and / or the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 34.

[0208] Bispecific-V4 structure As shown in Figure 19A, a cMET / EGFR bispecific antibody can be prepared to have a bispecific-V4 structure. Specifically, the cMET / EGFR bispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain variable region (VH1), a first hinge region, a first Fc region, a first linker peptide sequence, and a first heavy chain antibody variable domain (VHH1); (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain variable region (VH2), a second hinge region, a second Fc region, a second linker peptide sequence, and a second heavy chain antibody variable domain (VHH2); and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and / or VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other and specifically bind to EGFR.

[0209] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 38 or 39. In some embodiments, the first and / or second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0210] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29.

[0211] In some embodiments, the sequences of VHH1 and VHH2 are identical. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 32. In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 69 or 70. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 71. In some embodiments, the third polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 69 or 70. In some embodiments, the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:71.

[0212] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0213] In some embodiments, the first polypeptide and / or the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 33. In some embodiments, the second polypeptide and / or the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 34.

[0214] In some embodiments, the VHH that specifically binds cMET of a cMET / EGFR bispecific antibody having a bispecific-V1, bispecific-V2, bispecific-V3, or bispecific-V4 structure can be selected from any of the VHHs that target cMET described in this disclosure.

[0215] In some embodiments, the VH of a cMET / EGFR bispecific antibody having a bispecific-V1, bispecific-V2, bispecific-V3, or bispecific-V4 structure that specifically binds EGFR when associated with a VL can be selected from any of the EGFR-targeting VHs described in this disclosure.

[0216] In some embodiments, the VL of a cMET / EGFR bispecific antibody having a bispecific-V1, bispecific-V2, bispecific-V3, or bispecific-V4 structure that, when associated with the VH, specifically binds to EGFR can be selected from any of the EGFR-targeting VLs described in this disclosure.

[0217] Structure of the cMET / EGFR multispecific antibody In some embodiments, multispecific (e.g., trispecific) antibodies are designed to include a VHH that targets cMET. In some embodiments, multispecific (e.g., trispecific) antibodies are designed to include an additional VHH that targets cMET. Multispecific (e.g., trispecific) antibodies are described below.

[0218] cMET (tyrosine-protein kinase Met, or hepatocyte growth factor receptor (HGFR)) is a single-pass tyrosine kinase receptor essential for embryonic development, organogenesis, and wound healing. The present disclosure provides multispecific (e.g., trispecific) antibodies that bind to both cMET and EGFR. The trispecific antibodies can be used to treat cMET- or EGFR-positive cancers (e.g., non-small cell lung cancer) in a subject.

[0219] cMET / EGFR trispecific antibodies with particular structures are described below.

[0220] Triple specificity-V1 structure As shown in Figure 16B, a cMET / EGFR trispecific antibody can be prepared to have a trispecific-V1 structure. Specifically, a cMET / EGFR trispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH), a linker peptide sequence, a first VHH, a first hinge region, and a first Fc region; (b) a second polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a second hinge region, and a second Fc region; and (c) a third polypeptide comprising a light chain variable region (VL). In some embodiments, the first VHH and the second VHH specifically bind to cMET. In some embodiments, the VH and VL associate with each other to specifically bind to EGFR.

[0221] In some embodiments, the first hinge region and / or second hinge region comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29. In some embodiments, the first Fc region and / or second Fc region comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30 or 31.

[0222] In some embodiments, the linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 38 or 39. In some embodiments, the linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0223] In some embodiments, the first polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 48 or 49. In some embodiments, the second polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 50 or 51. In some embodiments, the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 52.

[0224] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0225] In some embodiments, the second polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 33. In some embodiments, the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 34.

[0226] Triple specificity-V2 structure As shown in Figure 17B, a cMET / EGFR trispecific antibody can be prepared to have a trispecific-V2 structure. Specifically, the cMET / EGFR trispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH), a second linker peptide sequence, a first VHH, a first hinge region, and a first Fc region; and (b) a second polypeptide comprising, from N-terminus to C-terminus, a single-chain variable fragment (scFv), a second hinge region, and a second Fc region.

[0227] In some embodiments, the first and second VHHs specifically bind to cMET. In some embodiments, the scFv comprises a heavy chain variable region (VH), a first linker peptide sequence, and a light chain variable region (VL). In some embodiments, the VH and VL associate with each other to specifically bind to EGFR.

[0228] In some embodiments, the first hinge region and / or second hinge region comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29. In some embodiments, the first Fc region and / or second Fc region comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30 or 31.

[0229] In some embodiments, the cMET / EGFR trispecific antibody comprises knobs-into-holes mutations. In some embodiments, the Fc region is an IgG1 Fc region.

[0230] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 38 or 39. In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0231] In some embodiments, the first polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 57 or 58. In some embodiments, the second polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 59 or 60.

[0232] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0233] Triple specificity-V3 structure As shown in Figure 18B, a cMET / EGFR trispecific antibody can be prepared to have a trispecific-V3 structure. Specifically, the cMET / EGFR trispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH1), a first linker peptide sequence, a first heavy chain variable region (VH1), a first hinge region, and a first Fc region; (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH2), a second linker peptide sequence, a second heavy chain variable region (VH2), a second hinge region, and a second Fc region; and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other and specifically bind to EGFR.

[0234] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80% identical to SEQ ID NO: 38 or 39. In some embodiments, the first and / or second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0235] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29.

[0236] In some embodiments, the sequences of VHH1 and VHH2 as described in the trispecific-V3 structure are different. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30 or 31. In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 64 or 65. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 68. In some embodiments, the third polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 66 or 67. In some embodiments, the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:68.

[0237] In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 85. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 68. In some embodiments, the third polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 86. In some embodiments, the fourth polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 68.

[0238] In some embodiments, the Fc region is an IgG1 (e.g., human IgG1) Fc region. In some embodiments, the cMET / EGFR trispecific antibodies described herein comprise knobs-into-hole mutations.

[0239] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0240] In some embodiments, the first polypeptide and / or the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 33. In some embodiments, the second polypeptide and / or the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 34.

[0241] Triple specificity-V4 structure As shown in Figure 19B, a cMET / EGFR trispecific antibody can be prepared to have a trispecific-V4 structure. Specifically, the cMET / EGFR trispecific antibody comprises: (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain variable region (VH1), a first hinge region, a first Fc region, a first linker peptide sequence, and a first heavy chain antibody variable domain (VHH1); (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain variable region (VH2), a second hinge region, a second Fc region, a second linker peptide sequence, and a second heavy chain antibody variable domain (VHH2); and (d) a fourth polypeptide comprising a second light chain variable region (VL2). In some embodiments, VHH1 and / or VHH2 specifically bind to cMET. In some embodiments, VH1 and VL1 associate with each other and specifically bind to EGFR. In some embodiments, VH2 and VL2 associate with each other and specifically bind to EGFR.

[0242] In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the first linker peptide sequence and / or the second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 38 or 39. In some embodiments, the first and / or second linker peptide sequence comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0243] In some embodiments, the first hinge region and / or the second hinge region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 25-29.

[0244] In some embodiments, the sequences of VHH1 and VHH2 as described in the trispecific-V4 structure are different. In some embodiments, the first Fc region and / or the second Fc region comprise a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30 or 31. In some embodiments, the first polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 72 or 73. In some embodiments, the second polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 76. In some embodiments, the third polypeptide comprises a sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 74 or 75. In some embodiments, the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:76.

[0245] In some embodiments, the Fc region is an IgG1 (e.g., human IgG1) Fc region. In some embodiments, the cMET / EGFR trispecific antibodies described herein comprise knobs-into-hole mutations.

[0246] In some embodiments, the first Fc region and / or the second Fc region comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the first Fc region and / or the second Fc region comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0247] In some embodiments, the first polypeptide and / or the third polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 33. In some embodiments, the second polypeptide and / or the fourth polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 34.

[0248] In some embodiments, the VHH that specifically binds to cMET of a cMET / EGFR trispecific antibody having a trispecific-V1, trispecific-V2, trispecific-V3, or trispecific-V4 structure can be selected from any of the VHHs that target cMET described in this disclosure.

[0249] In some embodiments, the VH of a cMET / EGFR trispecific antibody having a trispecific-V1, trispecific-V2, trispecific-V3, or trispecific-V4 structure that specifically binds to EGFR when associated with a VL can be selected from any of the EGFR-targeting VHs described in this disclosure.

[0250] In some embodiments, the VL of a cMET / EGFR trispecific antibody having a trispecific-V1, trispecific-V2, trispecific-V3, or trispecific-V4 structure that, when associated with the VH, specifically binds to EGFR can be selected from any of the EGFR-targeting VLs described in this disclosure.

[0251] Antibody Characteristics An anti-cMET, anti-EGFR, or anti-cMET / EGFR antigen-binding protein construct (e.g., an antibody, bispecific antibody, trispecific antibody, multispecific antibody, or antibody fragment thereof) can comprise an antigen-binding site derived from any anti-cMET antibody, anti-EGFR antibody, or any antigen-binding fragment thereof, as described herein.

[0252] In some embodiments, the antibody or antigen-binding fragment thereof described herein is an EGFR antagonist. In some embodiments, the antibody or antigen-binding fragment thereof is an EGFR agonist. In some embodiments, the antibody or antigen-binding fragment thereof described herein is a cMET antagonist. In some embodiments, the antibody or antigen-binding fragment thereof is a cMET agonist.

[0253] In some embodiments, the antibodies or antigen-binding fragments thereof described herein are capable of binding to cMET and / or EGFR, thereby blocking the interaction of these receptors with their respective ligands; reducing phosphorylation of cMET and / or EGFR; reducing phosphorylation of downstream signaling pathways (e.g., the ERK and / or Akt pathways); and / or directly killing cancer cells by ADCC and / or CDC.

[0254] In some embodiments, the antibodies or antigen-binding fragments thereof described herein have a cMET binding ability (e.g., as measured by ELISA) that is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 100%, at least or about 110%, at least or about 120%, at least or about 130%, at least or about 140%, at least or about 150%, or at least or about 200% of that of JNJ-372 or a JNJ-372 analog.

[0255] In some embodiments, the antibodies or antigen-binding fragments thereof described herein have an EGFR binding ability (e.g., as measured by ELISA) that is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 70%, at least or about 80%, at least or about 90%, at least 100% or about 100%, at least 110% or about 110%, at least 120% or about 120%, at least 130% or about 130%, at least 140% or about 140%, at least 150% or about 150%, or at least 200% or about 200% of that of JNJ-372 or a JNJ-372 analog.

[0256] In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to cMET is less than or about 50 ng / ml, less than or about 40 ng / ml, less than or about 40 ng / ml, less than or about 30 ng / ml, less than or about 20 ng / ml, less than or about 15 ng / ml, less than or about 10 ng / ml, less than or about 9 ng / ml, less than or about 8 ng / ml, less than or about 7 ng / ml, less than or about 6 ng / ml, less than or about 5 ng / ml, less than or about 4 ng / ml, less than or about 3 ng / ml, less than or about 2 ng / ml, less than or about 1 ng / ml. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to cMET is between about 1 ng / ml and about 20 ng / ml, between about 1 ng / ml and about 10 ng / ml, or between about 5 ng / ml and about 10 ng / ml.

[0257] In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for blocking cMET / HGF interaction is less than or about 1 nM, less than or about 0.9 nM, less than or about 0.8 nM, less than or about 0.8 nM, less than or about 0.7 nM, less than or about 0.6 nM, less than or about 0.5 nM, less than or about 0.4 nM, less than or about 0.4 nM, or less than or about 0.3 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for blocking cMET / HGF interaction is about 0.1 nM to about 1 nM, about 0.1 nM to about 0.8 nM, or about 0.1 nM to about 0.6 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for blocking cMET / HGF interaction is less than 80%, less than 70%, less than 60%, less than 50%, or less than 40% of the EC50 of JNJ372 or a JNJ372 analog using a substantially identical assay.

[0258] In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to EGFR is less than or about 50 ng / ml, less than or about 40 ng / ml, less than or about 30 ng / ml, less than or about 20 ng / ml, less than or about 15 ng / ml, less than or about 10 ng / ml, less than or about 9 ng / ml, less than or about 8 ng / ml, less than or about 7 ng / ml, less than or about 6 ng / ml, less than or about 5 ng / ml, less than or about 4 ng / ml, less than or about 3 ng / ml, less than or about 2 ng / ml, or less than or about 1 ng / ml. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to EGFR is between about 1 ng / ml and about 20 ng / ml, between about 1 ng / ml and about 15 ng / ml, between about 1 ng / ml and about 10 ng / ml, or between about 5 ng / ml and about 10 ng / ml.

[0259] In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for blocking EGFR / EGF interaction is less than or about 1 nM, less than or about 0.9 nM, less than or about 0.8 nM, less than or about 0.8 nM, less than or about 0.7 nM, less than or about 0.6 nM, less than or about 0.5 nM, less than or about 0.4 nM, less than or about 0.4 nM, or less than or about 0.3 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for blocking EGFR / EGF interaction is about 0.2 nM to about 1 nM, about 0.2 nM to about 0.8 nM, or about 0.2 nM to about 0.6 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for blocking EGFR / EGF interaction is less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 3% of the EC50 of JNJ372 or a JNJ372 analog using a substantially identical assay.

[0260] In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to an NSCLC cell (e.g., any one of the NSCLC cells described herein) is less than or about 1 nM, less than or about 0.9 nM, less than or about 0.9 nM, less than or about 0.8 nM, less than or about 0.8 nM, less than or about 0.7 nM, less than or about 0.7 nM, less than or about 0.6 nM, less than or about 0.6 nM, less than or about 0.5 nM, less than or about 0.5 nM, less than or about 0.4 nM, less than or about 0.4 nM, less than or about 0.3 nM, less than or about 0.2 nM, less than or about 0.15 nM, less than or about 0.14 nM, less than or about 0.13 nM, less than or about 0.1 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to NSCLC cells is about 0.1 nM to about 1 nM, about 0.1 nM to about 0.5 nM, about 0.1 nM to about 0.2 nM, or about 0.1 nM to about 0.15 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to NSCLC cells is less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the EC50 of JNJ372 or a JNJ372 analog using a substantially identical assay.

[0261] In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for inhibiting proliferation of NSCLC cells (e.g., any one of the NSCLC cells described herein) is less than or about 2 nM, less than or about 1.5 nM, less than or about 1 nM, less than or about 1 nM, less than or about 0.9 nM, less than or about 0.9 nM, less than or about 0.8 nM, less than or about 0.8 nM, less than or about 0.7 nM, less than or about 0.7 nM, less than or about 0.6 nM, less than or about 0.5 nM, less than or about 0.4 nM, less than or about 0.3 nM, less than or about 0.2 nM, less than or about 0.2 nM, less than or about 0.1 nM, less than or about 0.05 nM, less than or about 0.05 nM, less than or about 0.04 nM, less than or about 0.03 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for inhibiting proliferation of NSCLC cells is about 0.03 nM to about 2 nM, about 0.03 nM to about 1 nM, or about 0.03 nM to about 0.3 nM. In some embodiments, the EC50 of an antibody or antigen-binding fragment thereof described herein for binding to NSCLC cells is less than 20%, less than 10%, less than 5%, less than 3%, less than 1%, less than 0.5%, less than 0.1%, less than 0.05%, or less than 0.01% of the EC50 of JNJ372 or a JNJ372 analog using a substantially identical assay.

[0262] In some embodiments, the IC50 of an antibody or antigen-binding fragment thereof described herein for inducing internalization is less than or about 0.5 nM, less than or about 0.4 nM, less than or about 0.3 nM, less than or about 0.3 nM, less than or about 0.2 nM, less than or about 0.15 nM, less than or about 0.1 nM, less than or about 0.1 nM, less than or about 0.09 nM, less than or about 0.09 nM, less than or about 0.08 nM, less than or about 0.08 nM, less than or about 0.07 nM, less than or about 0.06 nM, less than or about 0.06 nM, less than or about 0.05 nM, less than or about 0.02 nM, less than or about 0.02 nM. In some embodiments, the IC50 of an antibody or antigen-binding fragment thereof described herein for inducing internalization is about 0.01 nM to about 0.1 nM, about 0.01 nM to about 0.05 nM, or about 0.05 nM to about 0.1 nM. In some embodiments, the IC50 of an antibody or antigen-binding fragment thereof described herein for inducing internalization is less than 70%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 3% of the IC50 of JNJ372 or a JNJ372 analog using a substantially identical assay.

[0263] In some embodiments, the antibodies or antigen-binding fragments thereof described herein have better effector function (e.g., ADCC effect) than JNJ372 or a JNJ372 analog in NSCLC cells (e.g., H1975 cells).

[0264] In some embodiments, the antibodies or antigen-binding fragments thereof described herein have better cancer cell killing efficacy than JNJ372 or JNJ372 analogs in NSCLC cell transplant animal models.

[0265] In some embodiments, the antibodies or antigen-binding fragments thereof described herein can block the interaction of cMET with a cMET ligand (e.g., HGF). In some embodiments, the antibodies or antigen-binding fragments thereof reduce the binding of cMET to a cMET ligand (e.g., HGF) by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to that of an isotype control antibody or JNJ-372 or a JNJ-372 analog. In some embodiments, the antibody or antigen-binding fragment thereof has a cMET / HGF blocking ability (e.g., as measured by ELISA) that is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 100%, at least or about 110%, at least or about 120%, at least or about 130%, at least or about 140%, at least or about 150%, or at least or about 200% compared to that of JNJ-372 or a JNJ-372 analog.

[0266] In some embodiments, the antibodies or antigen-binding fragments thereof described herein can block the interaction of EGFR with an EGFR ligand (e.g., EGF). In some embodiments, the antibodies or antigen-binding fragments thereof reduce the binding of EGFR to an EGFR ligand (e.g., EGF) by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to that of an isotype control antibody or JNJ-372 or a JNJ-372 analog. In some embodiments, the antibody or antigen-binding fragment thereof has an EGFR / EGF blocking ability (e.g., as measured by an immunofluorescence assay as described herein) that is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 100%, at least or about 110%, at least or about 120%, at least or about 130%, at least or about 140%, at least or about 150%, or at least or about 200% compared to that of JNJ-372 or a JNJ-372 analog.

[0267] In some embodiments, the antibodies or antigen-binding fragments thereof described herein reduce the phosphorylation (e.g., HGF-induced phosphorylation) level of cMET in cells (e.g., cMET-expressing cells) by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to that of a non-specific antibody, an isotype control antibody, JNJ372, or a JNJ372 analog. In some embodiments, after treatment with the antibody or antigen-binding fragment thereof, the percentage of cells containing phosphorylated cMET (e.g., as measured by FACS as described herein) is less than or about 50%, less than or about 60%, less than or about 70%, less than or about 80%, less than or about 90%, less than or about 100%, less than or about 110%, less than or about 120%, less than or about 130%, less than or about 140%, less than or about 150%, or less than or about 200% compared to that after treatment with JNJ-372 or a JNJ-372 analog. In some embodiments, after treatment with the antibody or antigen-binding fragment thereof, the percentage of cells containing phosphorylated cMET (e.g., as measured by FACS as described herein) is less than or about 6%, less than or about 5%, less than or about 4%, less than or about 3%, less than or about 2%, or less than or about 1%.

[0268] In some embodiments, the antibodies or antigen-binding fragments thereof described herein reduce the level of phosphorylation (e.g., EGF-induced phosphorylation) of EGFR in a cell (e.g., an EGFR-expressing cell) by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to that of a non-specific antibody, an isotype control antibody, JNJ372, or a JNJ-372 analog. In some embodiments, cells (e.g., EGFR-expressing cells) treated with the antibody or antigen-binding fragment thereof have a percentage of phosphorylated EGFR (e.g., as measured by ELISA as described herein) that is less than or about 90%, less than or about 80%, less than or about 80%, less than or about 70%, less than or about 60%, less than or about 60%, less than or about 50%, less than or about 40%, less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, compared to that of cells treated with JNJ-372 or a JNJ-372 analog.

[0269] In some embodiments, the antibodies or antigen-binding fragments thereof described herein reduce the phosphorylation level of downstream signaling pathways involved in cancer cell proliferation, survival, and / or apoptosis. In some embodiments, the antibodies or antigen-binding fragments thereof described herein reduce the phosphorylation level of ERK in cells (e.g., cMET- or EGFR-expressing cells) by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to that of a nonspecific antibody, an isotype control antibody, JNJ372, or a JNJ372 analog. In some embodiments, cells (e.g., cMET- or EGFR-expressing cells) treated with the antibody or antigen-binding fragment thereof have a ratio of phosphorylated ERK to total ERK (e.g., as measured by ELISA as described herein) of less than or about 90%, less than or about 80%, less than or about 80%, less than or about 70%, less than or about 70%, less than or about 60%, less than or about 60%, less than or about 50%, less than or about 40%, less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, compared to that of cells treated with JNJ-372 or a JNJ-372 analog. In some embodiments, cells (e.g., cMET- or EGFR-expressing cells) treated with the antibody or antigen-binding fragment thereof have a β-glucanase activity of less than or about 0.95, less than or about 0.95, less than or about 0.90, less than or about 0.90, less than or about 0.85, less than or about 0.80, less than or about 0.80, less than or about 0.75, less than or about 0.75, less than or about 0.75, less than or about 0.70, less than or about 0.65, less than or about 0.60, less than or about 0.60, less than or about 0.55, have a ratio of phosphorylated ERK to total ERK (e.g., as measured by ELISA as described herein) of less than or about 0.50, less than or about 0.45, less than or about 0.40, less than or about 0.40, less than or about 0.35, less than or about 0.30, less than or about 0.25, less than or about 0.20, less than or about 0.20, less than or about 0.15, less than or about 0.10, less than or about 0.05.

[0270] In some embodiments, the antibodies or antigen-binding fragments thereof described herein reduce the phosphorylation level of Akt in cells (e.g., cMET- or EGFR-expressing cells) by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% compared to that of a nonspecific antibody, an isotype control antibody, JNJ372, or a JNJ-372 analog. In some embodiments, cells (e.g., cMET- or EGFR-expressing cells) treated with the antibody or antigen-binding fragment thereof have a percentage of phosphorylated Akt (e.g., as measured by ELISA as described herein) that is less than or about 90%, less than or about 80%, less than or about 80%, less than or about 70%, less than or about 70%, less than or about 60%, less than or about 60%, less than or about 50%, less than or about 40%, less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, compared to that of cells treated with JNJ-372 or a JNJ-372 analog. In some embodiments, cells (e.g., cMET- or EGFR-expressing cells) treated with the antibody or antigen-binding fragment thereof have a IL-1 / IL-2 ... have a ratio of phosphorylated Akt to total Akt (e.g., as measured by ELISA as described herein) of less than or about 0.45, less than or about 0.40, less than or about 0.40, less than or about 0.35, less than or about 0.35, less than or about 0.30, less than or about 0.25, less than or about 0.20, less than or about 0.20, less than or about 0.15, less than or about 0.12, less than or about 0.12, less than or about 0.10, less than or about 0.08, less than or about 0.06.

[0271] In some embodiments, the antibody (or antigen-binding fragment thereof) is -1 Less than 0.01 s -1 Less than 0.001 s -1 Less than 0.0001 s -1 Less than, or 0.00001 seconds -1 Specifically binds to an antigen (e.g., a cancer antigen) with a k of less than 0.01 s. In some embodiments, the k is less than 0.01 s. -1 Greater than or equal to 0.001 s -1 Greater than or equal to 0.0001 s -1 Greater than or equal to 0.00001 s -1 Greater than or 0.000001 s -1 In some embodiments, the kinetic binding rate (k) is greater than 1×10 2 / Ms or greater than 1×10 3 / Ms or greater than 1×10 4 / Ms or greater than 1×10 5 / Ms or greater than 2 × 10 5 / Ms or greater than 2.2 × 10 5 / Ms or greater than 2.4 × 10 6 In some embodiments, the kinetic binding rate (k) is greater than 1×10 5 / Ms less than 1 × 10 6 / Ms or less than 1 × 10 7 / Ms is less than.

[0272] Affinity can be inferred from the quotient of the kinetic rate constants (Kd=koff / kon). In some embodiments, Kd is greater than or equal to 1×10 -4 Less than M, 1 x 10 -5 Less than M, 1 x 10 -6 Less than M, 1 x 10 -7 Less than M, 1 x 10 -8 Less than M, 1 x 10 -9 Less than M or 1 x 10 -10In some embodiments, the Kd is less than 50 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. In some embodiments, the Kd is less than 1 x 10 -4 Larger than M or 1 x 10 -5 Larger than M or 1 x 10 -6 Larger than M or 1 x 10 -7 Larger than M or 1 x 10 -8 Larger than M or 1 x 10 -9 Larger than M or 1 x 10 -10 Larger than M or 1 x 10 -11 Greater than M or 1 x 10 -12 is greater than M. Furthermore, Ka can be deduced from Kd by the formula Ka=1 / Kd.

[0273] In some embodiments, the binding affinity to cMET or EGFR is carefully tuned, e.g., the Kd can be between 100 nM and 0.1 nM, between 100 nM and 1 nM, between 100 nM and 10 nM, between 10 nM and 0.1 nM, between 10 nM and 1 nM, or between 1 nM and 0.1 nM.

[0274] Common techniques for measuring the affinity of an antibody for an antigen include, for example, ELISA, RIA, and surface plasmon resonance (SPR).

[0275] In some embodiments, the antibody has a tumor growth inhibition percentage (TGI%) that is greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. In some embodiments, the antibody has a tumor growth inhibition percentage that is less than 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. TGI% can be measured, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days after treatment begins, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after treatment begins. As used herein, tumor growth inhibition percentage (TGI%) is calculated using the following formula: TGI(%)=[1-(Ti-T0) / (Vi-V0)]×100 Ti is the mean tumor volume in the treatment group on day i. T0 is the mean tumor volume in the treatment group on day 0. Vi is the mean tumor volume in the control group on day i. V0 is the mean tumor volume in the control group on day 0.

[0276] In some embodiments, an antibody or antigen-binding fragment thereof described herein has antibody-dependent cell-mediated cytotoxicity (ADCC) that is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 100%, at least or about 110%, at least or about 120%, at least or about 130%, at least or about 140%, at least or about 150%, or at least or about 200% compared to that of a reference antibody (e.g., JNJ372 or a JNJ-372 analog). In some embodiments, the antibodies or antigen-binding fragments thereof described herein can increase antibody-dependent cell-mediated cytotoxicity (ADCC) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, 20-fold, or 100-fold compared to that of a non-specific antibody control or an isotype antibody control.

[0277] In some embodiments, an antibody or antigen-binding fragment thereof described herein has complement dependent cytotoxicity (CDC) that is at least or about 50%, at least or about 60%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 100%, at least or about 110%, at least or about 120%, at least or about 130%, at least or about 140%, at least or about 150%, or at least or about 200% compared to that of a reference antibody (e.g., JNJ372 or a JNJ372 analog). In some embodiments, the antibodies or antigen-binding fragments thereof described herein can increase complement dependent cytotoxicity (CDC) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, 20-fold, or 100-fold compared to that of a non-specific antibody control or an isotype antibody control.

[0278] In some embodiments, the antibodies or antigen-binding fragments thereof described herein have a cell killing IC50 of less than or about 1000 ng / ml, less than or about 500 ng / ml, less than or about 400 ng / ml, less than or about 300 ng / ml, less than or about 250 ng / ml, less than or about 200 ng / ml, or less than or about 100 ng / ml. In some embodiments, an antibody or antigen-binding fragment thereof described herein has a cell killing IC50 value that is less than or about 50%, less than or about 60%, less than or about 60%, less than or about 70%, less than or about 70%, less than or about 80%, less than or about 80%, less than or about 90%, less than or about 100%, less than or about 110%, less than or about 120%, less than or about 120%, less than or about 130%, less than or about 140%, less than or about 150%, less than or about 200% compared to that of a reference antibody (e.g., JNJ372 or a JNJ372 analog). In some embodiments, the antibodies or antigen-binding fragments thereof described herein have a cell killing IC50 value that is less than or about 20%, less than or about 10%, less than or about 10%, less than or about 8%, less than or about 5%, less than or about 3%, less than or about 1%, compared to that of an isotype control antibody.

[0279] In some embodiments, the antibody or antigen-binding fragment can increase the internalization rate of cMET, EGFR, and / or the cMET / EGFR complex by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold compared to that of a control antibody (e.g., JNJ372 or a JNJ372 analog) or an isotype control antibody.

[0280] In some embodiments, a trispecific antibody described herein (e.g., 1H1-cMET / EGFR-Fc(WT)-V3 Tri) can increase the percentage of cells containing internalized cMET, EGFR, and / or cMET / EGFR complexes by at least or about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to that of a bispecific antibody described herein (e.g., 1H1-cMET / EGFR-Fc(WT)-V3), a reference antibody (e.g., JNJ372 or a JNJ372 analog), or an isotype control antibody. In some embodiments, an antibody or antigen-binding fragment thereof described herein can induce internalization of cMET, EGFR, and / or cMET / EGFR complex in at least or about 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% of cells.

[0281] In some embodiments, internalization of cMET, EGFR, and / or the cMET / EGFR complex induced by an antibody or antigen-binding fragment thereof can further reduce the interaction of cMET with a cMET ligand (e.g., HGF) and / or the interaction of EGFR with an EGFR ligand (e.g., EGF).

[0282] In some embodiments, the antibody or antigen-binding fragment can increase the phagocytosis rate by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold compared to that of a reference antibody (e.g., JNJ372 or a JNJ372 analog) or an isotype control.

[0283] In some embodiments, the antibody or antigen-binding fragment has a functional Fc region. In some embodiments, the effector function of the functional Fc region is antibody-dependent cell-mediated cytotoxicity (ADCC). In some embodiments, the effector function of the functional Fc region is phagocytosis. In some embodiments, the effector function of the functional Fc region is ADCC and phagocytosis. In some embodiments, the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4.

[0284] In some embodiments, the antibody or antigen-binding fragment is capable of inducing apoptosis.

[0285] In some embodiments, the antibody or antigen-binding fragment does not have a functional Fc region, e.g., the antibody or antigen-binding fragment is a Fab, Fab', F(ab')2, and Fv fragment.

[0286] In some embodiments, the antibody or antigen-binding fragment is a humanized antibody. The humanization percentage refers to the percentage identity of the heavy or light chain variable region sequence compared to the human antibody sequences in the International Immunogenetics Information System (IMGT) database. A top hit means that the heavy or light chain variable region sequence is closer to a particular species than to other species. For example, a top hit with humans means that the sequence is closer to humans than to other species. A top hit with humans and cynomolgus monkeys (Macaca fascicularis) means that the sequence has the same identity percentage with the human sequence and the cynomolgus monkey sequence, and these identity percentages are the highest compared to the sequences of other species. In some embodiments, the humanization percentage is greater than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. Detailed descriptions of methods for determining the humanization percentage and methods for determining the top hits are known in the art and are described, for example, in Jones, et al. "The INNs and outs of antibody nonproprietary names," MAbs. Vol. 8. No. 1. Taylor & Francis, 2016, the entire contents of which are incorporated herein by reference. A high humanization percentage often has various advantages, such as being safer and more effective in humans, more likely to be tolerated by human subjects, and / or less likely to have side effects.

[0287] In some embodiments, a multispecific antibody, including a bispecific antibody described herein (e.g., a cMET / EGFR bispecific antibody) or a trispecific antibody described herein (e.g., a cMET / EGFR trispecific antibody), has an asymmetric structure comprising two, three, four, five, or six antigen-binding sites. In some embodiments, a multispecific antibody described herein comprises two, three, four, five, or six antigen-binding sites (e.g., antigen-binding Fab domains, scFVs, or nanobodies (VHHs)) that target a cancer antigen (e.g., cMET or EGFR). In some embodiments, a multispecific antibody described herein (e.g., a cMET / EGFR bispecific antibody or a cMET / EGFR trispecific antibody) comprises at least two, three, four, five, six, or seven common light chains. In some embodiments, at least two, three, four, five, six, or seven common light chains have the same VL sequence. In some embodiments, at least two, three, four, five, six, or seven common light chains have different VL sequences. In some embodiments, the cancer antigen (e.g., cMET or EGFR)-binding Fab domains comprise the same VH sequence. In some embodiments, the cancer antigen (e.g., cMET or EGFR)-binding Fab domains comprise different VH sequences. In some embodiments, the C-terminus of a cancer antigen-binding Fab domain is connected (e.g., covalently or chemically connected) to the N-terminus of an adjacent cancer antigen-binding Fab domain within the same multispecific antibody.

[0288] The present disclosure also provides antibodies or antigen-binding fragments thereof that cross-compete with any of the antibodies or antigen-binding fragments described herein. Cross-competition assays are known in the art and are described, for example, in Moore et al., "Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein," Journal of Virology 70.3 (1996): 1863-1872, the entire contents of which are incorporated herein by reference. In one aspect, the present disclosure also provides antibodies or antigen-binding fragments thereof that bind to the same epitope or region as any of the antibodies or antigen-binding fragments described herein. Epitope binning assays are known in the art and are described, for example, in Estep et al., "High throughput solution-based measurement of antibody-antigen affinity and epitope binning," MAbs. Vol. 5, No. 2, Taylor & Francis, 2013, the entire contents of which are incorporated herein by reference.

[0289] Antibodies and antigen-binding fragments The present disclosure provides antibodies and antigen-binding fragments thereof comprising the complementarity-determining regions (CDRs), heavy chain variable regions, light chain variable regions, heavy chains, or light chains described herein. In some embodiments, the antibodies and antigen-binding fragments thereof are unbalanced bispecific antibodies and antigen-binding fragments thereof.

[0290] Generally, antibodies (also called immunoglobulins) are composed of two classes of polypeptide chains: light chains and heavy chains. Non-limiting antibodies of the present disclosure can be intact four-immunoglobulin chain antibodies, including two heavy chains and two light chains. The heavy chains of the antibodies can be of any isotype, including IgM, IgG, IgE, IgA, or IgD, or subisotypes, including IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc. The light chains can be kappa or lambda light chains. An antibody can include two identical copies of light chains and / or two identical copies of heavy chains. The heavy chains each contain one variable domain (or variable region, VH) and multiple constant domains (or constant regions), which are bound to each other via disulfide bonds within the constant domains to form the "stem" of the antibody. Each light chain contains one variable domain (or variable region, VL) and one constant domain (or constant region), which are each bound to one heavy chain via disulfide bonds. The variable region of each light chain is aligned with the variable region of the heavy chain to which it is bound. Both the light and heavy chain variable regions contain three hypervariable regions flanked by more conserved framework regions (FR).

[0291] These hypervariable regions, known as complementarity-determining regions (CDRs), form loops that constitute the major antigen-binding surface of an antibody. The four framework regions largely adopt a β-sheet conformation, and the CDRs form loops that connect, and in some cases form part of, the β-sheet structure. The CDRs in each chain are held in close proximity by the framework regions and, together with the CDRs from the other chain, contribute to the formation of the antigen-binding region.

[0292] Methods for identifying CDR regions of antibodies by analyzing their amino acid sequences are well known, and a number of CDR definitions are commonly used: the Kabat definition is based on sequence variability, and the Chothia definition is based on the location of structural loop regions. These methods and definitions are described, for example, in Martin, "Protein sequence and structure analysis of antibody variable domains," Antibody engineering, Springer Berlin Heidelberg, 2001. 422-439; Abhinandan, et al. "Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains," Molecular immunology 45.14 (2008): 3832-3839; Wu, TT and Kabat, EA (1970) J. Exp. Med. 132: 211-250; Martin et al., Methods Enzymol. 203:121-53 (1991); Morea et al., Biophys Chem. 68(1-3):9-16 (Oct. 1997); Morea et al., J. Mol. Biol. 275(2):269-94 (Jan. .1998); Chothia et al., Nature 342(6252):877-83 (Dec. 1989); Ponomarenko and Bourne, BMC Structural Biology 7:64 (2007); Kontermann, R., & Dubel, S. (Eds.). (2010). Antibody engineering: Volume 2. Springer; each of which is incorporated herein by reference in its entirety. In some embodiments, the CDRs are based on the Kabat definition. In some embodiments, the CDRs are based on the Chothia definition.In some embodiments, the CDR is the longest CDR sequence as determined by the Kabat, Chothia, AbM, IMGT, or contact definition.

[0293] CDR is important for recognizing the epitope of antigen.As used herein, " epitope " is the smallest part of target molecule that the antigen binding domain of antibody can specifically bind.The smallest size of epitope can be about 3, 4, 5, 6 or 7 amino acids, but these amino acids do not need to be in the continuous linear sequence of the primary structure of antigen, because epitope can depend on the three-dimensional arrangement of antigen based on the secondary structure and tertiary structure of antigen.

[0294] In some embodiments, antibodies are intact immunoglobulin molecules (e.g., IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA). The IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved and differ in their constant regions, particularly the hinge and upper CH2 domains. The sequences and differences between IgG subclasses are known in the art and are described, for example, in Vidarsson, et al., "IgG subclasses and allotypes: from structure to effector functions." Frontiers in immunology 5 (2014); Irani, et al. "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases." Molecular immunology 67.2 (2015): 171-182; Shakib, Farouk, ed. The human IgG subclasses: molecular analysis of structure, function and regulation. Elsevier, 2016; each of which is incorporated herein by reference in its entirety.

[0295] An antibody can also be an immunoglobulin molecule from any species (e.g., human, rodent, mouse, rat, camelid). Antibodies disclosed herein also include, but are not limited to, polyclonal, monoclonal, monospecific, multispecific antibodies, and chimeric antibodies comprising an immunoglobulin binding domain fused to another polypeptide. The term "antigen-binding domain" or "antigen-binding fragment" refers to a portion of an antibody that retains the specific binding activity of the intact antibody, i.e., any portion of an antibody that can specifically bind to an epitope on the intact antibody's target molecule. It includes, for example, Fab, Fab', F(ab')2, and variants of these fragments. Thus, in some embodiments, an antibody or antigen-binding fragment thereof can be, for example, an scFv, Fv, Fd, dAb, diabody, bispecific antibody, bispecific scFv, diabody, linear antibody, single-chain antibody molecule, multispecific antibody formed from antibody fragments, and any polypeptide comprising a binding domain that is or is homologous to an antibody binding domain. Non-limiting examples of antigen-binding domains include, for example, the heavy and / or light chain CDRs of an intact antibody, the heavy and / or light chain variable regions of an intact antibody, the full-length heavy or light chain of an intact antibody, or individual CDRs from either the heavy or light chain of an intact antibody.

[0296] In some embodiments, the scFV has two heavy chain variable domains and two light chain variable domains. In some embodiments, the scFV has two antigen-binding regions (antigen-binding regions: A and B), which can bind to their respective target antigens with different affinities.

[0297] In some embodiments, the antigen-binding fragment can form part of a chimeric antigen receptor (CAR). In some embodiments, the chimeric antigen receptor is a fusion of a single-chain variable fragment (scFv) as described herein fused to the CD3-zeta transmembrane domain and endodomain. In some embodiments, the chimeric antigen receptor also contains intracellular signaling domains from various costimulatory protein receptors (e.g., CD28, 41BB, ICOS). In some embodiments, the chimeric antigen receptor contains multiple signaling domains, e.g., CD3z-CD28-41BB or CD3z-CD28-OX40, to increase efficacy. Thus, in one aspect, the present disclosure further provides cells (e.g., T cells) expressing the chimeric antigen receptor as described herein.

[0298] In some embodiments, the antibody or antigen-binding fragment thereof is capable of binding to two different antigens or two different epitopes, hi some embodiments, the antibody or antigen-binding fragment thereof is capable of binding to three different antigens or three different epitopes.

[0299] An Fv fragment is an antibody fragment that contains the complete antigen recognition and binding site. This region consists of a dimer of one tightly associated heavy-chain variable domain and one light-chain variable domain, which can be covalently linked in nature, for example, in scFv. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs, or a subset thereof, confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific CDRs) can recognize and bind to an antigen, although usually with lower affinity than the entire binding site.

[0300] Single-chain Fv or (scFv) antibody fragments comprise the VH and VL domains (or regions) of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding.

[0301] In some embodiments, the scFvs described herein comprise, from N-terminus to C-terminus, a VH; a polypeptide linker; and a VL. In some embodiments, the scFvs described herein comprise, from N-terminus to C-terminus, a VL; a polypeptide linker; and a VH. In some embodiments, the linker peptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 37-42. In some embodiments, the linker peptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to, or about 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NOs: 38 or 39. In some embodiments, the linker peptide comprises a sequence that is at least, or about, 80%, 85%, 90%, 95%, or 100% identical to one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) repeats of GGGGS (SEQ ID NO: 37).

[0302] Fab fragments contain the variable and constant domains of the light chain and the variable and first constant domain (CH1) of the heavy chain. F(ab')2 antibody fragments comprise a pair of Fab fragments, which are generally covalently linked near their carboxy termini by hinge cysteines between them. Other chemical couplings of antibody fragments are also known in the art.

[0303] Diabodies are small antibody fragments with two antigen-binding sites, which comprise a VH connected to a VL (VH and VL) on the same polypeptide chain. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with complementary domains on another chain to create two antigen-binding sites.

[0304] Antibody multimerization can be achieved through natural antibody aggregation or through chemical or recombinant linkage techniques known in the art. For example, a certain percentage of purified antibody preparations (e.g., purified IgG1 molecules) spontaneously form protein aggregates containing antibody homodimers and other higher-order antibody multimers.

[0305] Linear antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1), which, together with complementary light chain polypeptides, form a pair of antigen-binding regions. Linear antibodies can be bispecific or monospecific.

[0306] Alternatively, antibody homodimers may be formed through chemical linkage techniques known in the art. For example, antibody multimers can be formed using heterobifunctional cross-linkers, including, but not limited to, SMCC (succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate) and SATA (N-succinimidyl S-acetylthioacetate). An exemplary protocol for forming antibody homodimers is described in Ghetie et al. (Proc. Natl. Acad. Sci. USA 94: 7509-7514, 1997). Antibody homodimers can be converted to Fab'2 homodimers through digestion with pepsin. Another method for forming antibody homodimers is through the use of the autophilic T15 peptide, as described in Zhao et al. (J. Immunol. 25:396-404, 2002).

[0307] The antibodies and antibody fragments of the present disclosure can be modified in the Fc region to provide desired effector functions or serum half-lives. In some embodiments, the Fc region of any one of the antibodies or antigen-binding fragments described herein comprises an aspartic acid (Asp) at position 239 according to EU numbering. In some embodiments, the Fc region of any one of the antibodies or antigen-binding fragments described herein comprises a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, the Fc region described herein is any one of the Fc regions described herein comprising an aspartic acid (Asp) at position 239 according to EU numbering and / or a glutamic acid (Glu) at position 332 according to EU numbering. In some embodiments, Asp239 and / or Glu332 described herein can increase an effector function (e.g., ADCC or CDC) of an antibody or antigen-binding fragment thereof by at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold compared to that of a wild-type antibody or antigen-binding fragment thereof. Details can be found, for example, in Lazar, GA et al., "Engineered antibody Fc variants with enhanced effector function." Proceedings of the National Academy of Sciences 103.11 (2006): 4005-4010, which is incorporated herein by reference in its entirety.

[0308] In some embodiments, the Fc region in any one of the antibodies or antigen-binding fragments described herein comprises a wild-type human IgG1 CH2 domain (e.g., SEQ ID NO: 35). In some embodiments, the Fc region in any one of the antibodies or antigen-binding fragments described herein comprises a mutated human IgG1 CH2 domain (e.g., SEQ ID NO: 36). In some embodiments, the Fc region described herein comprises a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 35 or 36.

[0309] Any of the antibodies or antigen-binding fragments described herein can be conjugated to a stabilizing molecule (e.g., a molecule that increases the half-life of the antibody or antigen-binding fragment in a subject or solution). Non-limiting examples of stabilizing molecules include polymers (e.g., polyethylene glycol) or proteins (e.g., serum albumins, such as human serum albumin). Conjugation of a stabilizing molecule can increase the half-life or extend the biological activity of the antibody or antigen-binding fragment in vitro (e.g., when stored in tissue culture or as a pharmaceutical composition) or in vivo (e.g., in humans).

[0310] In some embodiments, the antibodies or antigen-binding fragments (e.g., bispecific antibodies) described herein can be conjugated to a therapeutic agent. Antibody-drug conjugates comprising the antibodies or antigen-binding fragments thereof can be covalently or non-covalently bound to a therapeutic agent. In some embodiments, the therapeutic agent is a cytotoxic or cytostatic agent (e.g., cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracin, maytansinoids such as DM-1 and DM-4, ​​dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide, and analogs).

[0311] In some embodiments, a multispecific antibody or antigen-binding fragment thereof described herein (e.g., a cMET / EGFR bispecific antibody or a cMET / EGFR trispecific antibody) binds to an antigen (e.g., cMET) with a binding affinity that is about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, or about 200% of that of a heavy chain antibody (e.g., an anti-cMET heavy chain antibody) that comprises the same VHH of the multispecific antibody.

[0312] In some embodiments, a multispecific antibody or antigen-binding fragment thereof described herein (e.g., a cMET / EGFR bispecific antibody or a cMET / EGFR trispecific antibody) binds to an antigen (e.g., EGFR) with a binding affinity that is about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, or about 200% of that of an antibody or antigen-binding fragment comprising the same VH and VL that targets EGFR of the multispecific antibody (e.g., an anti-EGFR monoclonal antibody).

[0313] In some embodiments, a bispecific antibody or antigen-binding fragment thereof described herein (e.g., a cMET / EGFR bispecific antibody or a cMET / EGFR trispecific antibody) mediates complement-dependent cytotoxicity (CDC) that is at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 30-fold, 40-fold, or 50-fold greater than that mediated by an isotype control antibody.

[0314] In some embodiments, a multispecific antibody or antigen-binding fragment thereof described herein (e.g., a cMET / EGFR bispecific antibody or a cMET / EGFR trispecific antibody) is internalized at a percentage that is about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, or about 200% relative to that of a monoclonal antibody (e.g., an anti-cMET antibody, an anti-EGFR antibody, or an isotype antibody control).

[0315] Recombinant vector The present disclosure also provides recombinant vectors (e.g., expression vectors) comprising the isolated polynucleotides disclosed herein (e.g., polynucleotides encoding the polypeptides disclosed herein), host cells into which the recombinant vectors have been introduced (i.e., such that the host cell contains the polynucleotides and / or vectors comprising the polynucleotides), and the production of recombinant antibody polypeptides or fragments thereof by recombinant techniques.

[0316] As used herein, " vector " refers to any construct that can deliver one or more polynucleotides of interest to host cell when the vector is introduced into host cell. " expression vector " can deliver and express one or more polynucleotides of interest as coded polypeptides in the host cell that the expression vector is introduced into.Therefore, in expression vector, the polynucleotide of interest is located in the vector by being functionally linked with control elements such as promoter, enhancer, and / or polyA tail in the vector or in the genome of the host cell that is adjacent to or near the integration site of the polynucleotide of interest, so that the polynucleotide of interest is translated in the host cell that the expression vector is introduced into.

[0317] Vectors can be introduced into host cells by methods known in the art, such as electroporation, chemical transfection (e.g., DEAE-dextran), transformation, transfection, and infection and / or transduction (e.g., with recombinant viruses). Thus, non-limiting examples of vectors include viral vectors (which can be used to generate recombinant viruses), naked DNA or RNA, plasmids, cosmids, phage vectors, and DNA or RNA expression vectors associated with cationic condensing agents.

[0318] In some implementations, a polynucleotide disclosed herein (e.g., a polynucleotide encoding a polypeptide disclosed herein) is introduced using a viral expression system (e.g., vaccinia or other poxvirus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication-competent virus, or may use a replication-defective virus. In the latter case, viral propagation will generally occur only in complementing viral packaging cells. Suitable systems are described, for example, in Fisher-Hoch et al., 1989, Proc. Natl. Acad. Sci. USA 86:317-321; Flexner et al., 1989, Ann. NY Acad Sci. 569:86-103; Flexner et al., 1990, Vaccine, 8:17-21; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89 / 01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91 / 02805; Berkner-Biotechniques, 6:616-627, 1988; Rosenfeld et al., 1991, Science, 252:431-434; Kolls et al., 1994, Proc. Natl. Acad. Sci. USA, 91:215-219; Kass-Eisler et al., 1993, Proc. Natl. Acad. Sci. USA, 90:11498-11502; Guzman et al., 1993, Circulation, 88:2838-2848; and Guzman et al., 1993, Cir. Res., 73:1202-1207. Techniques for incorporating DNA into such expression systems are well known to those skilled in the art. The DNA may also be "naked," as described, for example, in Ulmer et al., 1993, Science, 259:1745-1749 and Cohen, 1993, Science, 259:1691-1692.The uptake of naked DNA can be increased by coating the DNA onto biodegradable beads, which are efficiently transported into cells.

[0319] For expression, a DNA insert containing a polynucleotide encoding an antibody or encoding a polypeptide disclosed herein can be operably linked to a suitable promoter (e.g., a heterologous promoter), such as the phage lambda PL promoter, the E. coli lac, trp, and tac promoters, the SV40 early and late promoters, and promoters of retroviral LTRs, to name a few. Other suitable promoters are known to those skilled in the art. The expression construct can further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the construct can include a translation initiation codon at the beginning of the polypeptide to be translated and a termination codon (UAA, UGA, or UAG) appropriately positioned at the end thereof.

[0320] As indicated, expression vectors can contain at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, and tetracycline or ampicillin resistance genes for culture in E. coli and other bacteria. Representative examples of suitable hosts include, but are not limited to, bacterial cells such as E. coli, Streptomyces, and Salmonella typhimurium cells; fungal cells such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, Bowes melanoma, and HK 293 cells; and plant cells. Appropriate culture media and conditions for the host cells described herein are known in the art.

[0321] Non-limiting vectors for use in bacteria include pQE70, pQE60, and pQE-9 available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, and pNH46A available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 available from Pharmacia. Non-limiting eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1, and pSG available from Stratagene; and pSVK3, pBPV, pMSG, and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to those skilled in the art.

[0322] Non-limiting bacterial promoters suitable for use include the E. coli lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters, and the trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, promoters of retroviral LTRs, such as those of Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

[0323] In the yeast Saccharomyces cerevisiae, numerous vectors containing constitutive or inducible promoters, such as α-factor, alcohol oxidase, and PGH, can be used. For reviews, see Ausubel et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, and Grant et al., Methods Enzymol., 153: 516-544 (1997).

[0324] Introduction of the construct into the host cell can be by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid mediated transfection, electroporation, transduction, infection, or other methods, which are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986), which is incorporated herein by reference in its entirety.

[0325] Transcription of DNA encoding the antibody of the present disclosure by higher eukaryotes can be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about 10 to 300 bp, that act to increase the transcriptional activity of a promoter in a given host cell type. Examples of enhancers include the SV40 enhancer, which is located at base pairs 100 to 270 on the late side of the replication origin, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

[0326] For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or may be heterologous signals.

[0327] Polypeptides (e.g., antibodies) can be expressed in modified forms, such as fusion proteins (e.g., GST fusions) or with histidine tags, and can contain not only secretion signals but also additional heterologous functional regions. For example, to improve stability and persistence in host cells, during purification, or during subsequent handling and storage, additional amino acids, particularly a region of charged amino acids, can be added to the N-terminus of the polypeptide. Also, peptide moieties can be added to polypeptides to facilitate purification. Such regions can be removed before the final preparation of the polypeptide. The addition of peptide moieties to polypeptides to, inter alia, induce secretion or excretion, improve stability, and facilitate purification, is a familiar and routine technique in the art.

[0328] The present disclosure also provides a nucleic acid sequence that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any nucleotide sequence as described herein, and amino acid sequences that are at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any amino acid sequence as described herein.

[0329] The present disclosure also provides a nucleic acid sequence having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homology to any of the nucleotide sequences as described herein, and amino acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homology to any amino acid sequence as described herein.

[0330] In some embodiments, the present disclosure relates to a nucleotide sequence encoding any of the peptides described herein, or any amino acid sequence encoded by any of the nucleotide sequences described herein. In some embodiments, the nucleic acid sequence is less than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides. In some embodiments, the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, or 400 amino acid residues.

[0331] In some embodiments, the amino acid sequence (i) comprises an amino acid sequence; or (ii) consists of an amino acid sequence, wherein the amino acid sequence is any one of the sequences as described herein.

[0332] In some embodiments, the nucleic acid sequence (i) comprises a nucleic acid sequence; or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any one of the sequences as described herein.

[0333] The percentage of sequence homology (e.g., amino acid sequence homology or nucleic acid homology) can also be determined. Methods for determining the percentage of sequence homology are known in the art. In some embodiments, conserved amino acid residues (percent homology) with similar physicochemical properties, such as leucine and isoleucine, can be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include, for example, amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). The percentage of homology is often higher than the percentage of identity.

[0334] How to generate antibodies An isolated fragment of a human protein (e.g., cMET, EGFR, or cancer antigen) can be used as an immunogen to generate antibodies using standard techniques for preparing polyclonal and monoclonal antibodies. Polyclonal antibodies can be raised in animals by multiple injections (e.g., subcutaneous or intraperitoneal) of the antigenic peptide or protein. In some embodiments, the antigenic peptide or protein is injected with at least one adjuvant. In some embodiments, the antigenic peptide or protein can be conjugated to an agent that is immunogenic in the species being immunized. Animals can be injected with the antigenic peptide or protein more than once (e.g., two, three, or four times).

[0335] The full-length polypeptide or protein can be used as an immunogen, or alternatively, an antigenic peptide fragment thereof. An antigenic peptide of a protein contains at least 8 (e.g., at least 10, 15, 20, or 30) amino acid residues of the amino acid sequence of the protein and encompasses an epitope of the protein, such that antibodies raised against the peptide will form specific immune complexes with the protein.

[0336] Immunogens are typically used to prepare antibodies by immunizing a suitable subject (e.g., a human or a transgenic animal expressing at least one human immunoglobulin locus). An appropriate immunogenic preparation can contain, for example, a recombinantly expressed or chemically synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulant.

[0337] Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with the polypeptide or an antigenic peptide thereof (e.g., a portion of the protein) as an immunogen. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as enzyme-linked immunosorbent assay (ELISA) using immobilized polypeptide or peptide. If desired, the antibody molecules can be isolated from the mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A or protein G chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the specific antibody titer is highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies using standard techniques, such as the hybridoma technique first described by Kohler et al. (Nature 256:495-497, 1975), human B cell hybridoma technique (Kozbor et al., Immunol. Today 4:72, 1983), EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985), or trioma technique. Techniques for producing hybridomas are well known (see generally Current Protocols in Immunology, 1994, Coligan et al. (Eds.), John Wiley & Sons, Inc., New York, NY). Hybridoma cells producing a monoclonal antibody are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide or epitope of interest, e.g., using a standard ELISA assay.

[0338] VHHs can also be obtained from naive or engineered synthetic llama VHH libraries. PBMCs can be obtained from llamas, RNA can be isolated, and cDNA can be generated by reverse transcription. The VHH genes can then be amplified by PCR and cloned into a phage display vector to construct a naive VHH library. Synthetic (e.g., humanized) VHH libraries can be prepared by incorporating shuffled VHH CDRs 1, 2, and 3, generated by overlap PCR, into a modified human VH scaffold to generate enhanced diversity and maintain low immunogenicity. The VHH library can then be panned against an antigen to obtain VHHs with the desired binding affinity.

[0339] Variants of the antibodies or antigen-binding fragments described herein can be prepared by introducing appropriate nucleotide changes into the DNA encoding the human, humanized, or chimeric antibodies or antigen-binding fragments thereof described herein, or by peptide synthesis. Such variants include, for example, deletion, insertion, or substitution of residues within the amino acid sequence constituting the antigen-binding site or domain of the antibody. In a population of such variants, some antibodies or antigen-binding fragments have increased affinity for the target protein. Any combination of deletion, insertion, and / or combination can be performed to arrive at an antibody or antigen-binding fragment thereof with increased binding affinity for the target. The amino acid changes introduced into the antibody or antigen-binding fragment can also alter or introduce new post-translational modifications in the antibody or antigen-binding fragment, such as changing the number (e.g., increasing or decreasing) of glycosylation sites, changing the type of glycosylation site (e.g., changing the amino acid sequence so that different sugars are added by enzymes present in the cell), or introducing new glycosylation sites.

[0340] The antibodies disclosed herein can be derived from any species of animal, including mammals. Non-limiting examples of natural antibodies include humans, primates, such as monkeys and apes, cows, pigs, horses, sheep, camelids (e.g., camels and llamas), chickens, goats, and rodents, including transgenic rodents (e.g., rats, mice, hamsters, and rabbits) that have been genetically engineered to produce human antibodies.

[0341] Phage display (panning) can be used to optimize antibody sequences with desired binding affinity.In this technology, a gene encoding a single-chain Fv (including VH or VL) is inserted into a phage coat protein gene, allowing the phage to "display" an scFv on its outside while containing the protein gene inside, resulting in a connection between genotype and phenotype.Then, these displaying phage can be screened against a target antigen to detect the interaction between the displayed antigen-binding site and the target antigen.Therefore, a large library of proteins can be screened and amplified in a process called in vitro selection, and an antibody sequence with desired binding affinity can be obtained.

[0342] Human and humanized antibodies include antibodies having variable and constant regions derived from (or having the same amino acid sequences as) human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs.

[0343] Humanized antibodies typically have a human framework (FR) into which nonhuman CDRs have been grafted. Thus, a humanized antibody has one or more amino acid sequences introduced into it from a nonhuman source. These nonhuman amino acid residues are often referred to as "import" residues and are typically obtained from an "import" variable domain. Humanization can be essentially performed, for example, by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. These methods are described, for example, in Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988); each of which is incorporated herein by reference in its entirety. Thus, a "humanized" antibody is a chimeric antibody in which substantially less than an intact human V domain has been substituted by the corresponding sequence from a nonhuman species. In practice, humanized antibodies are typically murine antibodies in which some CDR residues and some FR residues are substituted by residues from analogous sites in human antibodies.

[0344] It is further important that antibodies be humanized with high specificity and affinity for antigens, as well as retaining other favorable biological properties. To achieve this goal, humanized antibodies can be prepared by a process of analyzing parent sequences and various conceptual humanized products using three-dimensional models of the parent and humanized sequences. Three-dimensional immunoglobulin models are generally available and are familiar to those skilled in the art. Computer programs are available that illustrate and display the likely three-dimensional conformational structures of selected candidate immunoglobulin sequences. Examination of these displays allows for analysis of the likely role of residues in the function of the candidate immunoglobulin sequence, i.e., analysis of residues that affect the ability of the candidate immunoglobulin to bind to its antigen. In this way, FR residues can be selected and combined from recipient and import sequences to achieve desired antibody characteristics, such as increased affinity for the target antigen.

[0345] Identity or homology to the original sequence is usually the percentage of amino acid residues present in the candidate sequence that are identical to sequences present in the human, humanized, or chimeric antibody or fragment, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity.

[0346] In some embodiments, covalent modifications can be made to antibodies or antigen-binding fragments thereof. These covalent modifications can be made by chemical or enzymatic synthesis, or by enzymatic or chemical cleavage. Other types of covalent modifications of antibodies or antibody fragments can be introduced into the molecule by reacting targeted amino acid residues of the antibody or fragment with organic derivatizing agents that can react with selected side chains or N- or C-terminal residues.

[0347] In some embodiments, antibody variants are provided that lack fucose in the carbohydrate structure attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies can be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 relative to the sum of all glycans (e.g., complex, hybrid, and high-mannose structures) attached to Asn297 as measured by MALDI-TOF mass spectrometry, for example, as described in WO 2008 / 077546. Asn297 refers to an asparagine residue located at approximately position 297 in the Fc region (EU numbering of Fc region residues; or position 314 in Kabat numbering); however, due to minor sequence variations in antibodies, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylation variants may have improved ADCC function. In some embodiments, the Fc region of an antibody can be further engineered to replace the asparagine at position 297 with alanine (N297A) to reduce glycan heterogeneity.

[0348] In some embodiments, the Fc region of the antibody was further engineered to replace the serine at position 228 (EU numbering) of IgG4 with proline (S228P) to promote production efficiency by avoiding Fab arm exchange. A detailed description of the S228 mutation is provided, for example, in Silva et al. "The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation," Journal of Biological Chemistry 290.9 (2015): 5462-5469, the entire contents of which are incorporated by reference.

[0349] In some embodiments, the methods described herein are designed to generate bispecific antibodies. Bispecific antibodies can be generated by engineering the interface between a pair of antibody molecules to maximize the percentage of heterodimers recovered from recombinant cell culture. For example, the interface can contain at least a portion of the CH3 domain of the antibody constant domain. In this method, one or more small amino acid side chains from the interface of a first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the large amino acid side chain with a smaller one (e.g., alanine or threonine), a compensatory "cavity" of identical or similar size to the large side chain is created at the interface of the second antibody molecule. This provides a mechanism for increasing the yield of heterodimers over other unwanted end-products, such as homodimers. This method is described, for example, in WO 96 / 27011, the entire contents of which are incorporated by reference.

[0350] In some embodiments, one or more amino acid residues in the CH3 portion of the IgG are substituted. In some embodiments, one heavy chain has one or more of the following substitutions: Y349C and T366W. The other heavy chain can have one or more of the following substitutions: E356C, T366S, L368A, and Y407V. In addition, a substitution (-ppcpScp-->-ppcpPcp-) can also be introduced into the hinge region of both substituted IgGs. In some embodiments, one heavy chain has a T366Y (knob) substitution and the other heavy chain has a Y407T (hole) substitution (EU numbering).

[0351] One aspect of the present application provides a heteromultimeric (e.g., heterodimeric) protein comprising a first polypeptide comprising a first heavy chain constant domain 3 (CH3) domain and a second polypeptide comprising a second CH3 domain, wherein the first CH3 domain comprises a substitution of a bulky hydrophobic amino acid at amino acid position 354 relative to the wild-type CH3 domain, and / or the second CH3 domain comprises a substitution of a negatively charged amino acid at amino acid position 347 relative to the wild-type CH3 domain, and the numbering of amino acid residues is based on EU numbering. In some embodiments, the bulky hydrophobic amino acid at amino acid position 354 forms a hydrophobic interaction with an amino acid residue in the second CH3 domain. In some embodiments, the second CH3 domain comprises a bulky hydrophobic residue at amino acid position 349 (e.g., Y349). In some embodiments, the negatively charged amino acid at amino acid position 347 forms an ionic bond with an amino acid residue in the first CH3 domain. In some embodiments, the first CH3 domain comprises a positively charged residue at amino acid position 360 (e.g., K360). In some embodiments, the first CH3 domain and the second CH3 domain are human CH3 domains. In some embodiments, the first CH3 domain comprises a substitution selected from the group consisting of S354Y, S354F, and S354W. In some embodiments, the first CH3 domain comprises S354Y. In some embodiments, the second CH3 domain does not comprise a compensatory substitution to the S354 substitution in the first CH3 domain (e.g., a substitution with Y349). In some embodiments, the second CH3 domain comprises a substitution selected from the group consisting of Q347E and Q347D. In some embodiments, the second CH3 domain comprises Q347E. In some embodiments according to any one of the above heteromultimeric proteins, the first CH3 domain and the second CH3 domain further comprise a knob-into-hole (KIH) residue. In some embodiments, the knob-into-hole residues are T366Y and Y407T.In some embodiments, the first CH3 domain includes T366Y and S354Y, and the second CH3 domain includes Y407T and Q347E. In some embodiments, the first CH3 domain includes Y407T and S354Y, and the second CH3 domain includes T366Y and Q347E. Details can be found in PCT / US2020 / 025469, which is hereby incorporated by reference.

[0352] Furthermore, anion exchange chromatography can be used to purify the bispecific antibody. Anion exchange chromatography is a process of separating substances based on their charges using an ion exchange resin containing a positively charged group such as a diethylaminoethyl group (DEAE). In solution, the resin is coated with positively charged counterions (cations). The anion exchange resin binds to negatively charged molecules and replaces the counterions. Protein can be purified based on its isoelectric point (pI) using anion exchange chromatography. The isoelectric point is defined as the pH at which the protein has no net charge. When pH > pI, the protein has a net negative charge, and when pH < pI, the protein has a net positive charge. Thus, in some embodiments, different amino acid substitutions can be introduced into the two heavy chains such that the pI of the homodimer containing two arm A's and the pI of the homodimer containing two arm B's are different. The pI of the bispecific antibody having arm A and arm B will be somewhere between the two pI's of the homodimers. Thus, the two homodimers and the bispecific antibody can be eluted under different pH conditions. The present disclosure shows that a small number of amino acid residue substitutions can be introduced into the heavy chain to adjust the pI.

[0353] Thus, in some embodiments, the amino acid residue at position 83 (Kabat numbering) is lysine, arginine, or histidine. In some embodiments, one or more of the amino acid residues at positions 1, 6, 43, 81, and 105 (Kabat numbering) are aspartic acid or glutamic acid.

[0354] In some embodiments, one or more amino acid residues at positions 13 and 105 (Kabat numbering) are aspartic acid or glutamic acid. In some embodiments, one or more amino acid residues at positions 13 and 42 (Kabat numbering) are lysine, arginine, histidine, or glycine.

[0355] Bispecific antibodies can also include, for example, cross-linked antibodies, or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, and the other to biotin. Heteroconjugate antibodies can also be produced using any convenient cross-linking method. Suitable cross-linking agents and techniques are well known in the art and are disclosed in U.S. Pat. No. 4,676,980, the entire contents of which are incorporated herein by reference.

[0356] Methods for generating bispecific antibodies from antibody fragments are also known in the art. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al. (Science 229:81, 1985) describe a procedure in which intact antibodies are proteolytically cleaved to generate F(ab')2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The generated Fab' fragments are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' TNB derivatives is then reconverted to the Fab' thiol by reduction with mercaptoethylamine and mixed with an equimolar amount of another Fab' TNB derivative to form the bispecific antibody.

[0357] Treatment method The methods described herein include methods for the treatment of cancer-related disorders. Generally, the methods include administering a therapeutically effective amount of an engineered bispecific antibody (e.g., an unbalanced bispecific antibody) of an antigen-binding fragment thereof as described herein to a subject in need of, or determined to be in need of, such treatment.

[0358] As used in this context, "treating" means improving at least one symptom of a cancer-related disorder. Cancer often leads to death; therefore, treatment can result in an increase in life expectancy (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 years). Administration of a therapeutically effective amount of the agent (e.g., imbalanced bispecific antibody) described herein for the treatment of a cancer-related condition will result in a reduction in the number of cancer cells and / or a reduction in symptoms.

[0359] As used herein, the term "cancer" refers to an abnormal state or condition characterized by cells capable of autonomous growth, i.e., rapidly proliferating cell proliferation. The term is intended to include all types of cancerous growths or oncogenic processes, metastatic tissues, or malignantly transformed cells, tissues, or organs, regardless of histopathological type or stage of invasiveness. As used herein, the term "tumor" refers to a mass of cancerous cells, e.g., cancerous cells. Cancers that can be treated or diagnosed using the methods described herein include malignant tumors of various organ systems, such as those affecting the lung, breast, thyroid, lymphatic system, gastrointestinal, and genitourinary tract, as well as adenocarcinomas, including most colon cancers, renal cell carcinoma, prostate cancer, and / or testicular cancer, non-small cell lung cancer, small intestine cancer, and esophageal cancer. In some embodiments, the agents described herein are designed to treat or diagnose carcinoma in a subject. The term "carcinoma" is art-recognized and refers to malignant tumors of epithelial or endocrine tissues, including respiratory, gastrointestinal, genitourinary, testicular, breast, prostate, endocrine, and melanoma. In some embodiments, the cancer is renal carcinoma or melanoma. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon, and ovary. The term also includes carcinosarcomas, which include malignant tumors composed of carcinomatous and sarcomatous tissue. "Adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures. The term "sarcoma" is art-recognized and refers to a malignant tumor of mesenchymal origin.

[0360] In one aspect, the present disclosure also provides a method for treating cancer in a subject, a method for reducing the rate of tumor volume growth over time in a subject, a method for reducing the risk of developing metastasis, or a method for reducing the risk of developing further metastasis in a subject.In some embodiments, treatment can stop, slow, delay, or inhibit the progression of cancer.In some embodiments, treatment can result in the reduction of the number, severity, and / or duration of one or more symptoms of cancer in a subject.

[0361] In one aspect, the disclosure features a method including administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof, or antibody-drug conjugate disclosed herein to a subject in need thereof, e.g., a subject having, or identified or diagnosed as having, cancer, e.g., breast cancer (e.g., triple-negative breast cancer), carcinoid cancer, cervical cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, small cell lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer, gastric cancer, testicular cancer, thyroid cancer, bladder cancer, urethral cancer, or a hematological malignancy.

[0362] In some embodiments, the disclosure features a method that includes: identifying a subject having at least one resistance mutation in EGFR (e.g., C797S, T790M, and / or L858R); and administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof, or antibody-drug conjugate disclosed herein to a subject in need thereof, e.g., a subject having, or identified or diagnosed as having, cancer.

[0363] As used herein, the terms "subject" and "patient" are used interchangeably throughout the specification to describe a human or non-human animal to which treatment according to the methods of the present invention is provided. Veterinary and non-veterinary applications are contemplated by the present invention. A human patient can be an adult human or a young human (e.g., a human under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. Included are, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., pigs, miniature pigs), horses, dogs, cats, cows, and other domestic, farm, and zoo animals.

[0364] In some embodiments, the cancer is a cMET-expressing cancer. In some embodiments, the cancer is an EGFR-expressing cancer. In some embodiments, the cancer is a cancer that expresses both cMET and EGFR.

[0365] In some embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer).

[0366] In some embodiments, the cancer is unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, or metastatic hormone-refractory prostate cancer. In some embodiments, the subject has a solid tumor. In some embodiments, the cancer is head and neck squamous cell carcinoma (SCCHN), renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), or colorectal cancer. In some embodiments, the subject has Hodgkin's lymphoma. In some embodiments, the subject has triple-negative breast cancer (TNBC), gastric cancer, urothelial carcinoma, Merkel cell carcinoma, or head and neck cancer. In some embodiments, the cancer is melanoma, pancreatic cancer, mesothelioma, hematological malignancies, particularly non-Hodgkin's lymphoma, lymphoma, chronic lymphocytic leukemia, or an aggressive solid tumor. In some embodiments, the cancer is hereditary papillary renal cell carcinoma. In some embodiments, the cancer is gastric cancer, head and neck cancer, liver cancer, ovarian cancer, NSCLC, or thyroid cancer.

[0367] In some embodiments, the cancer is resistant to first-generation EGFR-TKIs (e.g., gefitinib or erlotinib). In some embodiments, the cancer is resistant to second-generation EGFR-TKIs (e.g., afatinib or dacomitinib). In some embodiments, the cancer is resistant to third-generation EGFR-TKIs (e.g., osimertinib (TAGRISSO) or rociletinib).

[0368] In some embodiments, a subject (e.g., a human) described herein has one or more mutations in the EGFR gene in one or more cells. In some embodiments, the mutations include an exon 19 deletion mutation and / or a single-point substitution mutation in exon 21 resulting in L858R.

[0369] In some embodiments, the subject (e.g., human) described herein has one or more resistance mutations in the EGFR protein in one or more cells. In some embodiments, the one or more resistance mutations include C797S, T790M, and / or L858R.

[0370] In some embodiments, the cancer cells described herein are cell lines, such as NCI-H1975 cells. In some embodiments, the cancer cells contain primary and / or secondary activating mutations of EGFR. In some embodiments, the cancer cells have elevated cMET levels, for example, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% higher than non-cancerous cells.

[0371] In some embodiments, the compositions and methods disclosed herein can be used to treat patients at risk for cancer. Patients with cancer can be identified by various methods known in the art.

[0372] As used herein, "effective amount" refers to an amount or dosage sufficient to bring about beneficial or desired results, including halting, slowing, retarding, or inhibiting the progression of a disease, e.g., cancer. The effective amount varies depending on, for example, the age and weight of the subject to whom the antibody, antigen-binding fragment, antibody-drug conjugate, polynucleotide encoding the antibody, vector comprising the polynucleotide, and / or composition thereof is to be administered, the severity of symptoms, and the route of administration, and therefore, administration can be determined individually.

[0373] An effective amount can be administered in one or more doses. For example, an effective amount of an antibody, antigen-binding fragment, or antibody-drug conjugate is an amount sufficient to improve, stop, stabilize, reverse, inhibit, slow, and / or delay the progression of an autoimmune disease or cancer in a patient, or an amount sufficient to improve, stop, stabilize, reverse, slow, and / or delay the proliferation of cells (e.g., biopsied cells, any of the cancer cells described herein, or cell lines (e.g., cancer cell lines)) in vitro. As understood in the art, the effective amount of an antibody, antigen-binding fragment, or antibody-drug conjugate can vary depending on other factors, such as the patient's medical history and the type (and / or dosage) of the antibody used, among others.

[0374] Effective amounts and schedules for administering the antibodies, antibody-encoding polynucleotides, antibody-drug conjugates, and / or compositions disclosed herein may be determined empirically, and making such determinations is within the skill of one in the art. One of ordinary skill in the art will understand that the dosage that must be administered will vary depending, for example, on the mammal that will receive the antibodies, antibody-encoding polynucleotides, antibody-drug conjugates, and / or compositions disclosed herein, the route of administration, the particular type of antibodies, antibody-encoding polynucleotides, antigen-binding fragments, antibody-drug conjugates, and / or compositions disclosed herein that are used, and other drugs that are being administered to the mammal. Guidance in selecting an appropriate dose of antibody or antigen-binding fragment can be found in literature on the therapeutic use of antibodies and antigen-binding fragments, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, NJ, 1985, ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York, 1977, pp. 365-389.

[0375] A typical daily dosage of an effective amount of antibody is 0.01 mg / kg to 100 mg / kg. In some embodiments, the dosage can be less than 100 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, or 0.1 mg / kg. In some embodiments, the dosage can be greater than 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, 0.1 mg / kg, 0.05 mg / kg, or 0.01 mg / kg. In some embodiments, the dosage is about 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.9 mg / kg, 0.8 mg / kg, 0.7 mg / kg, 0.6 mg / kg, 0.5 mg / kg, 0.4 mg / kg, 0.3 mg / kg, 0.2 mg / kg, or 0.1 mg / kg.

[0376] In any of the methods described herein, at least one antibody, antigen-binding fragment thereof, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding fragments, antibody-drug conjugates, or pharmaceutical compositions described herein) and optionally at least one additional therapeutic agent can be administered to a subject at least once a week (e.g., once a week, twice a week, three times a week, four times a week, once a day, twice a day, or three times a day). In some embodiments, at least two different antibodies and / or antigen-binding fragments are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one antibody, antigen-binding fragment, antibody-drug conjugate, and at least one additional therapeutic agent are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one antibody or antigen-binding fragment and at least one additional therapeutic agent are administered in two different compositions (e.g., a liquid composition containing at least one antibody or antigen-binding fragment, and a solid oral composition containing at least one additional therapeutic agent). In some embodiments, the at least one additional therapeutic agent is administered as a pill, tablet, or capsule. In some embodiments, the at least one additional therapeutic agent is administered in a sustained release oral formulation.

[0377] In some embodiments, the one or more additional therapeutic agents can be administered to the subject before or after administering at least one antibody, antigen-binding antibody fragment, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein). In some embodiments, the one or more additional therapeutic agents and at least one antibody, antigen-binding antibody fragment, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) are administered to the subject such that there is an overlap in the period of biological activity of the one or more additional therapeutic agents and the at least one antibody or antigen-binding fragment (e.g., any of the antibodies or antigen-binding fragments described herein) in the subject.

[0378] In some embodiments, a subject can be administered at least one antibody, antigen-binding antibody fragment, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) for an extended period of time (e.g., for a period of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years). A skilled medical professional can determine the length of the treatment period using any of the methods described herein for diagnosing or tracking the effectiveness of treatment (e.g., observing at least one symptom of cancer). As described herein, a skilled medical professional can also vary (e.g., increase or decrease) the identity and number of antibodies or antigen-binding antibody fragments, antibody-drug conjugates (and / or one or more additional therapeutic agents) administered to a subject, and can also adjust (e.g., increase or decrease) the dosage or frequency of administration of at least one antibody or antigen-binding antibody fragment (and / or one or more additional therapeutic agents) to a subject based on an evaluation of the effectiveness of treatment (e.g., using any of the methods described herein and known in the art).

[0379] In some embodiments, one or more additional therapeutic agents can be administered to the subject.The additional therapeutic agent can include one or more inhibitors selected from the group consisting of a B-Raf inhibitor, an EGFR inhibitor, a MEK inhibitor, an ERK inhibitor, a K-Ras inhibitor, a c-Met inhibitor, an anaplastic lymphoma kinase (ALK) inhibitor, a phosphatidylinositol 3-kinase (PI3K) inhibitor, an Akt inhibitor, an mTOR inhibitor, a PI3K / mTOR dual inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and an isocitrate dehydrogenase 1 (IDH1) and / or an isocitrate dehydrogenase 2 (IDH2) inhibitor.In some embodiments, the additional therapeutic agent is an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (e.g., epacadostat).

[0380] In some embodiments, the additional therapeutic agent can comprise one or more inhibitors selected from the group consisting of inhibitors of HER3, inhibitors of LSD1, inhibitors of MDM2, inhibitors of BCL2, inhibitors of CHK1, inhibitors of the activated hedgehog signaling pathway, and agents that selectively degrade the estrogen receptor.

[0381] In some embodiments, the additional therapeutic agent is trabectedin, nab-paclitaxel, trebananib, pazopanib, cediranib, palbociclib, everolimus, fluoropyrimidine, IFL, regorafenib, Reolysin, Alimta, Zykadia, Sutent, temsirolimus, axitinib, everolimus, sorafenib, Votrient, pazopanib, IMA-901, AGS-003, cabozantinib, vincristine, vincristine, vincristine serotonin ... The treatment may include one or more therapeutic agents selected from the group consisting of Flunine, Hsp90 inhibitors, Ad-GM-CSF, Temazolomide, IL-2, IFNa, Vinblastine, Thalomid, Dacarbazine, Cyclophosphamide, Lenalidomide, Azacitidine, Lenalidomide, Bortezomid, Amrubicin, Carfilzomib, Pralatrexate, and Enzastaurin.

[0382] In some embodiments, the additional therapeutic agents can comprise one or more therapeutic agents selected from the group consisting of an adjuvant, a TLR agonist, tumor necrosis factor (TNF) alpha, IL-1, HMGB1, an IL-10 antagonist, an IL-4 antagonist, an IL-13 antagonist, an IL-17 antagonist, an HVEM antagonist, an ICOS agonist, a CX3CL1 targeted treatment, a CXCL9 targeted treatment, a CXCL10 targeted treatment, a CCL5 targeted treatment, an LFA-1 agonist, an ICAM1 agonist, and a selectin agonist.

[0383] In some embodiments, carboplatin, nab-paclitaxel, paclitaxel, cisplatin, pemetrexed, gemcitabine, FOLFOX, or FOLFIRI is administered to the subject.

[0384] In some embodiments, the additional therapeutic agent is an anti-OX40 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, an anti-BTLA antibody, an anti-CTLA-4 antibody, or an anti-GITR antibody.

[0385] Pharmaceutical Compositions and Routes of Administration Also provided herein is a pharmaceutical composition containing at least one (e.g., one, two, three, or four) of the antibodies, antigen-binding fragments, or antibody-drug conjugates described herein. Two or more (e.g., two, three, or four) of any of the antibodies, antigen-binding fragments, or antibody-drug conjugates described herein can be present in the pharmaceutical composition in any combination. The pharmaceutical composition can be formulated by any method known in the art.

[0386] Pharmaceutical compositions are formulated to be compatible with their intended route of administration (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal). The compositions can contain a sterile diluent (e.g., sterile water or saline), fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents, antibacterial or antifungal agents, such as benzyl alcohol or methylparaben, chlorobutanol, phenol, ascorbic acid, thimerosal, or the like, antioxidants, such as ascorbic acid or sodium bisulfite, chelating agents, such as ethylenediaminetetraacetic acid, buffers, such as acetates, citrates, or phosphates, and isotonicity agents, such as sugars (e.g., dextrose), polyhydric alcohols (e.g., mannitol or sorbitol), or salts (e.g., sodium chloride), or any combination thereof. Liposomal suspensions can also be used as pharmaceutically acceptable carriers (see, e.g., U.S. Pat. No. 4,522,811). The composition preparation can be formulated and enclosed in ampoules, disposable syringes, or multiple-dose vials. Where necessary (e.g., as in injectable formulations), adequate fluidity can be maintained, for example, by the use of a coating such as lecithin or a surfactant. Absorption of the antibody or its antigen-binding fragment can be prolonged by including an agent that delays absorption (e.g., aluminum monostearate and gelatin). Alternatively, controlled release can be achieved by implants and microencapsulated delivery systems that can include biodegradable, biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc.).

[0387] Compositions containing any one or more of the antibodies, antigen-binding fragments, antibody-drug conjugates described herein can be formulated in unit dosage form (i.e., physically discrete units containing a predetermined amount of active compound for ease of administration and uniformity of dosage) for parenteral (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) administration.

[0388] The toxicity and therapeutic efficacy of a composition can be determined by standard pharmaceutical procedures in cell cultures or experimental animals (e.g., monkeys). The LD50 (the dose lethal to 50% of the population) and ED50 (the dose therapeutically effective in 50% of the population) can be determined; the therapeutic index is the ratio of LD50:ED50. Agents that exhibit a high therapeutic index are preferred. If an agent exhibits undesirable side effects, care should be taken to minimize potential harm (i.e., reduce undesired side effects). Toxicity and therapeutic efficacy can be determined by other standard pharmaceutical procedures.

[0389] Data obtained from cell culture assays and animal studies can be used to formulate an appropriate dosage of any given agent for use in a subject (e.g., a human). A therapeutically effective amount of one or more (e.g., one, two, three, or four) antibodies or antigen-binding fragments thereof (e.g., any of the antibodies or antibody fragments described herein) is an amount that treats the disease in a subject (e.g., a human subject identified as having cancer) or a subject identified as at risk for developing the disease (e.g., a subject who previously developed cancer but has now been cured) (e.g., kills cancer cells) or reduces the severity, frequency, and / or duration of one or more symptoms of the disease in a subject (e.g., a human). The efficacy and administration of any of the antibodies or antigen-binding fragments described herein can be determined by a medical or veterinary professional using methods known in the art and by observing one or more symptoms of the disease in a subject (e.g., a human). Certain factors (e.g., the severity of the disease or disorder, previous treatments, the subject's general health and / or age, and the presence of other diseases) can affect the dosage and timing required to effectively treat a subject.

[0390] Exemplary doses include milligram or microgram amounts of any of the antibodies or antigen-binding fragments, or antibody-drug conjugates described herein, per kilogram of subject body weight (e.g., about 1 μg / kg to about 500 mg / kg; about 100 μg / kg to about 500 mg / kg; about 100 μg / kg to about 50 mg / kg; about 10 μg / kg to about 5 mg / kg; about 10 μg / kg to about 0.5 mg / kg; or about 1 μg / kg to about 50 μg / kg). These doses cover a wide range, but one of skill in the art will understand that therapeutic agents, including antibodies and antigen-binding fragments thereof, vary in their efficacy and that effective amounts can be determined by methods known in the art. Typically, a relatively low dose is administered initially, and the attending medical or veterinary professional (for therapeutic applications) or researcher (when still working in the development stages) can subsequently and gradually increase the dose until an appropriate response is obtained. In addition, the specific dose level for any particular subject will depend on a variety of factors, including the activity of the particular compound used, the subject's age, weight, general health, sex, and diet, time of administration, route of administration, rate of excretion, and in vivo half-life of the antibody or antibody fragment.

[0391] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. The present disclosure also provides methods of producing the antibodies or antigen-binding fragments thereof, or antibody-drug conjugates for various uses as described herein. [Example]

[0392] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

[0393] Example 1. Panning of ABS VHH library for cMET binders Bispecific antibodies targeting both cMET and EGFR were developed by combining an EGFR-binding sequence with a cMET-binding sequence (e.g., a VHH) described herein. The development process can be divided into the following steps: 1) panning a phage VHH library for cMET binders; 2) screening and characterization of lead cMET-binder clones; 3) validation of receptor binding and receptor / ligand blocking by cell activation assays; 4) construction and characterization of cMET / EGFR BsAbs (bispecific antibodies) (e.g., receptor binding, receptor / ligand blocking, receptor phosphorylation, signaling inhibition, and / or cancer killing); 5) optimization and generation of lead sequences (e.g., structural optimization and lead characterization); 6) validation of BsAb function using cell-based assays (e.g., receptor binding, receptor / ligand blocking, receptor phosphorylation, signaling inhibition, and / or cancer killing) and / or animal studies (e.g., animal studies for the following CDX models: H1975 and H1975-HGF).

[0394] A heavy chain antibody variable domain (VHH) phage library was used in the panning process. The antigen included human cMET-His-tagged protein and transiently transfected CHO cells expressing human cMET. The panning strategy was designed as follows: two rounds of solid-phase phage panning, followed by one round of cell-based phage panning. Details of the panning process can be found in the table below.

[0395] (Table 1) TIFF2023549537000002.tif39128

[0396] After the panning process, ELISA was performed to screen and characterize the lead cMET binders. Primary screening was performed using two 96-well plates. ELISA readings were recorded. A total of 39 ELISA binders were identified, each with an ELISA signal greater than five times that of the negative control wells. Of these 39 ELISA binders, 16 clones were confirmed to be unique clones.

[0397] Example 2. Secondary Screening - Characterization through Competitive Ligand Binding A competitive binding assay (blocking ELISA) was performed to measure the binding of cMET to human HGF (Hu-HGF) in the presence of 16 unique clones. High-binding enzyme-linked immunosorbent assay (ELISA) plates were coated overnight with 200 ng / well of cMET-FLAG tagged protein (50 μl volume; 4 ng / μl) and maintained at 4°C. The following morning, wells were blocked with 1% bovine serum albumin (BSA) for 2 hours at room temperature (RT). After blocking, wells were washed four times with PBST (phosphate-buffered saline (PBS) supplemented with 0.05% Tween 20). Next, antibody samples to be tested (supernatants from 16 unique clones) or IgG isotype controls were added to each well in a volume of 25 μl and maintained at RT for 30 minutes. Then, 25 μl of biotinylated Hu-HGF protein was added to the corresponding wells. The plates were maintained at RT for 60 minutes. The wells were then washed four times with PBST. Subsequently, streptavidin-HRP conjugated secondary antibody (diluted 1:1000) was added and incubated at RT for 30 minutes. The plate was then washed four times with PBST. After washing, the plate was developed by adding Amplex reagent substrate, and the luminescence signal was then measured at 530 nm and 590 nm in a SpectraMax plate reader.

[0398] As shown in Figure 1, four clones, 1D5, 1F3, 1H1, and 2C7, were identified as having high competitive ligand binding ability and were therefore selected for the preparation of VHH mammalian expression systems.

[0399] Example 3. Cross-reactivity to cynomolgus monkey antigens A binding ELISA was performed to determine the binding similarity between 16 antibodies against human and monkey (Cynomolgus species) antigens. High-binding ELISA plates were coated with 1 μg / mL (diluted in 1x PBS) human or monkey antigens and kept at 4°C overnight. The next day, the plates were blocked with blocking buffer (4% nonfat milk in 1x PBS) for 1 hour at 37°C. After blocking, the plates were washed three times with PBST. Antibody samples to be tested were diluted in PBS and then added to the corresponding wells (10 μg / mL). The plates were incubated at 37°C and RT for 1 hour. After incubation, the plates were washed three times with PBST. Next, a secondary antibody (biotinylated anti-c-Myc antibody 9E-10, diluted 1:500) was added to the wells, and the plates were incubated at 37°C and RT for 1 hour. The plates were then washed three times with PBST. Streptavidin-HRP diluted 1:1000 was then added to each well, and the plate was then incubated for 1 hour at 37°C and RT. After incubation, the plate was washed four times with PBST. After washing, the plate was developed by adding Amplex reagent substrate, and the luminescence signal was then measured at 530 nm and 590 nm in a SpectraMax plate reader.

[0400] As shown in Figure 2, four clones, 1D5, 1F3, 1H1, and 2C7, were identified as cross-reactive with both human and monkey antigens and were therefore selected for the preparation of VHH mammalian expression systems.

[0401] Example 4. Expression analysis of cMET VHHs The expression of cMET VHH-Fc was measured using biolayer interferometry (BLI) (Probelife, Palo Alto, CA). Measurements were performed according to the manufacturer's instructions. As shown in Figure 3, 2C7 was found to have the greatest binding capacity for cMET. However, 2C7 was found to be a mixed clone. 1H1 was identified as a pure clone. 1D5 was also identified as a mixed clone (i.e., containing at least two clones).

[0402] Example 5. Testing the binding of cMET VHHs to cMET by ELISA A binding ELISA was performed to test the binding of the four identified cMET VHHs to cMET protein. The experiment was performed essentially as described herein. The results are shown in Figure 4. 2C7 was identified as a mixed clone, and 1H1 was identified as the clone showing the highest binding ability to cMET.

[0403] Example 6. Competitive ELISA for binding of cMET VHH (supernatant) to Hu-HGF To further characterize the cMET VHH clones, a competitive ELISA was performed. High-binding ELISA plates were coated with 4 μg / ml of c-MET-Fc tag protein and kept overnight at 4°C. The next morning, wells were blocked with 1% BSA for 2 hours at room temperature (RT). The wells were washed four times with PBST (PBS supplemented with 0.05% Tween 20). Test antibody samples (supernatants of 1D5, 1H1, and 2C7 clones) or an IgG isotype control (11F11) were added to the corresponding wells in a volume of 25 μl (final concentration of 25 μg / ml) and kept at room temperature for 30 minutes. Then, 25 μl of biotinylated Hu-HGF protein was added to the corresponding wells (final concentration of 5 nM), and the plate was kept at room temperature for 60 minutes. The wells were washed four times with PBST. Subsequently, streptavidin-HRP conjugated secondary antibody (diluted 1:1000) was added and incubated at room temperature for 30 minutes. The plate was then washed four times with PBST. After washing, the plate was developed by adding Amplex reagent substrate, and the luminescence signal was then measured at 530 nm and 590 nm (cutoff 570 nm) in a SpectraMax plate reader.

[0404] As shown in Figure 5, 1H1 VHH exhibited the highest binding ability to cMET among the three clones. In other words, 1H1 VHH exhibited the highest competition for the binding of biotinylated Hu-HGF to cMET. Therefore, 1H1 VHH was selected for the following experiments.

[0405] Example 7. Construction of bispecific Abs As shown in Figure 6, a bispecific antibody was prepared using anti-EGFR IgG as the backbone. The anti-cMET VHH was linked to the heavy chain variable region (VH) of the anti-EGFR IgG via a linker peptide to each arm. When the 1H1 VHH (SEQ ID NO: 19) was linked to both arms of an anti-EGFR IgG with a wild-type Fc region (VH: SEQ ID NO: 23; VL: SEQ ID NO: 24), the bispecific antibody was designated 1H1-cMET / EGFR-Fc(WT)-V3. Another schematic structure of 1H1-cMET / EGFR-Fc(WT)-V3 is shown in Figure 18A.

[0406] Example 8. Testing the binding of cMET-His tag with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3 BsAb To evaluate the cMET-binding ability of the bispecific antibody 1H1-cMET / EGFR-Fc(WT)-V3 against cMET, a binding ELISA was performed, using the JNJ372 analog as a positive control. Specifically, a high-binding ELISA plate was coated with 4 μg / ml of c-MET-His-tag protein and incubated overnight at 4°C. The binding ELISA was performed using two BsAbs (at a final concentration of 25 μg / ml). The following morning, wells were blocked with 1% BSA for 2 hours at room temperature. The wells were washed four times with PBST. BsAbs or an IgG isotype negative control (11F11) were added to the corresponding wells in a volume of 50 μl and incubated. After incubation, the wells were washed four times with PBST. Then, an HRP-conjugated goat anti-human Fc antibody was added to the corresponding wells as a secondary antibody, followed by incubation. The plate was then washed four times with PBST. After washing, the plate was developed by adding Amplex reagent substrate. Luminescence signals were measured at 530 nm and 590 nm (cutoff 570 nm) in a SpectraMax plate reader.

[0407] As shown in Figure 7, 1H1cMET / EGFR-Fc(WT) BsAb exhibited high binding ability to the cMET-His-tagged protein. 1H1cMET / EGFR-Fc(WT) exhibited similar binding ability to cMET compared with that of the JNJ372 analog.

[0408] Example 9. Testing EGFR-His tag binding with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3 BsAb To evaluate the binding ability of the bispecific antibody 1H1-cMET / EGFR-Fc(WT)-V3 against EGFR, a binding ELISA was performed, using the JNJ372 analog as a positive control. Specifically, a high-binding ELISA plate was coated with 4 μg / ml of EGFR-His tag protein and incubated overnight at 4°C. The binding ELISA was performed using two BsAbs (at a final concentration of 25 μg / ml). The following morning, wells were blocked with 1% BSA for 2 hours at room temperature. The wells were washed four times with PBST. The BsAb or IgG isotype negative control (11F11) was added to the corresponding wells in a volume of 50 μl and then incubated. After incubation, the wells were washed four times with PBST. An HRP-conjugated goat anti-human Fc antibody was then added to the corresponding wells as a secondary antibody, followed by incubation. The plate was then washed four times with PBST. After washing, the plate was developed by adding Amplex reagent substrate. Luminescence signals were measured at 530 nm and 590 nm (cutoff 570 nm) in a SpectraMax plate reader.

[0409] As shown in Figure 8, 1H1cMET / EGFR-Fc(WT) BsAb exhibited high binding ability to EGFR-His-tagged protein. 1H1cMET / EGFR-Fc(WT) exhibited similar binding ability to EGFR compared with that of the JNJ372 analog.

[0410] Example 10. Determination of EC50 for binding to cMET and EGFR by titration ELISA To determine the EC50 of the bispecific antibody 1H1-cMET / EGFR-Fc(WT)-V3, a binding titration ELISA was performed with five-fold serial dilutions of the test antibody starting at 50 μg / ml and ending at 50,000 ng / ml. A JNJ372 analog was used as a positive control. The dilution concentrations were 50 μg / ml, 10 μg / ml, 2 μg / ml, 0.4 μg / ml, 0.08 μg / ml, and 0.016 μg / ml.

[0411] Specifically, high-binding ELISA plates were coated with 4 μg / ml of c-MET-His tag or EGFR-His tag protein and kept overnight at 4°C. The next morning, the wells were blocked with 1% BSA for 2 hours at room temperature. After blocking, the wells were washed four times with PBST. Diluted antibody samples were added to the corresponding wells in a volume of 50 μl and incubated. After incubation, the wells were washed four times with PBST. Then, an HRP-conjugated goat anti-human Fc antibody was added to the corresponding wells as a secondary antibody, followed by incubation. The plate was then washed four times with PBST. After washing, the plate was developed by adding Amplex reagent substrate. The luminescence signal was measured at 530 nm and 590 nm (cutoff 570 nm) in a SpectraMax plate reader.

[0412] As shown in Figure 9, the EC50 values ​​for cMET binding were determined to be 8.6077 ng / ml and 4.8871 ng / ml for 1H1-cMET / EGFR-Fc(WT)-V3 and the JNJ372 analog, respectively. The schematic structure of 1H1-cMET / EGFR-Fc(WT)-V1 is shown in Figure 16A. As shown in Figure 10, the EC50 values ​​for EGFR binding were determined to be 9.27 ng / ml and 355.95 ng / ml for 1H1-cMET / EGFR-Fc(WT)-V3 and the JNJ372 analog, respectively.

[0413] Example 11. K for cMET Binding to JNJ372 Analogs and 1H1cMET / EGFR(WT) D , K. on , and K. off Decision K binding to cMET D , K. on , and K. off The values ​​were calculated using biolayer interferometry (BLI) technology (Probelife, Palo Alto CA) according to the manufacturer's instructions. The results are shown in the table below.

[0414] (Table 2)cMET / 1H1-cMET / EGFR-Fc(WT)-V3 TIFF2023549537000003.tif34128

[0415] Table 3. cMET / JNJ372 Analogs TIFF2023549537000004.tif34128

[0416] In separate experiments, K binding to cMET or EGFR D Values ​​were determined using the JNJ372 analog, 1H1-cMET / EGFR-Fc(WT)-V2, or 1H1-cMET / EGFR-Fc(WT)-V3. The schematic structures of 1H1-cMET / EGFR-Fc(WT)-V2 and 1H1-cMET / EGFR-Fc(WT)-V3 are shown in Figure 17A and Figure 18A, respectively. The results are shown in the table below.

[0417] (Table 4) TIFF2023549537000005.tif30128

[0418] Example 12. Testing cMET / HGF Blockade with JNJ372 Analogs and 1H1-cMET / EGFR-Fc(WT)-V3 by Competitive ELISA A competitive ELISA was performed to evaluate the effectiveness of the JNJ372 analog and 1H1-cMET / EGFR-Fc(WT)-V3 in blocking the interaction of cMET with its ligand, HGF. High-binding ELISA plates were coated with 4 μg / ml of c-MET-His-tag protein and incubated overnight at 4°C. Competitive ELISA was performed as described in Example 6 using antibody samples (final concentration of 25 μg / ml) and an isotype control (11F11). The effect of the antibody samples competing with biotinylated human HGF was determined. A streptavidin-HRP-conjugated secondary antibody was used.

[0419] As shown in Figure 11, 1H1-cMET / EGFR-Fc(WT)-V3 was more effective in blocking the cMET / HGF interaction than that of the JNJ372 analog.

[0420] Example 13. Determination of EGFR / EGF blockade using JNJ372 analogs and 1H1-cMET / EGFR-Fc(WT)-V3 by competitive binding assay To determine whether 1H1-cMET / EGFR-Fc(WT)-V3 can block the interaction between EGF and EGFR, microscopy and flow cytometry assays were used. NCIH1975 cells (ATCC® CRL-5908) were plated overnight in 48-well plates (2 × 10 cells) in RPMI1640 medium supplemented with 10% FBS. 5 (cells / well). The next morning, cells were washed three times with 1x PBS. Then, cells were fixed with 4% paraformaldehyde in PBS for 15 minutes at room temperature. Then, cells were washed three times with 1x PBS, followed by blocking in 10% normal goat serum (NGS) for 30 minutes at room temperature. After blocking, NGS was removed. JNJ372 analog, 1H1-cMET / EGFR-Fc(WT)-V3, and isotype control (11F11) were dissolved in NGS at a concentration of 20 μg / ml and added to the corresponding wells and kept at room temperature for 2 hours. Biotinylated EGF was then added to a final concentration of 2 μg / ml, and the plate was kept at room temperature for 1 hour.

[0421] Next, the cells were washed five times with 1x PBS. Secondary antibodies (streptavidin PE conjugates) were dissolved in NGS at a final dilution ratio of 1:50 and then added to the wells, followed by incubation at RT for 1 hour. Subsequently, the cells were washed six times with 1x PBS and imaged under a fluorescent microscope. After the imaging step, the cells were washed three times with FACS (fluorescence-activated cell sorting) buffer, and flow cytometry was performed to quantify the EGF / EGFR blocking effect of the tested antibodies.

[0422] As shown in Figures 12A-12F, 1H1-cMET / EGFR-Fc(WT)-V3 was more effective than the JNJ372 analog in blocking the interaction between EGF and EGFR.

[0423] Example 14. Determination of receptor phosphorylation of cMET and EGFR in NCI-H1975 cells treated with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3 NCI-H1975 cells are a human cancer cell line that harbors primary and secondary activating mutations in EGFR, conferring resistance to EGFR tyrosine kinase inhibitors (TKIs), in addition to MET gene amplification. In these cell lines, EGF and HGF, the ligands for EGFR and cMET, respectively, can induce phosphorylation of the EGFR and cMET receptors, which stimulates downstream signaling through the phosphorylation of ERK and Akt proteins. To determine whether 1H1-cMET / EGFR-Fc(WT)-V3 can inhibit ligand-induced phosphorylation of EGFR and cMET, NCI-H1975 cells were cultured with the JNJ372 analog or 1H1-cMET / EGFR-Fc(WT)-V3 in the presence of EGF and HGF, respectively.

[0424] Phospho-cMET was detected using a flow cytometry assay. Specifically, NCI-H1975 cells were grown overnight in cell starvation medium (RPMI medium supplemented with glutamax (diluted from a 100x solution)) in a 24-well plate at 50,000 cells / well. The next morning, the medium was discarded, and the cells were treated with test antibodies (1.5 μg / ml) dissolved in 250 μl / well of starvation medium at 37°C and 5% CO2 for 1 hour. Subsequently, the cells were treated with 200 ng / ml of HGF dissolved in 250 μl / well of starvation medium at 37°C and 5% CO2 for 15 minutes. The final HGF concentration was 100 ng / ml. After 15 minutes of treatment, the medium was discarded, and the cells were washed once with ice-cold 1x PBS. The cells were then fixed with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. After fixation, cells were washed three times with 1x PBS and stored in PBS overnight at 4°C. The next morning, cells were permeabilized with 0.1% Triton X-100 in PBS for 4–5 minutes on ice, washed three times with PBS, and then blocked in 10% NGS (normal goat serum) for 30 minutes. After blocking, primary antibody (human / mouse phospho-HGFR / c-MET (Y1349) (AF3950; Novusbio, Biotechne, MN) (15 μg / ml in 10% NGS) was added to the corresponding wells for 2 hours at room temperature. Subsequently, cells were washed three times with PBS, and then secondary antibody (goat anti-rabbit IgG (H+L) DyLight 594; Invitrogen, Thermo Fisher Scientific, MA) diluted 1:25 in FACS buffer (2% FBS in PBS) was added to the cells. The cells were then washed three times with PBS and then scraped off from the wells in FACS buffer, after which the cells were washed three times with FACS buffer and then analyzed by flow cytometer (BD FACS Calibur, NJ).

[0425] Phospho-EGFR was detected using the ELISA kit PathScan® Phospho-EGF Receptor (Tyr1173) Sandwich ELISA Kit #7187 (Cell Signaling Tech). Similar to the detection of phosphor-cMET as described herein, NCI-H1975 cells were grown overnight in cell starvation medium (RPMI medium supplemented with glutamax (diluted from a 100x solution)) in 24-well plates at 50,000 cells / well. The next morning, the medium was discarded, and the cells were treated with test antibodies (1.5 μg / ml) dissolved in 250 μl / well of starvation medium for 1 hour at 37°C and 5% CO2. Subsequently, the cells were treated with 100 ng / ml EGF dissolved in 250 μl / well of starvation medium for 15 minutes at 37°C and 5% CO2. The final EGF concentration was 50 ng / ml. After 15 minutes of treatment, the medium was discarded and the cells were washed once with ice-cold 1x PBS. Then, 300 μl of 1x lysis buffer supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) was added to the wells, and the plate was incubated at 4°C for 5 minutes. The cells were scraped off the plate and then collected in a 1.5 ml tube. The cell lysate was passed through a small-bore needle several times to disrupt the cells. The cell lysate was then centrifuged at 13,200 rpm for 10 minutes at room temperature. The supernatant collected after centrifugation was used as the cell lysate for ELISA. ELISA for detecting phosphor-EGFR was performed according to the manufacturer's instructions.

[0426] As shown in Figures 13A-13B, 1H1-cMET / EGFR-Fc(WT)-V3 was found to be more effective than the JNJ372 analog in reducing EGFR phosphorylation (Figure 13B), while the JNJ372 analog reduced cMET phosphorylation more than that of 1H1-cMET / EGFR-Fc(WT)-V3 (Figure 13A).

[0427] Example 15. Detection of pERK and pAkt in NCI-H1975 cells treated with JNJ372 analogs or 1H1-cMET / EGFR-Fc(WT)-V3 To further test the bispecific antibody 1H1-cMET / EGFR-Fc(WT)-V3, functional assays were performed. Specifically, the phosphorylation status of ERK and Akt proteins was determined. ERK and Akt proteins are involved in downstream signaling involved in cancer cell proliferation, survival, and disruption of apoptotic pathways. NCIH1975 cells (ATCC® CRL-5908) were plated in 24-well plates (2 × 10 cells) in RPMI 1640 medium supplemented with 10% FBS and 8 ng / ml Hu-HGF. 5 Cells were grown overnight in a 96-well plate (100 cells / well). To detect pERK, the ERK1 / 2 (pT202 / Y204 + Total) ELISA Kit (ab176660) from Abcam (Cambridge, UK) was used. To detect pAkt, the PathScan® Phospho-Akt1 (Ser473) Sandwich ELISA Kit #7160 from Cell Signaling Technology (Danvers, MA, US) was used. ELISAs were performed according to the respective manufacturer's instructions. Protein concentration was determined using the Pierce™ Coomassie Plus (Bradford) Assay Kit (150 μl of reagent (with 5 μl of lysate) per well in a 96-well plate).

[0428] For detection of phosphor-ERK (pERK), cells were treated with bispecific antibody (1.5 μg / ml) for 30 minutes. Subsequently, the medium was discarded, and the cells were rinsed twice with ice-cold PBS. Then, 350 μl of 1× lysis buffer (supplemented with 1 mM PMSF as a protease inhibitor) was added to the wells, and the lysed cells were collected in a 1.5 ml tube. The cell lysate was used according to the ELISA protocol.

[0429] Similarly, for detection of phosphor-Akt (pAkt), cells were treated with bispecific antibody (1.5 μg / ml) for 60 minutes. The medium was then discarded, and the cells were rinsed twice with ice-cold PBS. 350 μl of 1× lysis buffer (supplemented with 1 mM PMSF as a protease inhibitor) was then added to the wells, and the plate was kept on ice for 5 minutes. The cells were then scraped and collected in a 1.5 ml tube. The lysed cells were then passed through a small-bore needle several times to disrupt the cells. The cell lysate was then centrifuged at 13,200 rpm for 10 minutes at room temperature. The supernatant collected after centrifugation was used as the cell lysate for pAkt ELISA.

[0430] As shown in Figures 14A-14B, 1H1-cMET / EGFR-Fc(WT)-V3 was found to be more effective than the JNJ372 analog in reducing the ratio of pERK (to total ERK) and pAkt (to total Akt) in NCI-H1975 cells grown in the presence of Hu-HGF.

[0431] Example 16. Determination of effector function of 1H1-cMET / EGFR-Fc(WT)-V3 compared to JNJ372 analogs Higher levels of EGFR and cMET on the surface of tumor cells allow specific targeting and killing of these cells by immune effector cells (e.g., NK cells) through Fc-dependent effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To determine the effector function of 1H1-cMET / EGFR-Fc(WT)-V3 compared to the JNJ372 analog, ADCC and CDC assays were performed as described below.

[0432] Prior to the start of both assays, NCI-H1975 cells were labeled with calcein AM cell-permeable dye. The cells were then briefly washed with PBS and then treated with 0.5 M ethylenediaminetetraacetic acid (EDTA) for 20 minutes. The treated cells were then centrifuged at 1200 rpm for 5 minutes, counted, and resuspended in 4 ml of serum-free medium (approximately 3.7 million cells were used for labeling). 8 μl of 1 mM calcein AM (stock solution) was then added to the cells (final concentration of 2 μM calcein). The cells were then incubated in the dark at RT for 30 minutes. Afterwards, the cells were again centrifuged at 1200 rpm for 5 minutes, and the medium was removed. After medium removal, the cells were washed twice with serum-free medium and then equally distributed in 4.6 ml of medium into two separate 15 ml tubes. The medium was used directly for the CDC determination assay described below, and supplemented with 10% FBS for the ADCC determination assay described below.

[0433] Antibody-dependent cell-mediated cytotoxicity (ADCC) Calcein-labeled cells were added to a U-bottom 96-well plate at 100 μl per well. Test antibodies were added at a dilution of 80 μg / ml in 50 μl of medium for a final concentration of 20 μg / ml. 360,000 NK92-CD16 cells / well were then added to the labeled H1975 cells in 50 μl of medium. The effector cell to target cell ratio was 9:1. The cell mixture was incubated at 37°C for 2 hours and 45 minutes. 30 μl of 10x lysis buffer was then added to the maximum release wells, and 30 μl of RPMI medium was added to the maximum release control wells. The plate was incubated for an additional 15 minutes. After incubation, the plate was centrifuged at 1200 rpm for 5 minutes, and 50 μl of the resulting supernatant was transferred to a black, flat-bottom, clear-well 96-well plate (Greiner). 50 μl of PBS was then added to the supernatant. The luminescence signal of the plate was then measured at 485 nm and 538 nm (cutoff 530 nm) in a Spectramax fluorescent plate reader.

[0434] As shown in Figure 15A, JNJ372 analogs were more effective in ADCC-induced cell killing than 1H1-cMET / EGFR-Fc(WT)-V3. While 1H1-cMET / EGFR-Fc(WT)-V3 has a wild-type Fc region, JNJ372 analogs may have mutations engineered into the Fc region for ADCC function. Therefore, 1H1-cMET / EGFR-Fc(WT)-V3 can be mutated in the Fc region to enhance its ADCC effect.

[0435] Complement-dependent cytotoxicity (CDC) Calcein-labeled cells were added to a U-bottom 96-well plate at 100 μl per well. Test antibodies were added at a dilution of 80 μg / ml in 50 μl of medium for a final concentration of 20 μg / ml. Complement serum was added at a dilution of 20% in 50 μl of medium for a final concentration of 5%. Cells were incubated at 37°C for 2 hours and 45 minutes. 30 μl of 10x lysis buffer was then added to the maximum release wells, and 30 μl of RPMI medium was added to the maximum release control wells. The plate was incubated for an additional 15 minutes. After incubation, the plate was centrifuged at 1200 rpm for 5 minutes, and 50 μl of the resulting supernatant was transferred to a clear-well, black, flat-bottom 96-well plate (Greiner). 50 μl of PBS was then added to the supernatant. The luminescence signal of the plate was then measured at 485 nm and 538 nm (cutoff 530 nm) in a Spectramax fluorescent plate reader.

[0436] As shown in Figure 15B, 1H1-cMET / EGFR-Fc(WT)-V3 was found to be more effective in CDC than the JNJ372 analog.

[0437] The cancer cell killing ability of 1H1-cMET / EGFR-Fc(WT)-V3 and JNJ372 analogs at various concentrations was also evaluated. The IC50 results are shown in the table below.

[0438] (Table 5) TIFF2023549537000006.tif31128

[0439] As shown in Figure 15C, 1H1-cMET / EGFR-Fc(WT)-V3 exhibited similar cell-killing ability compared to that of the JNJ372 analog.

[0440] Example 17. Conclusion According to the experimental results as described herein, the following table provides a summary of the receptor binding, receptor / ligand blocking, signaling, and cancer cell killing effects of the bispecific antibodies described herein.

[0441] (Table 6) TIFF2023549537000007.tif214154

[0442] The schematic structures of 1H1-cMET / EGFR-Fc(WT)-V1, 1H1-cMET / EGFR-Fc(WT)-V2, and 1H1-cMET / EGFR-Fc(WT)-V3 are shown in Figure 16A, Figure 17A, and Figure 18A, respectively.

[0443] Example 18. Internalization induced by EGFR / cMET multispecific antibodies Experiments were performed to evaluate the internalization induced by EGFR / cMET bispecific and trispecific antibodies. Specifically, internalization assays were performed using the JNJ372 analog, the EGFR / cMET bispecific antibody 1H1-cMET / EGFR-Fc(WT)-V3, and the EGFR / cMET trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) (with the trispecific-V3 structure shown in Figure 18B). MDA231 cells were mixed with 20 μg / ml of antibody and incubated at 37°C for 30 minutes. pHrodo-labeled secondary antibody was then added and incubated with the cells at 37°C for 24 hours. Cells were then harvested and analyzed by FACS.

[0444] As shown in Figures 20A-20B, 1H1cMET / 1A12cMET / EGFR(WT) showed enhanced internalization of the cMET / EGFR complex compared to the JNJ372 analog or 1H1-cMET / EGFR-Fc(WT)-V3.

[0445] Example 19. cMET VHH epitope binning analysis cMET VHH-Fc epitope binning analysis for cMET 1H1 and cMET 1A12 was performed using Biolayer Interferometry (Probelife, Palo Alto, CA) according to the manufacturer's instructions (Figures 21A-B). Briefly, a baseline was established using the HIS probe in quantification (Q) buffer (phosphate-buffered saline containing bovine serum albumin to reduce nonspecific and background signals). The antigen for the HIS probe (cMET-HIS tagged) was added at 5 μg / ml cMET in Q buffer. The HIS probe in Q buffer was used to return to the baseline. Subsequently, the first antibody was conjugated through the HIS probe at 15 μg / ml antibody diluted in Q buffer. Finally, the second antibody was conjugated through the HIS probe at 5 μg / ml antibody diluted in Q buffer. The results indicated that the 1H1 VHH and 1A12 VHH can bind to different epitopes of cMET. Furthermore, binding of the 1H1 VHH at its cMET epitope can further expose the 1A12 epitope, thereby increasing the binding affinity of the 1A12 VHH to cMet (FIG. 21A).

[0446] Example 20. Construction of trispecific Abs As shown in Figure 18B, a trispecific antibody was prepared using anti-EGFR IgG as the backbone. Two separate VHH domains binding to two different epitopes of cMET were linked to the heavy chain variable region (VH) via linker peptides to the two arms of the anti-EGFR IgG. When the 1H1 VHH (SEQ ID NO: 84) was linked to one arm of the anti-EGFR IgG (VH: SEQ ID NO: 23; VL: SEQ ID NO: 24) and the 1A12 VHH (SEQ ID NO: 20) was linked to the other arm of the anti-EGFR IgG, the trispecific antibody was designated 1H1cMET / 1A12cMET / EGFR(WT). As discussed above, the 1H1 VHH and 1A12 VHH bind to different epitopes of cMET. Binding of the 1H1 VHH at its cMET epitope can further expose the 1A12 epitope, thereby increasing the binding affinity of the 1A12 VHH to cMet. Because the expression of cMET is relatively low compared to EGFR, the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) first binds to EGFR on cells. Binding of the trispecific antibody to EGFR brings the 1H1 VHH closer to cMET on cells. Binding of the 1H1 VHH at its cMET epitope can further increase the exposure of the 1A12 epitope, thereby increasing the binding affinity of the trispecific antibody to tumor cells.

[0447] Example 21. Comparison of the binding ability of 1H1cMET / 1A12cMET / EGFR(WT) and JNJ372 analogs to various NSCLC cells To determine the binding ability of 1H1cMET / 1A12cMET / EGFR (WT) and JNJ372 analogs to various cell models, cells included H1975, H1975.HGF (H1975 transfected cells overexpressing HGF), and EGFR mutant C797S-BaF3 cells. Briefly, cells were diluted in FACS buffer and added (5 x 10) to 96-well V-bottom non-treated plates. 42.04 x 10 cells / 100 μl / well of 1H1cMET / 1A12cMET / EGFR(WT), JNJ372 analogs, and control antibodies in a volume of 100 μl of medium. -4 Serial dilutions from 0.1 nM to 400 nM were added to different wells and incubated at room temperature (RT) for 60 minutes. The wells were then washed four times with PBS. Secondary Ab (goat anti-human Fc-FITC) in FACS buffer (1:200 dilution) was added to the wells and incubated at RT for 30 minutes. The wells were washed three times with FACS buffer. Cells were detached with Accutase™ cell detachment solution and analyzed using FACS.

[0448] As shown in Figures 22A-22C, the binding of the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) to NSCLC cells was better than that of the JNJ372 analog.

[0449] Example 22. Competitive binding assay to determine EGFR / EGF blockade using JNJ372 analogs and 1H1cMET / 1A12cMET / EGFR(WT) To determine whether the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) can block the interaction between EGF and EGFR, a flow cytometry assay was used. A biotinylated form of EGF was obtained for this assay. NSCLC cells (e.g., H1975, H1975.HGF, or EGFR mutant C797S-BaF3 cells) were plated in 96-well plates (3 × 10 cells) in RPMI 1640 medium supplemented with 10% FBS. 5 Cells / well) and cultured overnight. The next morning, cells were washed three times with 1x PBS. After washing, the desired concentration of antibody (2x) was added in a volume of 50 μl (2.04 x 10 -4Afterwards (without washing), 50 μl of biotinylated EGF (effective concentration 2 μg / ml; working concentration 4 μg / ml) was added to each well, followed by a 45-minute incubation. The cells were then washed twice with FACS buffer and once with Dulbecco's phosphate-buffered saline (DPBS). 50 μl of Accutase™ Cell Detachment Solution was added to each well, and the plate was incubated at 37°C for 5-7 minutes. The Accutase™ Cell Detachment Solution was neutralized by adding 50 μl of medium or FACS buffer. The contents of the wells were carefully transferred into a V-bottom 96-well plate. The cells were washed three times with FACS buffer. Secondary antibody (streptavidin conjugate-PE; 1:500 dilution) was added to each well of the plate, and the plate was then incubated for 30-45 minutes. After incubation, the plate was washed three times with FACS buffer. Cells were finally resuspended in FACS buffer and analyzed in a flow cytometer to quantify EGF / EGFR blockade by the test samples.

[0450] As shown in Figures 23A-23C, 1H1cMET / 1A12cMET / EGFR(WT) exhibited significantly better EGF / EGFR blocking ability than the JNJ372 analog in various cell models.

[0451] Example 23. Competitive binding assay to determine cMET / HGF blockade using JNJ372 analogs and 1H1cMET / 1A12cMET / EGFR(WT) To determine whether the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) can block the interaction between HGF (hepatocyte growth factor) and cMET, a flow cytometry assay was used. HGF was biotinylated using a standard biotinylation kit (Pierce, Invitrogen). NSCLC cells (H1975 or H1975.HGF) were plated in 96-well plates (3 × 10 cells) in RPMI 1640 medium supplemented with 10% FBS. 5Cells / well) and cultured overnight. The next morning, cells were washed three times with 1x PBS. After washing, the desired concentration of antibody (2x) was added in a volume of 50 μl (2.04 x 10 -4 Afterwards (without washing), 50 μl of biotinylated HGF (effective concentration 5 nM) was added to each well, followed by a 45-minute incubation. The cells were then washed twice with FACS buffer and once with DPBS (Dulbecco's Phosphate-Buffered Saline). 50 μl of Accutase™ Cell Detachment Solution was added to each well, and the plate was incubated at 37°C for 5-7 minutes. The Accutase™ Cell Detachment Solution was neutralized by adding 50 μl of medium or FACS buffer. The contents of the wells were carefully transferred into a V-bottom 96-well plate. The cells were washed three times with FACS buffer. A secondary antibody (streptavidin conjugate-PE; 1:500 dilution) was added to each well of the plate, and the plate was incubated for 30-45 minutes. After incubation, the plate was washed three times with FACS buffer. Cells were finally resuspended in FACS buffer and analyzed in a flow cytometer to quantify EGF / EGFR blockade by the test samples.

[0452] As shown in Figures 24A-24B, 1H1cMET / 1A12cMET / EGFR(WT) showed better HGF / cMET blocking ability than the JNJ372 analog in H1975.

[0453] Example 24. 1H1cMET / 1A12cMET / EGFR(WT) regulates downstream signaling of cMET and EGFR by reducing pMET and degrading EGFR The effects of cMET and EGFR on downstream signaling were studied using H1975, H1975.HGF, and C797S-BaF3 cells. NCI-H1975 cells represent a human cancer cell line that harbors MET gene amplification as well as primary and secondary activating mutations in EGFR, conferring resistance to EGFR TKIs. In these cell lines, EGF and HGF, the ligands for EGFR and cMet, respectively, induce phosphorylation of the EGFR and cMet receptors, which stimulate downstream signaling through phosphorylation of ERK and Akt proteins. C797S represents a cell line harboring the untreatable EGFR point mutation C797S.

[0454] To determine whether the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) can inhibit the activation of c-Met and EGFR, and the phosphorylation of Akt and Erk, NCI-H1975 cells were plated on 6-well plates (3 × 10 5 (cells / well). The following morning, H1975 cells were treated with antibodies for 66 hours in complete medium, serum-starved for 6 hours in medium containing 0.5% FBS, and then stimulated with HGF for 15 minutes. H1975-HGF cells were treated with antibodies for 48 hours in complete medium, then treated with fresh antibodies for an additional 24 hours. C797S-BaF3 cells were treated with antibodies for 24 hours in complete medium.

[0455] Cells were washed twice with ice-cold PBS and then lysed in 0.25 ml of 1x cell lysis buffer (Cell Signaling Tech, Catalog No. 9803) containing protease inhibitors (MedChemExpress, Catalog No. HY-K0010) and phosphatase inhibitor cocktail (Research Products International, Catalog No. P52100). Cell lysates were collected and centrifuged at 15,000 g for 15 minutes at 4°C. The cleared lysates were mixed with an equal volume of 2x SDS sample buffer and boiled at 100°C for 15 minutes. Samples were separated by SDS-PAGE, transferred to PVDF membranes, and blocked with 5% nonfat dry milk. Phosphorylation of EGFR, c-Met, Akt, and Erk was detected with anti-phospho-EGFR (Y1173) (R&D Systems, Catalog No. AF1095), anti-phospho-c-Met (Cell Signaling Tech, Catalog No. AF2480), anti-phospho-Akt (Cell Signaling Tech, Catalog No. 4060S), and anti-phospho-Erk (Cell Signaling Tech; Catalog No. 4377S), respectively. Total EGFR, c-Met, Akt, and Erk were detected with anti-EGFR (BioLegend, Catalog No. 617502), anti-c-Met (Cell Signaling Tech, Catalog No. 3148S), anti-Akt (Cell Signaling Tech, Catalog No. 2920S), and anti-Erk (Cell Signaling Tech, Catalog No. 9107S), respectively.

[0456] As shown in Figure 25A, 1H1cMET / 1A12cMET / EGFR(WT) was more effective than the JNJ372 analog in degrading EGFR in HGF-treated H1975 cells. Similarly, in HGF-expressing H1975 cells, the trispecific antibody was more effective than the JNJ372 analog in mediating EGFR degradation and inhibiting p-MET (Figure 25B). In addition, it induced dramatic degradation of EGFR and its downstream molecules (Akt and Erk) (Figure 25C). These results suggest that 1H1cMET / 1A12cMET / EGFR(WT) is more effective than the JNJ372 analog in inhibiting the cMet / EGFR signaling pathway.

[0457] Example 25. 1H1cMET / 1A12cMET / EGFR(WT) inhibits cell proliferation of NSCLC cell lines Binding of cMET and EGFR to their respective ligands leads to cell proliferation and survival, which occurs in response to activation of downstream pathways from cMET and EGFR ligand binding. To assess this, various cancer cells (H1975, H1975.HGF, and C797S-BaF3) were plated in 96-well plates (3 × 10 cells / well) in RPMI 1640 medium supplemented with 10% FBS. 5 cells / well) and cultured at 37°C. Subsequently, the cells were treated with a series of concentrations of 1H1cMET / 1A12cMET / EGFR (WT) and JNJ372 analogs (2.04 × 10 -4 The cells were treated with 1000 nM to 400 nM of HCl and maintained in a 37°C incubator for 72 hours. The effect on proliferation was assessed by luminescence detection using a Cell-Titer Glo (Promega, Madison, WI) kit according to the manufacturer's instructions.

[0458] As shown in Figures 26A-26C, 1H1cMET / 1A12cMET / EGFR(WT) was more effective than the JNJ372 analog in inhibiting NSCLC cancer cell proliferation.

[0459] Example 26. Study of internalization of JNJ372 analogs and 1H1cMET / 1A12cMET / EGFR(WT) antibodies To study the internalization of JNJ372 analogs and 1H1cMET / 1A12cMET / EGFR(WT) antibodies, various cell lines were used (H1975, H1975.HGF, C797S-BaF3, and the EGFR insertion mutant D770-BaF3). Cells were plated (3 × 10) in 96-well plates in 100 μL of RPMI 1640 medium (supplemented with 10% FBS). 4 Cells were incubated at 37°C and 5% CO2 (cells / well). Adherent cells were incubated overnight, while suspension cells (C797S-BaF3 and D770-BaF3) were plated on the day of treatment. Cells were then plated with a series of concentrations of 1H1cMET / 1A12cMET / EGFR (WT) and JNJ372 analogs (2.04 × 10) in 50 μL of RPMI 1640 medium (supplemented with 10% FBS). -4 Cells were treated with 1000 nM-400 nM of IgG4 (1000 nM-400 nM) and incubated for 20-30 minutes at 37°C and 5% CO2. Then, pHrodo™-labeled secondary Ab (AffiniPure goat anti-human IgG, Fcγ; Catalog No. 109005008) (50 μl, 10 μg / ml) was added to the cells and incubated for 20 hours at 37°C and 5% CO2. To quantify receptor internalization, adherent cells were detached using Accutase™ cell detachment solution, while suspension cells were used directly. Cells were washed four times with FACS buffer and finally resuspended in the same buffer and analyzed by FACS using the PE channel.

[0460] As shown in Figures 27A-27D, 1H1cMET / 1A12cMET / EGFR(WT) was more effective than the JNJ372 analog in antibody internalization in most NSCLC cells.

[0461] Example 27. Determination of effector function for 1H1cMET / 1A12cMET / EGFR(WT) compared to JNJ372 analogs To assess the effector function of 1H1cMET / 1A12cMET / EGFR(WT) compared with that of the JNJ372 analog, an ADCC (antibody-dependent cellular cytotoxicity) assay was performed as follows. Specifically, H1975.GFP.Luc and H1975.GFP.Luc stably expressing HGF (H1975.GFP.Luc.HGF) were used. The target (cancer cells) to effector (PBMC) ratio was 1:10, i.e., 9,000 target cells were mixed with 90,000 effector cells. Cancer cells were plated with PBMC and antibody in a total volume of 100 μl in a 96-well flat-bottom plate. The plate was incubated at 37°C for 24 hours. After 24 hours, the supernatant was collected and transferred to a 96-well V-bottom plate. The cells in the flat-bottom plate were washed with PBS. The cells were dissociated using Accutase™ cell detachment solution, and the effect of Accutase™ was neutralized using FBS-containing RPMI medium. Subsequently, the cells were transferred from the flat-bottom plate to a V-bottom plate. The cells along with the supernatant were centrifuged and washed three times with FACS buffer. After the final wash, 7AAD (Invitrogen) was added to a final dilution of 1:50. The cells were incubated in the dark for 20 minutes, and then the plate was subjected to a flow cytometer using the PerCP channel for fluorescence detection.

[0462] As shown in Figures 28A-28B, 1H1cMET / 1A12cMET / EGFR(WT) was comparable to the JNJ372 analog in ADCC in H1975 GFP.Luc cells, while the JNJ372 analog was better in H1975 GFP.Luc.HGF cells.

[0463] Example 28. Four-arm efficacy study in the H1975+Balb / c NU / NU in vivo model To evaluate the tumor-inhibitory effect of the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) in reference to the JNJ372 analog, a study was performed on Balb / c NU / NU mice as follows: Each mouse received 5.0 × 10 H1975 tumor cells in 0.1 mL of a 1:1 serum-free medium:Matrigel mix for tumor development. 6 ) was injected subcutaneously into the right flank. The average tumor size was approximately 100 mm 3 (e.g., 75-125 mm 3 ), tumor-bearing animals were randomly enrolled into test groups. Each group consisted of 3 to 4 mice. The day treatment began was designated as day 0, and animals in each group were treated as described in Figures 29A to 29C.

[0464] The results show that 1H1cMET / 1A12cMET / EGFR(WT) has better cancer cell killing efficacy compared to that of the JNJ372 analog in the H1975-implanted Balb / c mouse model.

[0465] Example 29. Four-arm efficacy study in the H1975-Luc-GFP-HGF+BALB / c NU / NU in vivo model To evaluate the tumor-inhibitory effect of the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) in comparison with the JNJ372 analog in HGF-overexpressing cell lines, a study was performed on Balb / c NU / NU mice as follows: Each mouse was inoculated with H1975-Luc-GFP-HGF tumor cells (5.0 × 10) in 0.1 mL of a 1:1 serum-free medium:Matrigel mix for tumor development. 6 ) was injected subcutaneously into the right flank. The average tumor size was approximately 100 mm 3 (e.g., 75-125 mm 3 When tumor-bearing animals reached 100 mg / kg, they were randomly enrolled into test groups. Each group consisted of 6 mice. The day treatment began was designated as day 0, and animals in each group were treated as shown in Figures 30A-30C.

[0466] The results show that 1H1cMET / 1A12cMET / EGFR(WT) has similar cancer cell killing potency compared to that of the JNJ372 analog in the H1975-Luc-GFP-HGF-implanted Balb / c mouse model.

[0467] Example 30. Efficacy evaluation of 1H1cMET / 1A12cMET / EGFR(WT) in female NOG mice bearing subcutaneous xenografts of the cell line C797S-BaF3 To evaluate the tumor-inhibitory effect of the trispecific antibody 1H1cMET / 1A12cMET / EGFR(WT) with reference to the JNJ372 analog in the exon 20 point-mutated cell line C797S-BaF3, a study was performed in NOG mice as follows: Each mouse was inoculated with C797S-BaF3 tumor cells (10.0 × 10) in 0.1 mL of a 1:1 serum-free medium:Matrigel mix for tumor development. 6 ) was injected subcutaneously into the right flank. The average tumor size was approximately 100 mm 3 (e.g., 75-125 mm 3 When tumor-bearing animals reached 100 mg / kg, they were randomly enrolled into test groups. Each group consisted of 6 mice. The day treatment began was designated as day 0, and animals in each group were treated as shown in Figures 31A-31C.

[0468] The results show that 1H1cMET / 1A12cMET / EGFR(WT) has comparable cancer cell killing efficacy compared to that of the JNJ372 analog in the C797S-BaF3-implanted NOG mouse model.

[0469] Other Aspects While the present invention has been described in conjunction with the detailed description thereof, it should be understood that the foregoing description is intended to illustrate, but not to limit, the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the appended claims.

Claims

1. An antibody or antigen-binding fragment thereof that binds to cMET (tyrosine protein kinase Met), comprising a heavy chain antibody variable domain (VHH) comprising complementarity determining regions (CDRs) 1, 2, and 3, the VHH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VHH CDR1 amino acid sequence, the VHH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VHH CDR2 amino acid sequence, and the VHH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VHH CDR3 amino acid sequence; The amino acid sequences of the selected VHH CDR1, 2, and 3 are as follows: (1) The amino acid sequences of the selected VHH CDR1, 2, and 3 are shown in SEQ ID NOs: 1, 2, and 3, respectively; (2) the amino acid sequences of the selected VHH CDR1, 2, 3 are shown in SEQ ID NOs: 4, 5, and 6, respectively; (3) The amino acid sequences of the selected VHH CDR1, 2, 3 are shown in SEQ ID NOs: 7, 8, and 9, respectively; and (4) The amino acid sequences of the selected VHH CDR1, 2, and 3 are shown in SEQ ID NOs: 10, 11, and 12, respectively. One of the The antibody or antigen-binding fragment thereof.

2. An antibody or antigen-binding fragment thereof that binds to cMET, comprising a heavy chain antibody variable domain (VHH) comprising an amino acid sequence that is at least 80% identical to a selected VHH sequence, wherein the selected VHH sequence is selected from the group consisting of SEQ ID NOs: 19-22 and 77-84.

3. An antibody or antigen-binding fragment thereof described in claim 1 or 2, which specifically binds to human cMET or monkey cMET.

4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, which is a humanized antibody or antigen-binding fragment thereof.

5. An antibody or antigen-binding fragment thereof comprising VHH CDR1, 2, 3 of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4.

6. (a) a first polypeptide comprising, from N-terminus to C-terminus, a first heavy chain antibody variable domain (VHH1), a first linker peptide sequence, a first heavy chain variable region (VH1), a first hinge region, and a first Fc region; (b) a second polypeptide comprising a first light chain variable region (VL1); (c) a third polypeptide comprising, from N-terminus to C-terminus, a second heavy chain antibody variable domain (VHH2), a second linker peptide sequence, a second heavy chain variable region (VH2), a second hinge region, and a second Fc region; and (d) a fourth polypeptide comprising a second light chain variable region (VL2). A polypeptide complex comprising: The VHH1 and the VHH2 specifically bind to cMET; the VH1 and the VL1, when associated with each other, specifically bind to EGFR (epidermal growth factor receptor); the VH2 and the VL2, when associated with each other, specifically bind to EGFR. The polypeptide complex.

7. The polypeptide complex of claim 6, wherein the VH1 and VH2 comprise a CDR1 region having an amino acid sequence at least 80% identical to SEQ ID NO: 13, a CDR2 region having an amino acid sequence at least 80% identical to SEQ ID NO: 14, and a CDR3 region having an amino acid sequence at least 80% identical to SEQ ID NO: 15, and the VL1 and VL2 comprise a CDR1 region having an amino acid sequence at least 80% identical to SEQ ID NO: 16, a CDR2 region having an amino acid sequence at least 80% identical to SEQ ID NO: 17, and a CDR3 region having an amino acid sequence at least 80% identical to SEQ ID NO:

18.

8. The VHH1 and VHH2 comprise CDR1, 2, and 3, the CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected CDR1 amino acid sequence, the CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected CDR2 amino acid sequence, and the CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected CDR3 amino acid sequence; The selected CDR1, 2, and 3 amino acid sequences are as follows: (1) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 1, 2, and 3, respectively; (2) the amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 4, 5, and 6, respectively; (3) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 7, 8, and 9, respectively; and (4) The amino acid sequences of the selected VHH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 10, 11, and 12, respectively.

8. The polypeptide complex of claim 6 or 7, which is one of:

9. The polypeptide complex of any one of claims 6 to 8, wherein the sequences of VHH1 and VHH2 are different.

10. The polypeptide complex described in claim 9, wherein the VHH1 comprises an sequence that is at least 80% identical to SEQ ID NO: 20, and the VHH2 comprises an sequence that is at least 80% identical to SEQ ID NO:

19.

11. (1) the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 64 or 65; the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68; the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 66 or 67; and the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68; or (2) the first polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 85; the second polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 68; the third polypeptide comprises a sequence at least 80% identical to SEQ ID NO: 86; and the fourth polypeptide comprises a sequence at least 80% identical to SEQ ID NO:

68.

11. The polypeptide complex of claim 9 or 10.

12. A nucleic acid comprising a polynucleotide encoding the antibody or antigen-binding fragment thereof of any one of claims 1 to 5.

13. A vector comprising the nucleic acid of claim 12.

14. A cell comprising the nucleic acid of claim 12.

15. 15. A method for producing an antibody or antigen-binding fragment thereof, comprising culturing the cell of claim 14 under conditions sufficient for the cell to produce the antibody or antigen-binding fragment thereof.

16. 6. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 5 covalently bound to a therapeutic agent.

17. 13. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 in the manufacture of a medicament for treating a subject with cancer.

18. 13. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 in the manufacture of a medicament for reducing the rate of tumor growth.

19. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 in the manufacture of a medicament for killing tumor cells.

20. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 5 and a pharma- ceutically acceptable carrier.